Medtronic (MDT) 10-Q 3 Dec 19 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Oct. 25, 2019	Nov. 27, 2019
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Oct. 25, 2019
Document Transition Report	false
Entity File Number	001-36820
Entity Registrant Name	Medtronic plc
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1183488
Entity Address, Address Line One	20 On Hatch, Lower Hatch Street
Entity Address, City or Town	Dublin 2
Entity Address, Country	IE
Country Region	353
City Area Code	1
Local Phone Number	438-1700
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Ordinary Shares Outstanding		1,340,377,511
Entity Central Index Key	0001613103
Amendment Flag	false
Current Fiscal Year End Date	--04-24
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020
Entity Address, Postal Zip Code	D02 XH02
Ordinary shares, par value $0.0001 per share
Entity Information [Line Items]
Title of 12(b) Security	Ordinary shares, par value $0.0001 per share
Trading Symbol	MDT
Security Exchange Name	NYSE
Floating Rate Notes due 2021
Entity Information [Line Items]
Title of 12(b) Security	Floating Rate Notes due 2021
Trading Symbol	MDT/21
Security Exchange Name	NYSE
0.000% Senior Notes due 2021
Entity Information [Line Items]
Title of 12(b) Security	0.000% Senior Notes due 2021
Trading Symbol	MDT/21A
Security Exchange Name	NYSE
0.000% Senior Notes due 2022
Entity Information [Line Items]
Title of 12(b) Security	0.000% Senior Notes due 2022
Trading Symbol	MDT/22B
Security Exchange Name	NYSE
0.375% Senior Notes due 2023
Entity Information [Line Items]
Title of 12(b) Security	0.375% Senior Notes due 2023
Trading Symbol	MDT/23B
Security Exchange Name	NYSE
0.25% Senior Notes due 2025
Entity Information [Line Items]
Title of 12(b) Security	0.25% Senior Notes due 2025
Trading Symbol	MDT/25
Security Exchange Name	NYSE
1.125% Notes due 2027
Entity Information [Line Items]
Title of 12(b) Security	1.125% Notes due 2027
Trading Symbol	MDT/27
Security Exchange Name	NYSE
1.625% Notes due 2031
Entity Information [Line Items]
Title of 12(b) Security	1.625% Notes due 2031
Trading Symbol	MDT/31
Security Exchange Name	NYSE
1.00% Senior Notes due 2031
Entity Information [Line Items]
Title of 12(b) Security	1.00% Senior Notes due 2031
Trading Symbol	MDT/31A
Security Exchange Name	NYSE
2.250% Notes due 2039
Entity Information [Line Items]
Title of 12(b) Security	2.250% Notes due 2039
Trading Symbol	MDT/39A
Security Exchange Name	NYSE
1.50% Senior Notes due 2039
Entity Information [Line Items]
Title of 12(b) Security	1.50% Senior Notes due 2039
Trading Symbol	MDT/39B
Security Exchange Name	NYSE
1.75% Senior Notes due 2049
Entity Information [Line Items]
Title of 12(b) Security	1.75% Senior Notes due 2049
Trading Symbol	MDT/49
Security Exchange Name	NYSE

Consolidated Statements of Inco

Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions	3 Months Ended				6 Months Ended
	Oct. 25, 2019	Jul. 26, 2019	Oct. 26, 2018	Jul. 27, 2018	Oct. 25, 2019	Oct. 26, 2018
Income Statement [Abstract]
Net sales	$ 7,706,000,000		$ 7,481,000,000		$ 15,199,000,000	$ 14,865,000,000
Costs and expenses:
Cost of products sold	2,394,000,000		2,203,000,000		4,760,000,000	4,407,000,000
Research and development expense	603,000,000		590,000,000		1,190,000,000	1,175,000,000
Selling, general, and administrative expense	2,620,000,000		2,605,000,000		5,163,000,000	5,202,000,000
Amortization of intangible assets	441,000,000		445,000,000		881,000,000	891,000,000
Restructuring charges, net	27,000,000		24,000,000		74,000,000	86,000,000
Certain litigation charges	121,000,000		0		168,000,000	103,000,000
Other operating expense, net	149,000,000		70,000,000		127,000,000	221,000,000
Operating profit (loss)	1,351,000,000		1,544,000,000		2,836,000,000	2,780,000,000
Other non-operating income, net	(108,000,000)		(52,000,000)		(209,000,000)	(238,000,000)
Interest expense	165,000,000		241,000,000		774,000,000	483,000,000
Income (loss) before income taxes	1,294,000,000		1,355,000,000		2,271,000,000	2,535,000,000
Income tax provision	(77,000,000)		235,000,000		23,000,000	338,000,000
Net income (loss)	1,371,000,000	$ 877,000,000	1,120,000,000	$ 1,077,000,000	2,248,000,000	2,197,000,000
Net income attributable to noncontrolling interests	(7,000,000)		(5,000,000)		(20,000,000)	(7,000,000)
Net income (loss) attributable to Medtronic	$ 1,364,000,000		$ 1,115,000,000		$ 2,228,000,000	$ 2,190,000,000
Basic earnings per share (usd per share)	$ 1.02		$ 0.83		$ 1.66	$ 1.62
Diluted earnings per share (usd per share)	$ 1.01		$ 0.82		$ 1.65	$ 1.61
Basic weighted average shares outstanding (shares)	1,340.8		1,349.2		1,340.8	1,350.9
Diluted weighted average shares outstanding (shares)	1,351.4		1,360.9		1,351.6	1,363

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 1,371	$ 1,120	$ 2,248	$ 2,197
Other comprehensive income (loss), net of tax:
Unrealized gain (loss) on investment securities	17	(9)	73	(9)
Translation adjustment	(214)	(431)	(148)	(1,255)
Net investment hedge	53		152
Net investment hedge		0		0
Net change in retirement obligations	12	21	25	48
Unrealized gain (loss) on cash flow hedges	5		(2)
Unrealized gain (loss) on cash flow hedges		127		340
Other comprehensive (loss) income	(127)	(292)	100	(876)
Comprehensive income including noncontrolling interests	1,244	828	2,348	1,321
Comprehensive income attributable to noncontrolling interests	(7)	(2)	(20)	(4)
Comprehensive income attributable to Medtronic	$ 1,237	$ 826	$ 2,328	$ 1,317

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Oct. 25, 2019	Apr. 26, 2019
Current assets:
Cash and cash equivalents	$ 3,962	$ 4,393
Investments	6,436	5,455
Accounts receivable, less allowances of $198 and $190, respectively	6,118	6,222
Inventories, net	4,042	3,753
Other current assets	2,095	2,144
Total current assets	22,653	21,967
Property, plant, and equipment	11,364	10,920
Accumulated depreciation	(6,608)	(6,245)
Property, plant, and equipment, net	4,756	4,675
Goodwill	39,952	39,959
Other intangible assets, net	19,775	20,560
Tax assets	1,804	1,519
Other assets	2,113	1,014
Total assets	91,053	89,694
Current liabilities:
Current debt obligations	875	838
Accounts payable	1,965	1,953
Accrued compensation	1,773	2,189
Accrued income taxes	442	567
Other accrued expenses	3,115	2,925
Total current liabilities	8,170	8,472
Long-term debt	24,752	24,486
Accrued compensation and retirement benefits	1,573	1,651
Accrued income taxes	2,705	2,838
Deferred tax liabilities	1,376	1,278
Other liabilities	1,758	757
Total liabilities	40,334	39,482
Commitments and contingencies (Note 17)
Shareholders’ equity:
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,340,375,745 and 1,340,697,595 shares issued and outstanding, respectively	0	0
Additional paid-in capital	26,171	26,532
Retained earnings	27,018	26,270
Accumulated other comprehensive loss	(2,611)	(2,711)
Total shareholders’ equity	50,578	50,091
Noncontrolling interests	141	121
Total equity	50,719	50,212
Total liabilities and equity	$ 91,053	$ 89,694

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Oct. 25, 2019	Apr. 26, 2019
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 198	$ 190
Ordinary shares, par value (usd per share)	$ 0.0001	$ 0.0001
Ordinary shares authorized (shares)	2,600,000,000	2,600,000,000
Ordinary shares issued (shares)	1,340,375,745	1,340,697,595
Ordinary shares outstanding (shares)	1,340,375,745	1,340,697,595

Consolidated Statements of Equi

Consolidated Statements of Equity (Unaudited) - USD ($) $ in Millions	Total	Total Shareholders’ Equity	Ordinary Shares	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interests
Beginning balance (shares) at Apr. 27, 2018			1,354,000,000
Beginning balance at Apr. 27, 2018	$ 50,822	$ 50,720	$ 0	$ 28,127	$ 24,379	$ (1,786)	$ 102
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,077	1,075			1,075		2
Other comprehensive income (loss)	(584)	(584)				(584)
Dividends to shareholders	(677)	(677)			(677)
Issuance of shares under stock purchase and award plans (shares)			7,000,000
Issuance of shares under stock purchase and award plans	446	446		446
Repurchase of ordinary shares (shares)			(9,000,000)
Repurchase of ordinary shares	(820)	(820)		(820)
Stock-based compensation	64	64		64
Changes to noncontrolling ownership interests	1						1
Ending balance (shares) at Jul. 27, 2018			1,352,000,000
Ending balance at Jul. 27, 2018	50,329	50,224	$ 0	27,817	24,730	(2,323)	105
Beginning balance (shares) at Apr. 27, 2018			1,354,000,000
Beginning balance at Apr. 27, 2018	50,822	50,720	$ 0	28,127	24,379	(1,786)	102
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	2,197
Other comprehensive income (loss)	(876)					(873)
Ending balance (shares) at Oct. 26, 2018			1,346,000,000
Ending balance at Oct. 26, 2018	49,714	49,607	$ 0	27,048	25,171	(2,612)	107
Beginning balance (shares) at Jul. 27, 2018			1,352,000,000
Beginning balance at Jul. 27, 2018	50,329	50,224	$ 0	27,817	24,730	(2,323)	105
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,120	1,115			1,115		5
Other comprehensive income (loss)	(292)	(289)				(289)	(3)
Dividends to shareholders	(674)	(674)			(674)
Issuance of shares under stock purchase and award plans (shares)			7,000,000
Issuance of shares under stock purchase and award plans	298	298		298
Repurchase of ordinary shares (shares)			(13,000,000)
Repurchase of ordinary shares	(1,171)	(1,171)		(1,171)
Stock-based compensation	104	104		104
Ending balance (shares) at Oct. 26, 2018			1,346,000,000
Ending balance at Oct. 26, 2018	$ 49,714	49,607	$ 0	27,048	25,171	(2,612)	107
Beginning balance (shares) at Apr. 26, 2019	1,340,697,595		1,341,000,000
Beginning balance at Apr. 26, 2019	$ 50,212	50,091	$ 0	26,532	26,270	(2,711)	121
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	877	864			864		13
Other comprehensive income (loss)	227	227				227
Dividends to shareholders	(724)	(724)			(724)
Issuance of shares under stock purchase and award plans (shares)			3,000,000
Issuance of shares under stock purchase and award plans	205	205		205
Repurchase of ordinary shares (shares)			(3,000,000)
Repurchase of ordinary shares	(328)	(328)		(328)
Stock-based compensation	61	61		61
Ending balance (shares) at Jul. 26, 2019			1,341,000,000
Ending balance at Jul. 26, 2019	$ 50,497	50,363	$ 0	26,470	26,377	(2,484)	134
Beginning balance (shares) at Apr. 26, 2019	1,340,697,595		1,341,000,000
Beginning balance at Apr. 26, 2019	$ 50,212	50,091	$ 0	26,532	26,270	(2,711)	121
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	2,248
Other comprehensive income (loss)	$ 100					100
Ending balance (shares) at Oct. 25, 2019	1,340,375,745		1,340,000,000
Ending balance at Oct. 25, 2019	$ 50,719	50,578	$ 0	26,171	27,018	(2,611)	141
Beginning balance (shares) at Jul. 26, 2019			1,341,000,000
Beginning balance at Jul. 26, 2019	50,497	50,363	$ 0	26,470	26,377	(2,484)	134
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,371	1,364			1,364		7
Other comprehensive income (loss)	(127)	(127)				(127)
Dividends to shareholders	(723)	(723)			(723)
Issuance of shares under stock purchase and award plans (shares)			4,000,000
Issuance of shares under stock purchase and award plans	145	145		145
Repurchase of ordinary shares (shares)			(5,000,000)
Repurchase of ordinary shares	(552)	(552)		(552)
Stock-based compensation	$ 108	108		108
Ending balance (shares) at Oct. 25, 2019	1,340,375,745		1,340,000,000
Ending balance at Oct. 25, 2019	$ 50,719	$ 50,578	$ 0	$ 26,171	$ 27,018	$ (2,611)	$ 141

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Oct. 25, 2019	Jul. 26, 2019	Oct. 26, 2018	Jul. 27, 2018
Statement of Stockholders' Equity [Abstract]
Dividends to shareholders (usd per share)	$ 0.54	$ 0.54	$ 0.50	$ 0.50

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018
Operating Activities:
Net income	$ 2,248	$ 2,197
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,328	1,317
Provision for doubtful accounts	44	32
Deferred income taxes	(245)	(80)
Stock-based compensation	169	168
Loss on debt extinguishment	406	0
Other, net	119	55
Change in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable, net	39	(37)
Inventories, net	(267)	(312)
Accounts payable and accrued liabilities	(294)	24
Other operating assets and liabilities	(170)	(499)
Net cash provided by operating activities	3,377	2,865
Investing Activities:
Acquisitions, net of cash acquired	(201)	(119)
Additions to property, plant, and equipment	(584)	(497)
Purchases of investments	(4,226)	(1,444)
Sales and maturities of investments	3,260	2,824
Other investing activities	(16)	0
Net cash (used in) provided by investing activities	(1,767)	764
Financing Activities:
Change in current debt obligations, net	42	(700)
Issuance of long-term debt	5,568	1
Payments on long-term debt	(5,594)	(17)
Dividends to shareholders	(1,447)	(1,351)
Issuance of ordinary shares	432	800
Repurchase of ordinary shares	(962)	(2,047)
Other financing activities	(54)	11
Net cash provided by (used in) financing activities	(2,015)	(3,303)
Effect of exchange rate changes on cash and cash equivalents	(26)	(84)
Net change in cash and cash equivalents	(431)	242
Cash and cash equivalents at beginning of period	4,393	3,669
Cash and cash equivalents at end of period	3,962	3,911
Cash paid for:
Income taxes	494	941
Interest	$ 322	$ 482

Basis of Presentation

Basis of Presentation	6 Months Ended
	Oct. 25, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation.

New Accounting Pronouncements

New Accounting Pronouncements	6 Months Ended
	Oct. 25, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted Leases In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. This guidance also requires additional qualitative and quantitative lease related disclosures in the notes to the consolidated financial statements. The Company adopted this guidance using the modified retrospective method in the first quarter of fiscal year 2020. During the implementation of this recently adopted accounting standard, the Company elected the package of practical expedients available under the transition guidance that allowed an entity not to reassess whether any expired or existing contracts are or contain leases, the classification for any expired or existing leases or any initial direct costs for existing leases. Further, the Company made accounting policy elections to not apply the recognition requirements to short-term leases and to account for lease and nonlease components as a single lease component. The adoption of this guidance resulted in the recognition of right-of-use assets and lease liabilities in an amount of approximately $1.0 billion, an immaterial cumulative-effect adjustment to retained earnings as of April 27, 2019, and expansion of lease related disclosures . The adoption of this guidance did not have a material impact on the Company's consolidated statements of income or consolidated statements of cash flows. Others

Revenue

Revenue	6 Months Ended
	Oct. 25, 2019
Revenue from Contract with Customer [Abstract]
Revenue	Revenue The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, renal disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. The table below illustrates net sales by segment and division for the three and six months ended October 25, 2019 and October 26, 2018: Three months ended (1) Six months ended (1) (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Cardiac Rhythm & Heart Failure $ 1,426 $ 1,472 $ 2,807 $ 2,898 Coronary & Structural Heart 955 906 1,896 1,823 Aortic, Peripheral, & Venous 474 480 942 948 Cardiac and Vascular Group 2,855 2,858 5,645 5,669 Surgical Innovations 1,454 1,393 2,871 2,790 Respiratory, Gastrointestinal, & Renal 688 654 1,371 1,309 Minimally Invasive Therapies Group 2,142 2,047 4,242 4,099 Brain Therapies 772 701 1,512 1,375 Spine 692 656 1,349 1,308 Specialty Therapies 333 322 656 631 Pain Therapies 315 314 607 628 Restorative Therapies Group 2,112 1,993 4,124 3,942 Diabetes Group 596 583 1,188 1,155 Total $ 7,706 $ 7,481 $ 15,199 $ 14,865 (1) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum. During the first quarter of fiscal year 2020, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from Transformative Solutions product lines previously included in Specialty Therapies to a product line under Brain Therapies. As a result, net sales for fiscal year 2019 have been recast to adjust for this realignment. The table below illustrates net sales by market geography for each segment for the three and six months ended October 25, 2019 and October 26, 2018: U.S. (1)(4) Non-U.S. Developed Markets (2)(4) Emerging Markets (3)(4) Three months ended Three months ended Three months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Cardiac and Vascular Group $ 1,455 $ 1,482 $ 890 $ 895 $ 510 $ 481 Minimally Invasive Therapies Group 922 872 782 772 438 403 Restorative Therapies Group 1,440 1,357 416 412 256 224 Diabetes Group 311 334 226 203 59 46 Total $ 4,129 $ 4,045 $ 2,315 $ 2,282 $ 1,262 $ 1,154 U.S. (1)(4) Non-U.S. Developed Markets (2)(4) Emerging Markets (3)(4) Six months ended Six months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Cardiac and Vascular Group $ 2,816 $ 2,871 $ 1,820 $ 1,842 $ 1,009 $ 956 Minimally Invasive Therapies Group 1,835 1,729 1,573 1,600 834 770 Restorative Therapies Group 2,778 2,651 842 840 504 451 Diabetes Group 618 658 457 406 113 91 Total $ 8,046 $ 7,909 $ 4,692 $ 4,688 $ 2,460 $ 2,268 (1) U.S. includes the United States and U.S. territories. (2) Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe. (3) Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above. (4) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum. The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases of revenue. At October 25, 2019, $797 million of rebates were classified as other accrued expenses and $439 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheets. At April 26, 2019, $764 million of rebates were classified as other accrued expenses and $432 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheets. The Company includes obligations for returns in other accrued expenses in the consolidated balance sheets and the right-of-return asset in other current assets in the consolidated balance sheets. The right-of-return asset and liability at October 25, 2019 and April 26, 2019 were not material. For the three and six months ended October 25, 2019 and October 26, 2018, adjustments to rebate and return reserves recognized in revenue that were included in the rebate and return reserves at the beginning of the period were not material. Deferred Revenue and Remaining Performance Obligations The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue at October 25, 2019 and April 26, 2019 was $291 million and $315 million, respectively. At October 25, 2019 and April 26, 2019, $189 million and $211 million, respectively, was included in other accrued expenses and $102 million and $104 million, respectively, was included in other liabilities . During the six months ended October 25, 2019, the Company recognized $150 million of revenue that was included in deferred revenue as of April 26, 2019. Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At October 25, 2019, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed contracts with an original duration of one year or more was approximately $1.1 billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next four years.

Acquisitions

Acquisitions	6 Months Ended
	Oct. 25, 2019
Business Combinations [Abstract]
Acquisitions	Acquisitions The Company had acquisitions during the three and six months ended October 25, 2019 and October 26, 2018 that were accounted for as business combinations. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The pro forma impact of these acquisitions was not significant, either individually or in the aggregate, to the consolidated results of the Company for the three and six months ended October 25, 2019 and October 26, 2018. The results of operations of acquired businesses have been included in the Company's consolidated statements of income since the date each business was acquired. Fiscal Year 2020 The acquisition date fair value of net assets acquired during the six months ended October 25, 2019 was $272 million, consisting of $324 million of assets acquired and $52 million of liabilities assumed. Based upon preliminary valuations, assets acquired were primarily comprised of $139 million of technology-based intangible assets and $26 million of customer-related intangible assets with estimated useful lives ranging from 8 to 16 years, $92 million of goodwill, and $40 million of inventory. The goodwill is not deductible for tax purposes. The Company recognized $65 million of contingent consideration liabilities in connection with business combinations during the six months ended October 25, 2019, which are comprised of revenue milestone-based payments. For the six months ended October 25, 2019, purchase price allocation adjustments were not significant. Fiscal Year 2019 The acquisition date fair value of net assets acquired during the six months ended October 26, 2018 was $166 million, consisting of $187 million of assets acquired and $21 million of liabilities assumed. Assets acquired were primarily comprised of $60 million of goodwill and $100 million of technology-based intangible assets with estimated useful lives ranging from 4 to 15 years. The Company recognized $46 million of contingent consideration liabilities in connection with business combinations during the six months ended October 26, 2018. For the six months ended October 26, 2018, purchase price allocation adjustments were not significant. Acquired In-Process Research & Development In-process research and development (IPR&D) acquired outside of a business combination is expensed immediately. During the three and six months ended October 25, 2019, the Company acquired no IPR&D in connection with an asset acquisition. During the three and six months ended October 26, 2018, the Company acquired $15 million of IPR&D in connection with an asset acquisition, which was recognized in other operating expense, net in the consolidated statements of income. Contingent Consideration Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within other operating expense, net in the consolidated statements of income. Contingent consideration payments made soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows. The fair value of contingent consideration at October 25, 2019 and April 26, 2019 was $260 million and $222 million, respectively. At October 25, 2019, $83 million was recorded in other accrued expenses and $177 million was recorded in other liabilities in the consolidated balance sheets. At April 26, 2019, $73 million was recorded in other accrued expenses and $149 million was recorded in other liabilities in the consolidated balance sheets. The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Beginning balance $ 269 $ 208 $ 222 $ 173 Purchase price contingent consideration 7 11 65 46 Payments (15) (1) (29) (7) Change in fair value (1) (15) 2 (9) Ending balance $ 260 $ 203 $ 260 $ 203 The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based consideration). Projected revenues are based on the Company's most recent internal operational budgets and long-range strategic plans. Changes in projected payment dates, discount rates, probabilities of payment, and projected revenues may result in adjustments to the fair value measurement. The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: Fair Value at (in millions) October 25, 2019 Valuation Technique Unobservable Input Range Discount rate 11.5% - 32.5% Revenue and other performance-based payments $135 Discounted cash flow Probability of payment 40% - 100% Projected fiscal year of payment 2020 - 2026 Discount rate 5.5% Product development and other milestone-based payments $125 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2020 - 2027

Restructuring

Restructuring	6 Months Ended
	Oct. 25, 2019
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the third quarter of fiscal year 2018, the Company announced its Enterprise Excellence restructuring program, which is expected to leverage the Company's global size and scale, as well as enhance the customer and employee experience, with a focus on three objectives: global operations, functional optimization, and commercial optimization. Primary activities of the restructuring program include integrating and enhancing global manufacturing and supply processes, systems and site presence, enhancing and leveraging global operating models across several enabling functions, and optimizing certain commercial processes, systems, and models. The Company estimates that, in connection with its Enterprise Excellence restructuring program, it will recognize pre-tax exit and disposal costs and other costs across all segments of approximately $1.6 billion to $1.8 billion, the majority of which are expected to be incurred by the end of fiscal year 2022. Approximately half of the estimated charges are related to employee termination benefits. The remaining charges are costs associated with the restructuring program, such as salaries for employees supporting the program and consulting expenses. These charges are recognized within restructuring charges, net, cost of products sold, and selling, general, and administrative expense in the consolidated statements of income. For the three and six months ended October 25, 2019, the Company recognized charges of $95 million and $231 million, respectively. Additionally, the Company incurred accrual adjustments of $1 million and $13 million for the three and six months ended October 25, 2019, respectively, related to certain employees identified for termination finding other positions within Medtronic. For the three and six months ended October 25, 2019, charges included $32 million and $67 million, respectively, recognized within cost of products sold and $35 million and $77 million, respectively, recognized within selling, general, and administrative expense in the consolidated statements of income. For the three and six months ended October 26, 2018, the Company recognized charges of $75 million and $195 million, respectively. Additionally, the Company incurred accrual adjustments of $4 million and $2 million for the three and six months ended October 26, 2018, respectively, related to employee termination benefits being more than initially estimated. For the three and six months ended October 26, 2018, charges included $22 million and $37 million, respectively, recognized within cost of products sold and $31 million and $54 million, respectively, recognized within selling, general, and administrative expense in the consolidated statements of income. The following table summarizes the activity related to the Enterprise Excellence restructuring program for the six months ended October 25, 2019: (in millions) Employee Termination Benefits Associated Costs (1) Asset Write-Downs (2) Other Costs Total April 26, 2019 $ 101 $ 9 $ — $ 12 $ 122 Charges 79 139 6 7 231 Cash payments (118) (136) — (8) (262) Settled non-cash — — (6) — (6) Accrual adjustments (6) — — (7) (13) October 25, 2019 $ 56 $ 12 $ — $ 4 $ 72 (1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses. (2) Recognized within cost of products sold in the consolidated statements of income.

Financial Instruments

Financial Instruments	6 Months Ended
	Oct. 25, 2019
Investments [Abstract]
Financial Instruments	Financial Instruments Debt Securities The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. For information regarding the valuation techniques and inputs used in the fair value measurements, refer to Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2019. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at October 25, 2019 and April 26, 2019: October 25, 2019 Valuation Balance Sheet Classification (in millions) Cost Unrealized Unrealized Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 565 $ 15 $ — $ 580 $ 580 $ — Level 2: Corporate debt securities 3,814 43 (16) 3,841 3,841 — U.S. government and agency securities 858 — (1) 857 857 — Mortgage-backed securities 634 11 (13) 632 632 — Non-U.S. government and agency securities 13 — — 13 13 — Other asset-backed securities 514 2 (3) 513 513 — Total Level 2 5,833 56 (33) 5,856 5,856 — Level 3: Auction rate securities 47 — (3) 44 — 44 Total available-for-sale debt securities $ 6,445 $ 71 $ (36) $ 6,480 $ 6,436 $ 44 April 26, 2019 Valuation Balance Sheet Classification (in millions) Cost Unrealized Unrealized Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 529 $ 1 $ (7) $ 523 $ 523 $ — Level 2: Corporate debt securities 3,500 14 (21) 3,493 3,493 — U.S. government and agency securities 387 1 (7) 381 381 — Mortgage-backed securities 537 3 (20) 520 520 — Non-U.S. government and agency securities 11 — — 11 11 — Other asset-backed securities 529 1 (3) 527 527 — Total Level 2 4,964 19 (51) 4,932 4,932 — Level 3: Auction rate securities 47 — (3) 44 — 44 Total available-for-sale debt securities $ 5,540 $ 20 $ (61) $ 5,499 $ 5,455 $ 44 The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at October 25, 2019 and April 26, 2019: October 25, 2019 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Fair Value Unrealized U.S. government and agency securities $ 140 $ — $ 180 $ (1) Corporate debt securities 484 (9) 129 (7) Mortgage-backed securities 91 (1) 89 (12) Non-U.S. government and agency securities 2 — — — Other asset-backed securities 167 (1) 156 (2) Auction rate securities — — 44 (3) Total $ 884 $ (11) $ 598 $ (25) April 26, 2019 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Fair Value Unrealized U.S. government and agency securities $ 130 $ (1) $ 649 $ (13) Corporate debt securities 582 (5) 1,153 (16) Mortgage-backed securities 73 (1) 250 (19) Other asset-backed securities 290 (2) 85 (1) Auction rate securities — — 44 (3) Total $ 1,075 $ (9) $ 2,181 $ (52) The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no transfers between Level 1, Level 2, or Level 3 during the three and six months ended October 25, 2019 and October 26, 2018. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. There were no purchases, sales, settlements, or gains or losses recognized in earnings or other comprehensive income for available-for-sale securities classified as Level 3 during the three and six months ended October 25, 2019 and October 26, 2018. Activity related to the Company’s debt securities portfolio is as follows: Three months ended Six months Ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Proceeds from sales $ 1,691 $ 804 $ 3,258 $ 1,916 Gross realized gains 4 2 8 8 Gross realized losses (4) (12) (12) (19) Credit losses represent the difference between the present value of cash flows expected to be collected on certain mortgage-backed securities and auction rate securities and the amortized cost of these securities. Based on the Company’s assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which the Company is invested, the Company believes it has recognized all necessary other-than-temporary impairments, as the Company does not have the intent to sell, nor is it more likely than not that the Company will be required to sell, before recovery of the amortized cost. At October 25, 2019 and April 26, 2019, the credit loss portion of other-than-temporary impairments on debt securities was not significant. No available-for-sale securities were sold for significantly less than carrying value during the three and six months ended October 25, 2019 and October 26, 2018. The October 25, 2019 balance of available-for-sale debt securities by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) October 25, 2019 Due in one year or less $ 1,975 Due after one year through five years 2,578 Due after five years through ten years 1,881 Due after ten years 46 Total $ 6,480 Equity Securities, Equity Method Investments, and Other Investments The Company holds investments in equity securities without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity method investments and investments without readily determinable fair values are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. The following table summarizes the Company's equity and other investments at October 25, 2019 and April 26, 2019, which are classified as other assets in the consolidated balance sheets: (in millions) October 25, 2019 April 26, 2019 Investments without readily determinable fair values $ 366 $ 308 Equity method and other investments 66 64 Total equity and other investments $ 432 $ 372 The table below includes activity related to the Company’s portfolio of equity and other investments. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income. Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Proceeds from sales $ — $ — $ 2 $ 908 Gross gains 14 9 14 123 Gross losses — (13) — (29) Impairment losses recognized (2) (12) (3) (12)

Financing Arrangements

Financing Arrangements	6 Months Ended
	Oct. 25, 2019
Debt Disclosure [Abstract]
Financing Arrangements	Financing Arrangements Commercial Paper The Company maintains a commercial paper program that allows the Company to have a maximum of $3.5 billion in commercial paper outstanding. No commercial paper was outstanding at both October 25, 2019 and April 26, 2019. The issuance of commercial paper reduces the amount of credit available under the Company’s existing Credit Facility, as defined below. Line of Credit The Company has a $3.5 billion five Interest rates on advances on the Credit Facility are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The agreement also contains customary covenants, all of which the Company was in compliance with at October 25, 2019. Debt Obligations The Company's debt obligations consisted of the following: (in millions) Maturity by October 25, 2019 April 26, 2019 Current debt obligations 2020 $ 875 $ 838 Long-term debt 0.000 percent two 2021 1,666 1,681 Floating rate two 2021 833 560 4.125 percent ten 2021 — 500 3.150 percent seven 2022 1,534 2,500 3.125 percent ten 2022 — 675 3.200 percent ten 2023 650 650 0.375 percent four 2023 1,666 1,681 2.750 percent ten 2023 530 530 0.000 percent four 2023 833 — 2.950 percent ten 2024 310 310 3.625 percent ten 2024 432 850 3.500 percent ten 2025 2,700 4,000 0.250 percent seven 2026 1,111 — 1.125 percent eight 2027 1,666 1,681 3.350 percent ten 2027 368 850 1.625 percent twelve 2031 1,111 1,121 1.000 percent thirteen 2032 1,111 — 4.375 percent twenty 2035 1,932 2,382 6.550 percent thirty 2038 253 284 2.250 percent twenty 2039 1,111 1,121 6.500 percent thirty 2039 158 183 5.550 percent thirty 2040 224 306 1.500 percent twenty 2040 1,111 — 4.500 percent thirty 2042 105 129 4.000 percent thirty 2043 305 325 4.625 percent thirty 2044 127 177 4.625 percent thirty 2045 1,813 1,963 1.750 percent thirty 2050 1,111 — Bank borrowings 2021 - 2022 80 83 Debt (discount) premium, net 2020 - 2050 (15) 29 Finance lease obligations 2021 - 2033 27 10 Interest rate swaps N/A — 9 Deferred financing costs 2020 - 2050 (111) (104) Long-term debt $ 24,752 $ 24,486 Senior Notes The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which the Senior Notes were issued contain customary covenants, all of which the Company remained in compliance with at October 25, 2019. In June 2019, Medtronic Luxco issued six tranches of Euro-denominated Senior Notes with an aggregate principal of €5.0 billion, with maturities ranging from fiscal year 2021 to fiscal year 2050, resulting in cash proceeds of approximately $5.6 billion, net of discounts and issuance costs. The issuance included €250 million of floating rate Senior Notes due in fiscal year 2021, €750 million of 0.000 percent Senior Notes due in fiscal year 2023, €1.0 billion of 0.250 percent Senior Notes due in fiscal year 2026, €1.0 billion of 1.000 percent Senior Notes due in fiscal year 2032, €1.0 billion of 1.500 percent Senior Notes due in fiscal year 2040, and €1.0 billion of 1.750 percent Senior Notes due in fiscal year 2050. The Company used the net proceeds of the offering to fund the cash tender offer and early redemption, described below. The Euro-denominated debt is designated as a net investment hedge of certain of the Company's European operations. Refer to Note 8 for additional information regarding the net investment hedge. The Company completed the cash tender offer of $4.6 billion of Medtronic Inc., CIFSA, and Medtronic Luxco Senior Notes for $5.0 billion of total consideration in July 2019. The Company recognized a loss on debt extinguishment of $413 million during the first quarter of fiscal year 2020, which primarily included cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. The loss on debt extinguishment also included a $16 million charge for the estimated early redemption premium for $533 million of senior notes which were redeemed in August 2019. The loss on debt extinguishment was recognized in interest expense in the consolidated statements of income. Financial Instruments Not Measured at Fair Value At October 25, 2019, the estimated fair value of the Company’s Senior Notes was $27.3 billion compared to a principal value of $25.3 billion. At April 26, 2019, the estimated fair value was $26.2 billion compared to a principal value of $25.0 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.

Derivatives and Currency Exchan

Derivatives and Currency Exchange Risk Management	6 Months Ended
	Oct. 25, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Currency Exchange Risk Management	Derivatives and Currency Exchange Risk Management The Company uses operational and economic hedges, including currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. The primary currencies of the derivative instruments are the Euro, Japanese Yen, and British Pound. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding was $10.9 billion and $11.1 billion at October 25, 2019 and April 26, 2019, respectively. The Company also uses derivative and non-derivative instruments to manage the impact of currency exchange rate changes on net investments in foreign currency-denominated operations. The information that follows explains the various types of derivatives and financial instruments used by the Company, reasons the Company uses such instruments, and the impact such instruments have on the Company’s consolidated balance sheets and statements of income. Freestanding Derivative Contracts Freestanding derivative contracts are primarily used to offset the Company’s exposure to the change in value of specific foreign-currency-denominated assets and liabilities, and to offset variability of cash flows associated with forecasted transactions denominated in foreign currencies. The gross notional amount of the Company's currency exchange rate contracts outstanding at October 25, 2019 and April 26, 2019 was $4.3 billion. The Company's freestanding currency exchange rate contracts are not designated as hedges, and therefore, changes in the value of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related change in value of foreign-currency-denominated assets, liabilities, and cash flows. The Company also uses total return swaps to hedge the liability of a non-qualified, deferred compensation plan. The gross notional amount of the Company's total return swaps outstanding at October 25, 2019 and April 26, 2019 was $191 million. The Company's total return swaps are not designated as hedges, and therefore, changes in the value of these instruments are recognized in earnings. The cash flows related to the Company's freestanding derivative contracts are reported as operating activities in the consolidated statements of cash flows. The amounts and classification of the gains (losses) in the consolidated statements of income related to derivative instruments not designated as hedging instruments for the three and six months ended October 25, 2019 and October 26, 2018 were as follows: Three months ended Six months ended (in millions) Classification October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Currency exchange rate contracts Other operating expense, net $ 12 $ 71 $ 6 $ 201 Total return swaps Other operating expense, net (1) (11) 4 — Total $ 11 $ 60 $ 10 $ 201 Cash Flow Hedges Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. The gross notional amount of these contracts, designated as cash flow hedges, outstanding at October 25, 2019 and April 26, 2019 was $6.5 billion and $6.8 billion, respectively, and will mature within the subsequent two accumulated other comprehensive loss . The gain or loss on the derivative instrument is reclassified into earnings and is included in other operating expense, net in the consolidated statements of income in the same period or periods during which the hedged transaction affects earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings in the current period. The cash flows related to all of the Company's derivative instruments designated as cash flow hedges are reported as operating activities in the consolidated statements of cash flows. No components of the hedge contracts were excluded in the measurement of hedge effectiveness, and no forward contracts designated as cash flow hedges were derecognized or discontinued during the three and six months ended October 25, 2019 and October 26, 2018. The amount of the gains (losses) recognized in AOCI related to the currency exchange rate contract derivative instruments designated as cash flow hedges for the three and six months ended October 25, 2019 and October 26, 2018 were as follows: Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Currency exchange rate contracts $ 76 $ 174 $ 103 $ 444 The amount of the gains (losses) recognized in the consolidated statements of income related to derivative instruments designated as cash flow hedges for the three and six months ended October 25, 2019 and October 26, 2018 were as follows: Three months ended Six months ended October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 (in millions) Other operating expense, net Other operating expense, net Other operating expense, net Other operating expense, net Total amounts of income and expense line items presented in the consolidated statements of income in which the effects of cash flow hedges are recorded $ 149 $ 70 $ 127 $ 221 Currency exchange rate contracts designated as cash flow hedges: Amount of gain (loss) reclassified from AOCI into income 68 11 125 8 Forecasted Debt Issuance Interest Rate Risk Forward starting interest rate derivative instruments designated as cash flow hedges are designed to manage the exposure to interest rate volatility with regard to future issuances of fixed-rate debt. The gains or losses on forward starting interest rate derivative instruments that are designated and qualify as cash flow hedges are reported as a component of accumulated other comprehensive loss . Beginning in the period in which the planned debt issuance occurs and the related derivative instruments are terminated, the gains or losses are then reclassified into interest expense over the term of the related debt. For the three and six months ended October 25, 2019 and October 26, 2018, the reclassifications of net gains (losses) on forward starting interest rate derivative instruments from accumulated other comprehensive loss to interest expense were not significant. At October 25, 2019 and April 26, 2019 the Company had $192 million and $194 million, respectively, in after-tax net unrealized gains associated with cash flow hedging instruments recorded in accumulated other comprehensive loss . The Company expects that $165 million of after-tax net unrealized gains at October 25, 2019 will be recognized in the consolidated statements of income over the next 12 months. Fair Value Hedges Interest rate derivative instruments designated as fair value hedges are designed to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. Changes in the fair value of the derivative instrument are recognized in interest expense and are offset by changes in the fair value of the underlying debt instrument. The gains (losses) from terminated interest rate swap agreements are recognized in long-term debt , increasing (decreasing) the outstanding balances of the debt, and amortized as a reduction of (addition to) interest expense over the remaining life of the related debt. The cash flows related to the Company's interest rate derivative instruments designated as fair value hedges are reported as operating activities in the consolidated statements of cash flows. At October 25, 2019 the Company had no interest rate swaps outstanding designated as fair value hedges, as the Company terminated previously held swaps in connection with the tender and early redemption of the underlying senior notes during the first quarter of fiscal year 2020. At April 26, 2019, the Company had interest rate swaps in gross notional amounts of $1.2 billion, designated as fair value hedges of underlying fixed-rate senior note obligations, including the Company's $500 million 4.125 percent 2011 Senior Notes due fiscal year 2021 and the $675 million 3.125 percent 2012 Senior Notes due fiscal year 2022. The gain recognized upon termination of interest rate swaps was not significant for the three and six months ended October 25, 2019. At April 26, 2019, the market value of outstanding interest rate swap agreements was an unrealized gain of $9 million which was recorded in other assets , with the offset recorded in long-term debt on the consolidated balance sheets. The Company did not recognize any gains or losses during the three or six months ended October 25, 2019 and October 26, 2018 on firm commitments that no longer qualify as fair value hedges. The following amounts were recorded on the consolidated balance sheet related to the cumulative basis adjustments for fair value hedges: (in millions) Carrying Amount of Hedged Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Assets/(Liabilities) Location on the Consolidated Balance Sheet October 25, 2019 April 26, 2019 October 25, 2019 April 26, 2019 Long-term debt $ — $ (1,175) $ — $ 9 Net Investment Hedges The Company has designated Euro-denominated debt as a net investment hedge of certain of its European operations to manage the exposure to currency and exchange rate movements for foreign currency-denominated net investments in foreign operations. At October 25, 2019, the Company had €12.0 billion, or $13.3 billion, of outstanding Euro-denominated debt designated as a hedge of its net investment in certain of its European operations, which will mature in fiscal years 2021 through 2050. Additionally, during the first quarter of fiscal year 2020, the Company entered into and settled forward currency exchange rate contracts to manage the exposure to exchange rate movements in anticipation of the issuance of Euro-denominated senior notes. Certain of these forward currency exchange rate contracts were designated as a net investment hedge of certain of the Company's European operations. These contracts matured in conjunction with the issuance of Euro-denominated debt in the first quarter of fiscal year 2020. For instruments that are designated and qualify as net investment hedges, the gains or losses are reported as a component of accumulated other comprehensive loss . The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in other operating expense, net . The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. At October 25, 2019 and April 26, 2019 the Company had $17 million and $169 million, respectively, in after-tax unrealized losses associated with net investment hedges recorded in accumulated other comprehensive loss . The Company does not expect any of the after-tax unrealized losses at October 25, 2019 to be recognized in the consolidated statements of income over the next 12 months. The Company did not recognize any gains or losses during the three or six months ended October 25, 2019 or October 26, 2018 on instruments that no longer qualify as net investment hedges. The amount and classifications of the gains recognized in the consolidated statements of income for the portion of the net investment hedges excluded from the measurement of hedge effectiveness were as follows: Three months ended Six months ended (in millions) Classification October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Net investment hedges Other operating expense, net $ — $ — $ (7) $ — The amount of the gains recognized in AOCI related to instruments designated as net investment hedges for the three and six months ended October 25, 2019 and October 26, 2018 were as follows: Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Net investment hedges $ 53 $ — $ 152 $ — Balance Sheet Presentation The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at October 25, 2019 and April 26, 2019. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments and are further segregated by type of contract within those two categories. October 25, 2019 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 204 Other accrued expenses $ 3 Currency exchange rate contracts Other assets 86 Other liabilities 4 Total derivatives designated as hedging instruments 290 7 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 21 Other accrued expenses 24 Total return swap Other current assets 2 Other accrued expenses — Cross currency interest rate contracts Other current assets 6 Other accrued expenses — Total derivatives not designated as hedging instruments 29 24 Total derivatives $ 319 $ 31 April 26, 2019 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 234 Other accrued expenses $ 1 Interest rate contracts Other assets 9 Other liabilities — Currency exchange rate contracts Other assets 78 Other liabilities 1 Total derivatives designated as hedging instruments 321 2 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 23 Other accrued expenses 17 Total return swaps Other current assets 15 Other accrued expenses — Cross currency interest rate contracts Other current assets 6 Other accrued expenses — Total derivatives not designated as hedging instruments 44 17 Total derivatives $ 365 $ 19 The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis. October 25, 2019 April 26, 2019 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 311 $ 8 $ 335 $ 30 Derivative liabilities 31 — 19 — The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows. The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. October 25, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 311 $ (29) $ (10) $ 272 Total return swaps 2 — — 2 Cross currency interest rate contracts 6 — — 6 319 (29) (10) 280 Derivative liabilities: Currency exchange rate contracts (31) 29 — (2) Total return swaps — — — — Total $ 288 $ — $ (10) $ 278 April 26, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 335 $ (9) $ (43) $ 283 Interest rate contracts 9 — (1) 8 Total return swaps 15 — — 15 Cross currency interest rate contracts 6 — — 6 365 (9) (44) 312 Derivative liabilities: Currency exchange rate contracts (19) 9 — (10) (19) 9 — (10) Total $ 346 $ — $ (44) $ 302

Inventories

Inventories	6 Months Ended
	Oct. 25, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories Inventory balances, net of reserves, were as follows: (in millions) October 25, 2019 April 26, 2019 Finished goods $ 2,686 $ 2,476 Work in-process 594 572 Raw materials 762 705 Total $ 4,042 $ 3,753

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
	Oct. 25, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill The following table presents the changes in the carrying amount of goodwill by segment: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 26, 2019 $ 6,854 $ 20,381 $ 10,821 $ 1,903 $ 39,959 Goodwill as a result of acquisitions — 11 65 16 92 Purchase accounting adjustments 9 2 (5) — 6 Currency translation and other (1) (62) (42) — (105) October 25, 2019 $ 6,862 $ 20,332 $ 10,839 $ 1,919 $ 39,952 The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting unit level. The test for impairment of goodwill requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis. The Company did not recognize any goodwill impairment during the three and six months ended October 25, 2019 or October 26, 2018. Intangible Assets The following table presents the gross carrying amount and accumulated amortization of intangible assets: October 25, 2019 April 26, 2019 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,967 $ (4,581) $ 16,944 $ (4,095) Purchased technology and patents 10,528 (3,990) 11,405 (4,570) Trademarks and tradenames 464 (224) 570 (324) Other 83 (53) 85 (59) Total $ 28,042 $ (8,848) $ 29,004 $ (9,048) Indefinite-lived: IPR&D $ 581 $ — $ 604 $ — The Company assesses definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying value of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company recognized $33 million of definite-lived intangible asset charges during the three and six months ended October 25, 2019 in connection with the exit of businesses within the Restorative Therapies Group segment. During the six months ended October 26, 2018, the Company recognized $61 million of definite-lived intangible asset charges in connection with the exit of a business within the Cardiac and Vascular Group segment. The Company did not recognize any definite-lived intangibles asset charges during the three months ended October 26, 2018. Intangible asset impairment charges are recognized in other operating expense, net in the consolidated statements of income. The Company assesses indefinite-lived intangibles for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying value may be impaired. The Company did not recognize any indefinite-lived intangible asset impairments during the three and six months ended October 25, 2019 or October 26, 2018. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation a certain projects, and as a result, may recognize impairment losses in the future. Amortization Expense Intangible asset amortization expense for the three and six months ended October 25, 2019 was $441 million and $881 million, respectively, as compared to $445 million and $891 million for the three and six months ended October 26, 2018, respectively. Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at October 25, 2019, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows: (in millions) Amortization Expense Remaining 2020 $ 868 2021 1,725 2022 1,684 2023 1,621 2024 1,592 2025 1,565

Income Taxes

Income Taxes	6 Months Ended
	Oct. 25, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company's effective tax rate for the three and six months ended October 25, 2019 was (6.0) percent and 1.0 percent, respectively, as compared to 17.3 percent and 13.3 percent for the three and six months ended October 26, 2018, respectively. The decrease in the effective tax rate for the three and six months ended October 25, 2019, as compared to the corresponding periods in the prior fiscal year, was primarily due to the impact of certain tax adjustments. Certain Tax Adjustments During the three months ended October 25, 2019, the net benefit from certain tax adjustments of $251 million, recognized in income tax provision in the consolidated statements of income, included the following: • A benefit of $251 million related to tax legislative changes in Switzerland which abolished certain preferential tax regimes the Company benefited from and replaced them with a new set of internationally accepted measures. The legislation provided for higher effective tax rates but allowed for a transitional period whereby an amortizable asset was created for Swiss federal income tax purposes which will be amortized and deducted over a 10-year period. During the six months ended October 25, 2019, the net benefit from certain tax adjustments of $281 million, recognized in income tax provision in the consolidated statements of income, included the following: • A net benefit of $30 million related to U.S. Treasury’s issuance of certain Final Regulations associated with U.S. Tax Reform. The primary impact of these regulations resulted in the Company re-establishing its permanently reinvested assertion on certain foreign earnings and reversing the previously accrued tax liability. This benefit was partially offset by additional tax associated with a previously executed internal reorganization of certain foreign subsidiaries. • A benefit of $251 million related to tax legislative changes in Switzerland which abolished certain preferential tax regimes the Company benefited from and replaced them with a new set of internationally accepted measures. The legislation provided for higher effective tax rates but allowed for a transitional period whereby an amortizable asset was created for Swiss federal income tax purposes which will be amortized and deducted over a 10-year period. During the three months ended October 26, 2018, the charge from certain tax adjustments of $58 million, recognized in income tax provision in the consolidated statements of income, included the following: • A charge of $37 million associated with the transition tax liability recorded in connection with U.S. Tax Reform. • A charge of $21 million related to the recognition of a prepaid tax expense resulting from the reduction in the U.S. statutory tax rate due to U.S. Tax Reform and the sale of U.S. manufactured inventory held as of April 27, 2018. During the six months ended October 26, 2018, the net charge from certain tax adjustments of $29 million, recognized in income tax provision in the consolidated statements of income, included the following: • A benefit of $13 million associated with the transition tax liability recorded in connection with U.S. Tax Reform. • A charge of $42 million related to the recognition of a prepaid tax expense resulting from the reduction in the U.S. statutory tax rate due to U.S. Tax Reform and the sale of U.S. manufactured inventory held as of April 27, 2018. At October 25, 2019 and April 26, 2019, the Company's gross unrecognized tax benefits were $1.8 billion. In addition, the Company had accrued gross interest and penalties of $196 million at October 25, 2019. If all of the Company’s unrecognized tax benefits were recognized, approximately $1.8 billion would impact the Company’s effective tax rate. At both October 25, 2019 and April 26, 2019, the total balance of the Company's gross unrecognized tax benefits was recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheets. The Company recognizes interest and penalties related to income tax matters within income tax provision in the consolidated statements of income and records the liability within either current or noncurrent accrued income taxes on the consolidated balance sheets. Refer to Note 17 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Oct. 25, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Earnings per share is calculated using the two-class method, as the Company's A Preferred Shares are considered participating securities. Accordingly, earnings are allocated to both ordinary shares and participating securities in determining earnings per ordinary share. Due to the limited number of A Preferred Shares outstanding, this allocation had no effect on ordinary earnings per share; therefore, it is not presented below. Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted average number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. The table below sets forth the computation of basic and diluted earnings per share: Three months ended Six months ended (in millions, except per share data) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Numerator: Net income attributable to ordinary shareholders $ 1,364 $ 1,115 $ 2,228 $ 2,190 Denominator: Basic – weighted average shares outstanding 1,340.8 1,349.2 1,340.8 1,350.9 Effect of dilutive securities: Employee stock options 8.0 8.5 7.4 8.4 Employee restricted stock units 2.6 3.1 3.1 3.3 Other — 0.1 0.3 0.4 Diluted – weighted average shares outstanding 1,351.4 1,360.9 1,351.6 1,363.0 Basic earnings per share $ 1.02 $ 0.83 $ 1.66 $ 1.62 Diluted earnings per share $ 1.01 $ 0.82 $ 1.65 $ 1.61

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Oct. 25, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, and employee stock purchase plan shares recognized for the three and six months ended October 25, 2019 and October 26, 2018: Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Stock options $ 31 $ 33 $ 40 $ 51 Restricted stock 71 65 113 101 Employee stock purchase plan 6 6 16 16 Total stock-based compensation expense $ 108 $ 104 $ 169 $ 168 Cost of products sold $ 10 $ 12 $ 16 $ 18 Research and development expense 13 13 20 21 Selling, general, and administrative expense 85 79 133 129 Total stock-based compensation expense 108 104 169 168 Income tax benefits (19) (21) (29) (32) Total stock-based compensation expense, net of tax $ 89 $ 83 $ 140 $ 136

Retirement Benefit Plans

Retirement Benefit Plans	6 Months Ended
	Oct. 25, 2019
Retirement Benefits [Abstract]
Retirement Benefit Plans	Retirement Benefit Plans The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three months and six months ended October 25, 2019 and October 26, 2018: U.S. Non-U.S. Three months ended Three months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Service cost $ 26 $ 27 $ 15 $ 15 Interest cost 32 33 7 7 Expected return on plan assets (56) (54) (15) (14) Amortization of net actuarial loss 14 19 4 3 Net periodic benefit cost $ 16 $ 25 $ 11 $ 11 U.S. Non-U.S. Six months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Service cost $ 52 $ 54 $ 30 $ 30 Interest cost 64 66 14 14 Expected return on plan assets (112) (108) (30) (28) Amortization of net actuarial loss 28 38 7 6 Net periodic benefit cost $ 32 $ 50 $ 21 $ 22 Components of net periodic benefit cost other than the service component are recognized in other non-operating income, net

Leases

Leases	6 Months Ended
	Oct. 25, 2019
Leases [Abstract]
Leases	Leases The Company leases office, manufacturing, and research facilities and warehouses, as well as transportation, data processing, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Company's right to use the underlying asset for the lease term. Lease liabilities are the Company's obligation to make the lease payments arising from a lease. As the Company’s leases typically do not provide an implicit rate, the Company’s lease liabilities are measured on a discounted basis using the Company's incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed. The Company's lease agreements include leases that have both lease and associated nonlease components. The Company has elected to account for lease components and the associated nonlease components as a single lease component. The consolidated balance sheets do not include recognized assets or liabilities for leases that, at the commencement date, have a term of twelve months or less and do not include an option to purchase the underlying asset that is reasonably certain to be exercised. The Company recognizes such leases in the consolidated statements of income on a straight-line basis over the lease term. Additionally, the Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. Variable lease payments for the three and six months ended October 25, 2019 were not material. The Company's lease agreements include leases accounted for as operating leases and those accounted for as finance leases. The right-of-use assets, lease liabilities, lease costs, cash flows, and lease maturities associated with the Company's finance leases are not material to the consolidated financial statements at or for the three and six months ended October 25, 2019. Finance lease right-of-use assets are included in property, plant, and equipment, net , and finance lease liabilities are included in current debt obligations and long-term debt on the consolidated balance sheets. Additionally, from time to time, the Company subleases portions of its real-estate property, resulting in sublease income. Sublease income and the related assets and cash flows were not material to the consolidated financial statements at or for the three and six months ended October 25, 2019. The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at October 25, 2019: (in millions) Balance Sheet Classification October 25, 2019 Right-of-use assets Other assets $ 989 Current liability Other accrued expenses 176 Non-current liability Other liabilities 834 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at October 25, 2019: October 25, 2019 Weighted-average remaining lease term 7.7 years Weighted-average discount rate 3.0% The following table summarizes the components of total operating lease cost for the three and six months ended October 25, 2019: Three months ended Six Months Ended (in millions) October 25, 2019 October 25, 2019 Operating lease cost $ 56 $ 111 Short-term lease cost 11 22 Total operating lease cost $ 67 $ 133 The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for the six months ended October 25, 2019: Six months ended (in millions) October 25, 2019 Cash paid for amounts included in the measurement of operating lease liabilities $ 110 Right-of-use assets obtained in exchange for operating lease liabilities 105 The following table summarizes the maturities of the Company's operating leases at October 25, 2019: (in millions) Operating Leases Remaining 2020 $ 105 2021 193 2022 161 2023 140 2024 117 Thereafter 451 Total expected lease payments 1,167 Less: Imputed interest (157) Total lease liability $ 1,010 The Company makes certain products available to customers under lease arrangements, including arrangements whereby equipment is placed with customers who then purchase consumable products to accompany the use of the equipment. Income arising from arrangements where the Company is the lessor is recognized within net sales in the consolidated statements of income and the Company's net investments in sales-type leases are included in other current assets and other assets in the consolidated balance sheets. Lessor income and the related assets and lease maturities were not material to the consolidated financial statements at or for the three and six months ended October 25, 2019. As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended April 26, 2019, minimum payments under non-cancelable operating leases at April 26, 2019 were: (in millions) Operating Leases 2020 $ 216 2021 157 2022 103 2023 61 2024 34 Thereafter 81 Total minimum lease payments $ 652

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Oct. 25, 2019
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The following table provides changes in AOCI, net of tax, and by component: (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustments Net Investment Hedges Net Change in Retirement Obligations Unrealized Gain (Loss) on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 26, 2019 $ (45) $ (1,383) $ (169) $ (1,308) $ 194 $ (2,711) Other comprehensive income (loss) before reclassifications 68 (148) 152 (1) 82 153 Reclassifications 5 — — 26 (84) (53) Other comprehensive income (loss) 73 (148) 152 25 (2) 100 October 25, 2019 $ 28 $ (1,531) $ (17) $ (1,283) $ 192 $ (2,611) (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustment Net Investment Hedges Net Change in Retirement Obligations Unrealized (Loss) Gain on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 27, 2018 $ (194) $ (11) $ (257) $ (1,117) $ (207) $ (1,786) Other comprehensive (loss) income before reclassifications (19) (1,252) — — 343 (928) Reclassifications 10 — — 48 (3) 55 Other comprehensive (loss) income (9) (1,252) — 48 340 (873) Cumulative effect of change in accounting principle (1) 47 — — — — 47 October 26, 2018 $ (156) $ (1,263) $ (257) $ (1,069) $ 133 $ (2,612) (1) The cumulative effect of change in accounting principle during the first quarter of fiscal year 2019 resulted from the adoption of accounting guidance that requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. As a result of the adoption, the Company reclassified $47 million from accumulated other comprehensive loss to the opening balance of retained earnings as of April 28, 2018. The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during the six months ended October 25, 2019 and October 26, 2018 was an expense of $1 million and a benefit of $1 million, respectively. During the six months ended October 25, 2019, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $2 million. There was no income tax on realized gains and losses on investment securities reclassified from AOCI for the six months ended October 26, 2018. When realized, gains and losses on investment securities reclassified from AOCI are recognized within other non-operating income, net . Refer to Note 6 to the consolidated financial statements for additional information. For the six months ended October 25, 2019, there was no income tax on cumulative translation adjustments. For the six months ended October 26, 2018, the income tax benefit on cumulative translation adjustments was $5 million. During the six months ended October 25, 2019 and October 26, 2018, there were no tax impacts on net investment hedges. Refer to Note 8 to the consolidated financial statements for additional information. The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. During the six months ended October 25, 2019 and October 26, 2018, there were no income tax impacts on the net change in retirement obligations in other comprehensive income before reclassifications. During the six months ended October 25, 2019 and October 26, 2018, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of $6 million and $10 million, respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within other non-operating income, net . Refer to Note 14 to the consolidated financial statements for additional information. The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during the six months ended October 25, 2019 and October 26, 2018 was an expense of $21 million and $100 million, respectively. During the six months ended October 25, 2019 and October 26, 2018, gains and losses on cash flow hedges reclassified from AOCI were reduced by income taxes of $26 million and $3 million, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within other operating expense, net, and gains and losses on forward starting interest rate derivatives reclassified from AOCI are recognized within interest expense. Refer to Note 8 to the consolidated financial statements for additional information.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Oct. 25, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Matters The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, income tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies litigation charges and gains related to significant legal matters as certain litigation charges. During the three and six months ended October 25, 2019, the Company recognized $121 million and $168 million, respectively, of certain litigation charges related to probable and estimable damages for significant legal matters. During the six months ended October 26, 2018, the Company recognized $103 million of certain litigation charges. There were 0 certain litigation charges recognized during the three months ended October 26, 2018. At October 25, 2019 and April 26, 2019, accrued litigation was approximately $0.6 billion and $0.5 billion, respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other accrued expenses and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. Product Liability Matters Pelvic Mesh Litigation The Company is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company $121 million towards the settlement of 11,000 of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional 5,000 claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 15,800 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of November 6, 2019, the Company had reached agreements to settle approximately 15,400 of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. Patent Litigation Ethicon On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015. Following appeal, the case was remanded back to the District Court with respect to one patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. Following consolidation of the cases, Ethicon dismissed six of the asserted patents, leaving a single asserted patent. In addition to claims of non-infringement, the Company asserts an affirmative defense of invalidity. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter. Sasso The Company is involved in litigation in Indiana relating to certain patent and royalty disputes with Dr. Sasso under agreements originally entered into in 1999 and 2001. On November 28, 2018, a jury in Indiana state court returned a verdict against the Company for approximately $112 million. The Company has strong arguments to appeal the verdict and has filed post-trial motions and appeals with the appropriate appellate courts. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. Shareholder Related Matters Covidien Acquisition On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the Merenstein and Steiner matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On March 20, 2015, the District Court issued an order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, and reversed in part. On April 19, 2016 the Minnesota Supreme Court granted the Company’s petition to review the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. In August of 2017, the Minnesota Supreme Court affirmed the decision of the Minnesota State Court of Appeals, sending the matter back to the trial court for further proceedings, which are ongoing. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters. Environmental Proceedings The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills. The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order. Since the early 2000s, the Company or its predecessors have also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring the Company's predecessor to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary. Following a trial in March 2002, the Court held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that the Company’s predecessor was liable for the cost of performing a study of the River and Bay. Following a second trial in June 2014, the Court ordered that further engineering study and engineering design work was needed to determine the nature and extent of remediation in the Penobscot River and Bay. The Court also appointed an engineering firm to conduct such studies and issue a report on potential remediation alternatives. In connection with these proceedings, reports have been produced including a variety of cost estimates for a variety of potential remedial options. A third trial to determine the course of remediation to be pursued is scheduled to occur in fiscal year 2021. The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above. Government Matters Since 2017, the Company has been responding to requests from the Department of Justice and U.S. Department of Health and Human Services for information about business practices relating to a neurovascular product developed and first marketed by ev3 and Covidien. The Company has provided information in response to these requests and is cooperating with the inquiry. The Company has not recognized an expense in connection with any ongoing investigation, because any such potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from the ongoing information requests. Income Taxes In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court reviewed this dispute, and on June 9, 2016, issued its opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. On April 21, 2017, the IRS filed their Notice of Appeal to the U.S. Court of Appeals for the 8th Circuit regarding the Tax Court Opinion. Oral argument for the Appeal occurred on March 14, 2018. The 8th Circuit Court of Appeals issued their opinion on August 16, 2018, and remanded the case back to the U.S. Tax Court for additional factual findings. U.S. Tax Court trial is scheduled to occur in April of 2020. In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2007 and 2008 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2009, 2010, and 2011 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. In May 2017, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2012, 2013, and 2014. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the utilization of certain net operating losses. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level. Medtronic, Inc.’s fiscal years 2015 and 2016 U.S. federal income tax returns are currently being audited by the IRS. Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for all tax years through 2012. The statute of limitations for Covidien’s 2013 and 2014 U.S. federal income tax returns lapsed during the first quarter of fiscal years 2018 and 2019, respectively. Covidien's fiscal year 2015 U.S. federal income tax returns are currently being audited by the IRS. While it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. Refer to Note 11 for additional discussion of income taxes. Guarantees As a result of the acquisition of Covidien, the Company has a guarantee commitment related to certain contingent tax liabilities as a party to the Tax Sharing Agreement that was entered into on June 29, 2007, between Covidien, Tyco International (now Johnson Controls), and Tyco Electronics (now TE Connectivity), associated with the spin-off from Tyco. The Tax Sharing Agreement covers certain income tax liabilities for periods prior to and including the spin-off. Medtronic’s share of the income tax liabilities for these periods is 42 percent, with Johnson Controls and TE Connectivity share being 27 percent, and 31 percent, respectively. If Johnson Controls and TE Connectivity default on their obligations to the Company under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. The most significant amounts at risk under this Tax Sharing Agreement were resolved with the U.S. Tax Court and IRS Appeals resolutions reached in May 2016. However, the Tax Sharing Agreement remains in place with respect to income tax liabilities that are not the subject of such resolution, including certain state and international tax matters that remain open. The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tax Sharing Agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, primarily related to tax years that remain open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien and/or Tyco Electronics legal entities for periods prior to the 2007 separation. Refer to Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2019 for additional information. As part of the Company’s sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal on July 29, 2017, the Company has indemnified Cardinal for certain contingent tax liabilities related to the divested businesses that existed prior to the date of divestiture. The actual amounts that the Company may be required to ultimately accrue or pay could vary depending upon the outcome of the unresolved tax matters. In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees. The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, or cash flows.

Segment and Geographic Informat

Segment and Geographic Information	6 Months Ended
	Oct. 25, 2019
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Segment disclosures are on a performance basis consistent with internal management reporting. Net sales of the Company's reportable segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. There are certain corporate and centralized expenses that are not allocated to the segments. The Company’s management evaluates performance of the segments and allocates resources based on segment operating profit. Segment operating profit represents income before income taxes, excluding interest expense, amortization of intangible assets, centralized distribution costs, non-operating income or expense items, certain corporate charges, and other items not allocated to the segments. The financial information that is regularly reviewed by the Company's chief operating decision maker to assess performance and allocate resources changed during the first quarter of fiscal year 2020 to remove the impact of non-service pension and post-retirement benefit costs from segment results. This change did not have a material impact on the segment results reviewed. As a result of the change, the Company has revised the disclosure for the prior period to align with the current presentation. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2019. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment. The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements: Net Sales Three months ended (1) Six months ended (1) (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Cardiac and Vascular Group $ 2,855 $ 2,858 $ 5,645 $ 5,669 Minimally Invasive Therapies Group 2,142 2,047 4,242 4,099 Restorative Therapies Group 2,112 1,993 4,124 3,942 Diabetes Group 596 583 1,188 1,155 Total $ 7,706 $ 7,481 $ 15,199 $ 14,865 (1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Segment Operating Profit Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Cardiac and Vascular Group $ 1,128 $ 1,137 $ 2,183 $ 2,186 Minimally Invasive Therapies Group 823 792 1,593 1,568 Restorative Therapies Group 840 804 1,633 1,570 Diabetes Group 148 176 297 348 Segment operating profit 2,939 2,909 5,706 5,672 Interest expense (165) (241) (774) (483) Other non-operating income, net 108 52 209 238 Amortization of intangible assets (441) (445) (881) (891) Corporate (350) (342) (657) (645) Centralized distribution costs (424) (482) (768) (928) Restructuring and associated costs (94) (77) (218) (190) Acquisition-related items (27) (4) (46) (40) Certain litigation charges (121) — (168) (103) IPR&D charges — (15) — (15) Exit of businesses (41) — (41) (80) Debt tender premium and other charges — — 7 — Medical device regulations (10) — (18) — Contribution to Medtronic Foundation (80) — (80) — Income before income taxes $ 1,294 $ 1,355 $ 2,271 $ 2,535 Geographic Information Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. The following table presents net sales for the three and six months ended October 25, 2019 and October 26, 2018 for the Company's country of domicile, countries with significant concentrations, and all other countries: Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Ireland $ 23 $ 22 $ 43 $ 44 United States 4,129 4,045 8,046 7,909 Rest of world 3,554 3,414 7,110 6,912 Total other countries, excluding Ireland 7,683 7,459 15,156 14,821 Total $ 7,706 $ 7,481 $ 15,199 $ 14,865

Guarantor Financial Information

Guarantor Financial Information	6 Months Ended
	Oct. 25, 2019
Condensed Financial Statements, Captions [Line Items]
Guarantor Financial Information	Guarantor Financial Information Medtronic plc and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a wholly-owned subsidiary guarantor, each have provided full and unconditional guarantees of the obligations of Medtronic, Inc., a wholly-owned subsidiary issuer, under the Senior Notes (Medtronic Senior Notes) and full and unconditional guarantees of the obligations of Covidien International Finance S.A. (CIFSA), a wholly-owned subsidiary issuer, under the Senior Notes (CIFSA Senior Notes). The guarantees of the CIFSA Senior Notes are in addition to the guarantees of the CIFSA Senior Notes by Covidien Ltd. and Covidien Group Holdings Ltd., both of which are wholly-owned subsidiary guarantors of the CIFSA Senior Notes. Additionally, Medtronic plc and Medtronic, Inc. each have provided a full and unconditional guarantee of the obligations of Medtronic Luxco under the Medtronic Luxco Senior Notes. The following is a summary of these guarantees: Guarantees of Medtronic Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic, Inc. • Subsidiary Guarantor - Medtronic Luxco Guarantees of Medtronic Luxco Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic Luxco • Subsidiary Guarantor - Medtronic, Inc. Guarantees of CIFSA Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - CIFSA • Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. (CIFSA Subsidiary Guarantors) The following presents the Company’s consolidating statements of comprehensive income for the three and six months ended October 25, 2019 and October 26, 2018, condensed consolidating balance sheets at October 25, 2019 and April 26, 2019, and condensed consolidating statements of cash flows for the six months ended October 25, 2019 and October 26, 2018. The guarantees provided by the parent company guarantor and subsidiary guarantors are joint and several. Condensed consolidating financial information for Medtronic plc, Medtronic Luxco, Medtronic, Inc., CIFSA, and CIFSA Subsidiary Guarantors, on a stand-alone basis, is presented using the equity method of accounting for subsidiaries. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year.
Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Financial Statements, Captions [Line Items]
Guarantor Financial Information	Consolidating Statement of Comprehensive Income Three Months Ended October 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 385 $ — $ 7,706 $ (385) $ 7,706 Costs and expenses: Cost of products sold — 350 — 2,354 (310) 2,394 Research and development expense — 178 — 425 — 603 Selling, general, and administrative expense 4 431 — 2,185 — 2,620 Amortization of intangible assets — 3 — 438 — 441 Restructuring charges, net — 7 — 20 — 27 Certain litigation charges — — — 121 — 121 Other operating expense (income), net 13 (629) — 852 (87) 149 Operating profit (loss) (17) 45 — 1,311 12 1,351 Other non-operating (income) expense, net — (73) (241) (425) 631 (108) Interest expense 139 345 119 193 (631) 165 Equity in net (income) loss of subsidiaries (1,518) (581) (1,396) — 3,495 — Income (loss) before income taxes 1,362 354 1,518 1,543 (3,483) 1,294 Income tax provision (2) (30) — (45) — (77) Net income (loss) 1,364 384 1,518 1,588 (3,483) 1,371 Net income attributable to noncontrolling interests — — — (7) — (7) Net income (loss) attributable to Medtronic 1,364 384 1,518 1,581 (3,483) 1,364 Other comprehensive income (loss), net of tax (127) (76) (127) (192) 395 (127) Comprehensive income attributable to — — — (7) — (7) Total comprehensive income (loss) $ 1,237 $ 308 $ 1,391 $ 1,389 $ (3,088) $ 1,237
Guarantor Financial Information	Consolidating Statement of Comprehensive Income Six Months Ended October 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 811 $ — $ 15,199 $ (811) $ 15,199 Costs and expenses: Cost of products sold — 676 — 4,705 (621) 4,760 Research and development expense — 346 — 844 — 1,190 Selling, general, and administrative expense 7 809 — 4,347 — 5,163 Amortization of intangible assets — 6 — 875 — 881 Restructuring charges, net — 9 — 65 — 74 Certain litigation charges — 5 — 163 — 168 Other operating expense (income), net 26 (1,067) (7) 1,352 (177) 127 Operating profit (loss) (33) 27 7 2,848 (13) 2,836 Other non-operating (income) expense, net — (134) (486) (829) 1,240 (209) Interest expense 283 1,056 284 391 (1,240) 774 Equity in net (income) loss of subsidiaries (2,540) (1,192) (2,331) — 6,063 — Income (loss) before income taxes 2,224 297 2,540 3,286 (6,076) 2,271 Income tax provision (4) (159) — 186 — 23 Net income (loss) 2,228 456 2,540 3,100 (6,076) 2,248 Net income attributable to noncontrolling interests — — — (20) — (20) Net income (loss) attributable to Medtronic 2,228 456 2,540 3,080 (6,076) 2,228 Other comprehensive income (loss), net of tax 100 (29) 100 (83) 12 100 Comprehensive income attributable to — — — (20) — (20) Total comprehensive income (loss) $ 2,328 $ 427 $ 2,640 $ 2,997 $ (6,064) $ 2,328
Guarantor Financial Information	Consolidating Statement of Comprehensive Income Three Months Ended October 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 364 $ — $ 7,481 $ (364) $ 7,481 Costs and expenses: Cost of products sold — 280 — 2,162 (239) 2,203 Research and development expense — 176 — 414 — 590 Selling, general, and administrative expense 4 413 — 2,188 — 2,605 Amortization of intangible assets — 2 — 443 — 445 Restructuring charges, net — 1 — 23 — 24 Other operating expense (income), net 24 (672) — 834 (116) 70 Operating profit (loss) (28) 164 — 1,417 (9) 1,544 Other non-operating (income) expense, net — (138) (175) (429) 690 (52) Interest expense 108 482 113 228 (690) 241 Equity in net (income) loss of subsidiaries (1,249) (762) (1,187) — 3,198 — Income (loss) before income taxes 1,113 582 1,249 1,618 (3,207) 1,355 Income tax provision (2) (15) — 252 — 235 Net income (loss) 1,115 597 1,249 1,366 (3,207) 1,120 Net income attributable to noncontrolling interests — — — (5) — (5) Net income (loss) attributable to Medtronic 1,115 597 1,249 1,361 (3,207) 1,115 Other comprehensive income (loss), net of tax (289) (194) (289) (310) 790 (292) Comprehensive income attributable to noncontrolling interests — — — (2) — (2) Total comprehensive income (loss) $ 826 $ 403 $ 960 $ 1,054 $ (2,417) $ 826
Guarantor Financial Information	Consolidating Statement of Comprehensive Income Six Months Ended October 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 726 $ — $ 14,865 $ (726) $ 14,865 Costs and expenses: Cost of products sold — 553 — 4,330 (476) 4,407 Research and development expense — 344 — 831 — 1,175 Selling, general, and administrative expense 6 781 — 4,415 — 5,202 Amortization of intangible assets — 4 — 887 — 891 Restructuring charges, net — 11 — 75 — 86 Certain litigation charges — 78 — 25 — 103 Other operating expense (income), net 25 (931) — 1,349 (222) 221 Operating profit (loss) (31) (114) — 2,953 (28) 2,780 Other non-operating (income) expense, net — (297) (339) (934) 1,332 (238) Interest expense 208 946 216 445 (1,332) 483 Equity in net (income) loss of subsidiaries (2,425) (1,568) (2,302) — 6,295 — Income (loss) before income taxes 2,186 805 2,425 3,442 (6,323) 2,535 Income tax provision (4) (119) — 461 — 338 Net income (loss) 2,190 924 2,425 2,981 (6,323) 2,197 Net income attributable to noncontrolling interests — — — (7) — (7) Net income (loss) attributable to Medtronic 2,190 924 2,425 2,974 (6,323) 2,190 Other comprehensive income (loss), net of tax (873) (702) (873) (914) 2,486 (876) Comprehensive income attributable to noncontrolling interests — — — (4) — (4) Total comprehensive income (loss) $ 1,317 $ 222 $ 1,552 $ 2,063 $ (3,837) $ 1,317
Guarantor Financial Information	Condensed Consolidating Balance Sheet October 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ 20 $ 204 $ 3,738 $ — $ 3,962 Investments — — — 6,436 — 6,436 Accounts receivable, net — — — 6,118 — 6,118 Inventories, net — 200 — 4,079 (237) 4,042 Intercompany receivable 109 9,352 5 32,385 (41,851) — Other current assets 7 183 2 1,903 — 2,095 Total current assets 116 9,755 211 54,659 (42,088) 22,653 Property, plant, and equipment, net — 1,527 — 3,229 — 4,756 Goodwill — 2,009 — 37,943 — 39,952 Other intangible assets, net — 93 — 19,682 — 19,775 Tax assets — 520 — 1,284 — 1,804 Investment in subsidiaries 66,705 73,122 67,007 — (206,834) — Intercompany loans receivable 3,000 21 30,240 25,120 (58,381) — Other assets — 350 — 1,763 — 2,113 Total assets $ 69,821 $ 87,397 $ 97,458 $ 143,680 $ (307,303) $ 91,053 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 375 $ — $ 875 Accounts payable — 494 — 1,471 — 1,965 Intercompany payable — 21,687 10,697 9,467 (41,851) — Accrued compensation 6 728 — 1,039 — 1,773 Accrued income taxes — — — 442 — 442 Other accrued expenses 21 337 70 2,687 — 3,115 Total current liabilities 27 23,746 10,767 15,481 (41,851) 8,170 Long-term debt — 9,783 13,552 1,417 — 24,752 Accrued compensation and retirement benefits — 1,001 — 572 — 1,573 Accrued income taxes 10 722 — 1,973 — 2,705 Intercompany loans payable 19,206 9,011 13,459 16,705 (58,381) — Deferred tax liabilities — — — 1,376 — 1,376 Other liabilities — 265 — 1,493 — 1,758 Total liabilities 19,243 44,528 37,778 39,017 (100,232) 40,334 Shareholders’ equity 50,578 42,869 59,680 104,522 (207,071) 50,578 Noncontrolling interests — — — 141 — 141 Total equity 50,578 42,869 59,680 104,663 (207,071) 50,719 Total liabilities and equity $ 69,821 $ 87,397 $ 97,458 $ 143,680 $ (307,303) $ 91,053
Guarantor Financial Information	Condensed Consolidating Balance Sheet April 26, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ 18 $ 1 $ 4,374 $ — $ 4,393 Investments — — — 5,455 — 5,455 Accounts receivable, net — — — 6,222 — 6,222 Inventories, net — 188 — 3,792 (227) 3,753 Intercompany receivable 40 9,407 6 19,170 (28,623) — Other current assets 10 190 3 1,941 — 2,144 Total current assets 50 9,803 10 40,954 (28,850) 21,967 Property, plant, and equipment, net — 1,480 — 3,195 — 4,675 Goodwill — 2,009 — 37,950 — 39,959 Other intangible assets, net — 99 — 20,461 — 20,560 Tax assets — 568 — 951 — 1,519 Investment in subsidiaries 64,352 71,129 65,012 — (200,493) — Intercompany loans receivable 3,000 21 27,858 35,398 (66,277) — Other assets — 216 — 798 — 1,014 Total assets $ 67,402 $ 85,325 $ 92,880 $ 139,707 $ (295,620) $ 89,694 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 338 $ — $ 838 Accounts payable — 481 — 1,472 — 1,953 Intercompany payable — 11,971 7,200 9,452 (28,623) — Accrued compensation 3 913 — 1,273 — 2,189 Accrued income taxes — — — 567 — 567 Other accrued expenses 20 331 53 2,521 — 2,925 Total current liabilities 23 14,196 7,253 15,623 (28,623) 8,472 Long-term debt — 14,418 8,621 1,447 — 24,486 Accrued compensation and retirement benefits — 1,069 — 582 — 1,651 Accrued income taxes 10 692 — 2,136 — 2,838 Intercompany loans payable 17,278 12,613 19,682 16,704 (66,277) — Deferred tax liabilities — — — 1,278 — 1,278 Other liabilities — 133 — 624 — 757 Total liabilities 17,311 43,121 35,556 38,394 (94,900) 39,482 Shareholders' equity 50,091 42,204 57,324 101,192 (200,720) 50,091 Noncontrolling interests — — — 121 — 121 Total equity 50,091 42,204 57,324 101,313 (200,720) 50,212 Total liabilities and equity $ 67,402 $ 85,325 $ 92,880 $ 139,707 $ (295,620) $ 89,694
Guarantor Financial Information	Condensed Consolidating Statement of Cash Flows Six Months Ended October 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 49 $ (967) $ 295 $ 4,000 $ — $ 3,377 Investing Activities: Acquisitions, net of cash acquired — — — (201) — (201) Additions to property, plant, and equipment — (158) — (426) — (584) Purchases of investments — — — (4,226) — (4,226) Sales and maturities of investments — — — 3,260 — 3,260 Other investing activities — — (5) (11) — (16) Net cash provided by (used in) investing activities — (158) (5) (1,604) — (1,767) Financing Activities: Change in current debt obligations, net — — — 42 — 42 Issuance of long-term debt — — 5,567 1 — 5,568 Payments on long-term debt — (5,016) (515) (63) — (5,594) Dividends to shareholders (1,447) — — — — (1,447) Issuance of ordinary shares 432 — — — — 432 Repurchase of ordinary shares (962) — — — — (962) Net intercompany loan borrowings (repayments) 1,928 6,143 (5,105) (2,966) — — Other financing activities — — (34) (20) — (54) Net cash provided by (used in) financing activities (49) 1,127 (87) (3,006) — (2,015) Effect of exchange rate changes on cash and cash equivalents — — — (26) — (26) Net change in cash and cash equivalents — 2 203 (636) — (431) Cash and cash equivalents at beginning of period — 18 1 4,374 — 4,393 Cash and cash equivalents at end of period $ — $ 20 $ 204 $ 3,738 $ — $ 3,962
Guarantor Financial Information	Condensed Consolidating Statement of Cash Flows Six Months Ended October 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 147 $ (1,335) $ 123 $ 3,930 $ — $ 2,865 Investing Activities: Acquisitions, net of cash acquired — — — (119) — (119) Additions to property, plant, and equipment — (133) — (364) — (497) Purchases of investments — — — (1,444) — (1,444) Sales and maturities of investments — 76 — 2,748 — 2,824 Capital contribution paid (18) (32) — — 50 — Net cash provided by (used in) investing activities (18) (89) — 821 50 764 Financing Activities: Change in current debt obligations, net — — (696) (4) — (700) Issuance of long-term debt — — — 1 — 1 Payments on long-term debt — — — (17) — (17) Dividends to shareholders (1,351) — — — — (1,351) Issuance of ordinary shares 800 — — — — 800 Repurchase of ordinary shares (2,047) — — — — (2,047) Net intercompany loan borrowings (repayments) 2,469 1,428 1,067 (4,964) — — Capital contribution received — — — 50 (50) — Other financing activities — — — 11 — 11 Net cash provided by (used in) financing activities (129) 1,428 371 (4,923) (50) (3,303) Effect of exchange rate changes on cash and cash equivalents — — — (84) — (84) Net change in cash and cash equivalents — 4 494 (256) — 242 Cash and cash equivalents at beginning of period — 20 1 3,648 — 3,669 Cash and cash equivalents at end of period $ — $ 24 $ 495 $ 3,392 $ — $ 3,911
CIFSA Senior Notes
Condensed Financial Statements, Captions [Line Items]
Guarantor Financial Information	Consolidating Statement of Comprehensive Income Three Months Ended October 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,706 $ — $ 7,706 Costs and expenses: Cost of products sold — — — 2,394 — 2,394 Research and development expense — — — 603 — 603 Selling, general, and administrative expense 4 — 1 2,615 — 2,620 Amortization of intangible assets — — — 441 — 441 Restructuring charges, net — — — 27 — 27 Certain litigation charges — — — 121 — 121 Other operating expense (income), net 13 — — 136 — 149 Operating profit (loss) (17) — (1) 1,369 — 1,351 Other non-operating (income) expense, net — (32) (248) (362) 534 (108) Interest expense 139 191 119 250 (534) 165 Equity in net (income) loss of subsidiaries (1,518) (1,220) (1,390) — 4,128 — Income (loss) before income taxes 1,362 1,061 1,518 1,481 (4,128) 1,294 Income tax provision (2) — — (75) — (77) Net income (loss) 1,364 1,061 1,518 1,556 (4,128) 1,371 Net income attributable to noncontrolling interests — — — (7) — (7) Net income (loss) attributable to Medtronic 1,364 1,061 1,518 1,549 (4,128) 1,364 Other comprehensive income (loss), net of tax (127) (95) (127) (180) 402 (127) Comprehensive income attributable to — — — (7) — (7) Total comprehensive income (loss) $ 1,237 $ 966 $ 1,391 $ 1,369 $ (3,726) $ 1,237
Guarantor Financial Information	Consolidating Statement of Comprehensive Income Six Months Ended October 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 15,199 $ — $ 15,199 Costs and expenses: Cost of products sold — — — 4,760 — 4,760 Research and development expense — — — 1,190 — 1,190 Selling, general, and administrative expense 7 — 1 5,155 — 5,163 Amortization of intangible assets — — — 881 — 881 Restructuring charges, net — — — 74 — 74 Certain litigation charges — — — 168 — 168 Other operating expense (income), net 26 — (7) 108 — 127 Operating profit (loss) (33) — 6 2,863 — 2,836 Other non-operating (income) expense, net — (95) (501) (760) 1,147 (209) Interest expense 283 412 284 942 (1,147) 774 Equity in net (income) loss of subsidiaries (2,540) (2,188) (2,317) — 7,045 — Income (loss) before income taxes 2,224 1,871 2,540 2,681 (7,045) 2,271 Income tax provision (4) — — 27 — 23 Net income (loss) 2,228 1,871 2,540 2,654 (7,045) 2,248 Net income attributable to noncontrolling interests — — — (20) — (20) Net income (loss) attributable to Medtronic 2,228 1,871 2,540 2,634 (7,045) 2,228 Other comprehensive income (loss), net of tax 100 (11) 100 (53) (36) 100 Comprehensive income attributable to — — — (20) — (20) Total comprehensive income (loss) $ 2,328 $ 1,860 $ 2,640 $ 2,581 $ (7,081) $ 2,328
Guarantor Financial Information	Consolidating Statement of Comprehensive Income Three Months Ended October 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,481 $ — $ 7,481 Costs and expenses: Cost of products sold — — — 2,203 — 2,203 Research and development expense — — — 590 — 590 Selling, general, and administrative expense 4 — 1 2,600 — 2,605 Amortization of intangible assets — — — 445 — 445 Restructuring charges, net — — — 24 — 24 Other operating expense, net 24 — — 46 — 70 Operating profit (loss) (28) — (1) 1,573 — 1,544 Other non-operating (income) expense, net — (9) (183) (150) 290 (52) Interest expense 108 22 113 288 (290) 241 Equity in net (income) loss of subsidiaries (1,249) (629) (1,180) — 3,058 — Income (loss) before income taxes 1,113 616 1,249 1,435 (3,058) 1,355 Income tax provision (2) — — 237 — 235 Net income (loss) 1,115 616 1,249 1,198 (3,058) 1,120 Net income attributable to noncontrolling interests — — — (5) — (5) Net income (loss) attributable to Medtronic 1,115 616 1,249 1,193 (3,058) 1,115 Other comprehensive income (loss), net of tax (289) (91) (289) (295) 672 (292) Comprehensive income attributable to — — — (2) — (2) Total comprehensive income (loss) $ 826 $ 525 $ 960 $ 901 $ (2,386) $ 826
Guarantor Financial Information	Consolidating Statement of Comprehensive Income Six Months Ended October 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 14,865 $ — $ 14,865 Costs and expenses: Cost of products sold — — — 4,407 — 4,407 Research and development expense — — — 1,175 — 1,175 Selling, general, and administrative expense 6 — 1 5,195 — 5,202 Amortization of intangible assets — — — 891 — 891 Restructuring charges, net — — — 86 — 86 Certain litigation charges — — — 103 — 103 Other operating expense, net 25 — — 196 — 221 Operating profit (loss) (31) — (1) 2,812 — 2,780 Other non-operating (income) expense, net — (19) (352) (424) 557 (238) Interest expense 208 43 216 573 (557) 483 Equity in net (income) loss of subsidiaries (2,425) (1,602) (2,290) — 6,317 — Income (loss) before income taxes 2,186 1,578 2,425 2,663 (6,317) 2,535 Income tax provision (4) — — 342 — 338 Net income (loss) 2,190 1,578 2,425 2,321 (6,317) 2,197 Net income attributable to noncontrolling interests — — — (7) — (7) Net income (loss) attributable to Medtronic 2,190 1,578 2,425 2,314 (6,317) 2,190 Other comprehensive income (loss), net of tax (873) (132) (873) (879) 1,881 (876) Comprehensive loss attributable to — — — (4) — (4) Total comprehensive income (loss) $ 1,317 $ 1,446 $ 1,552 $ 1,438 $ (4,436) $ 1,317
Guarantor Financial Information	Condensed Consolidating Balance Sheet October 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 204 $ 3,758 $ — $ 3,962 Investments — — — 6,436 — 6,436 Accounts receivable, net — — — 6,118 — 6,118 Inventories, net — — — 4,042 — 4,042 Intercompany receivable 109 — 1,387 10,725 (12,221) — Other current assets 7 — 2 2,086 — 2,095 Total current assets 116 — 1,593 33,165 (12,221) 22,653 Property, plant, and equipment, net — — — 4,756 — 4,756 Goodwill — — — 39,952 — 39,952 Other intangible assets, net — — — 19,775 — 19,775 Tax assets — — — 1,804 — 1,804 Investment in subsidiaries 66,705 58,863 65,631 — (191,199) — Intercompany loans receivable 3,000 3,798 30,240 40,585 (77,623) — Other assets — — — 2,113 — 2,113 Total assets $ 69,821 $ 62,661 $ 97,464 $ 142,150 $ (281,043) $ 91,053 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 875 $ — $ 875 Accounts payable — — — 1,965 — 1,965 Intercompany payable — 1,322 10,698 201 (12,221) — Accrued compensation 6 — — 1,767 — 1,773 Accrued income taxes — — — 442 — 442 Other accrued expenses 21 11 75 3,008 — 3,115 Total current liabilities 27 1,333 10,773 8,258 (12,221) 8,170 Long-term debt — 1,309 13,552 9,891 — 24,752 Accrued compensation and retirement benefits — — — 1,573 — 1,573 Accrued income taxes 10 — — 2,695 — 2,705 Intercompany loans payable 19,206 27,126 13,458 17,833 (77,623) — Deferred tax liabilities — — — 1,376 — 1,376 Other liabilities — — 1 1,757 — 1,758 Total liabilities 19,243 29,768 37,784 43,383 (89,844) 40,334 Shareholders’ equity 50,578 32,893 59,680 98,626 (191,199) 50,578 Noncontrolling interests — — — 141 — 141 Total equity 50,578 32,893 59,680 98,767 (191,199) 50,719 Total liabilities and equity $ 69,821 $ 62,661 $ 97,464 $ 142,150 $ (281,043) $ 91,053
Guarantor Financial Information	Condensed Consolidating Balance Sheet April 26, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 1 $ 4,392 $ — $ 4,393 Investments — — — 5,455 — 5,455 Accounts receivable, net — — — 6,222 — 6,222 Inventories, net — — — 3,753 — 3,753 Intercompany receivable 40 — 1,374 7,212 (8,626) — Other current assets 10 — 3 2,131 — 2,144 Total current assets 50 — 1,378 29,165 (8,626) 21,967 Property, plant, and equipment, net — — — 4,675 — 4,675 Goodwill — — — 39,959 — 39,959 Other intangible assets, net — — — 20,560 — 20,560 Tax assets — — — 1,519 — 1,519 Investment in subsidiaries 64,352 39,557 63,651 — (167,560) — Intercompany loans receivable 3,000 4,119 27,858 29,002 (63,979) — Other assets — — — 1,014 — 1,014 Total assets $ 67,402 $ 43,676 $ 92,887 $ 125,894 $ (240,165) $ 89,694 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 838 $ — $ 838 Accounts payable — — — 1,953 — 1,953 Intercompany payable — 1,308 7,199 119 (8,626) — Accrued compensation 3 — — 2,186 — 2,189 Accrued income taxes — — — 567 — 567 Other accrued expenses 20 11 60 2,834 — 2,925 Total current liabilities 23 1,319 7,259 8,497 (8,626) 8,472 Long-term debt — 1,354 8,621 14,511 — 24,486 Accrued compensation and retirement benefits — — — 1,651 — 1,651 Accrued income taxes 10 — — 2,828 — 2,838 Intercompany loans payable 17,278 9,320 19,682 17,699 (63,979) — Deferred tax liabilities — — — 1,278 — 1,278 Other liabilities — — 1 756 — 757 Total liabilities 17,311 11,993 35,563 47,220 (72,605) 39,482 Shareholders' equity 50,091 31,683 57,324 78,553 (167,560) 50,091 Noncontrolling interests — — — 121 — 121 Total Equity 50,091 31,683 57,324 78,674 (167,560) 50,212 Total liabilities and equity $ 67,402 $ 43,676 $ 92,887 $ 125,894 $ (240,165) $ 89,694
Guarantor Financial Information	Condensed Consolidating Statement of Cash Flows Six Months Ended October 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 49 $ (319) $ 309 $ 3,338 $ — $ 3,377 Investing Activities: Acquisitions, net of cash acquired — — — (201) — (201) Additions to property, plant, and equipment — — — (584) — (584) Purchases of investments — — — (4,226) — (4,226) Sales and maturities of investments — — — 3,260 — 3,260 Capital contribution paid — (43) — — 43 — Other investing activities — — (5) (11) — (16) Net cash provided by (used in) investing activities — (43) (5) (1,762) 43 (1,767) Financing Activities: Change in current debt obligations, net — — — 42 — 42 Issuance of long-term debt — — 5,567 1 — 5,568 Payments on long-term debt — (44) (515) (5,035) — (5,594) Dividends to shareholders (1,447) — — — — (1,447) Issuance of ordinary shares 432 — — — — 432 Repurchase of ordinary shares (962) — — — — (962) Net intercompany loan borrowings (repayments) 1,928 406 (5,119) 2,785 — — Capital contribution received — — — 43 (43) — Other financing activities — — (34) (20) — (54) Net cash provided by (used in) financing activities (49) 362 (101) (2,184) (43) (2,015) Effect of exchange rate changes on cash and cash equivalents — — — (26) — (26) Net change in cash and cash equivalents — — 203 (634) — (431) Cash and cash equivalents at beginning of period — — 1 4,392 — 4,393 Cash and cash equivalents at end of period $ — $ — $ 204 $ 3,758 $ — $ 3,962
Guarantor Financial Information	Condensed Consolidating Statement of Cash Flows Six Months Ended October 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 147 $ (35) $ 136 $ 2,617 $ — $ 2,865 Investing Activities: Acquisitions, net of cash acquired — — — (119) — (119) Additions to property, plant, and equipment — — — (497) — (497) Purchases of investments — — — (1,444) — (1,444) Sales and maturities of investments — — — 2,824 — 2,824 Capital contributions paid (18) (187) — — 205 — Net cash provided by (used in) investing activities (18) (187) — 764 205 764 Financing Activities: Change in current debt obligations, net — — (697) (3) — (700) Issuance of long-term debt — — — 1 — 1 Payments on long-term debt — — — (17) — (17) Dividends to shareholders (1,351) — — — — (1,351) Issuance of ordinary shares 800 — — — — 800 Repurchase of ordinary shares (2,047) — — — — (2,047) Net intercompany loan borrowings (repayments) 2,469 222 1,056 (3,747) — — Capital contributions received — — — 205 (205) — Other financing activities — — — 11 — 11 Net cash provided by (used in) financing activities (129) 222 359 (3,550) (205) (3,303) Effect of exchange rate changes on cash and cash equivalents — — — (84) — (84) Net change in cash and cash equivalents — — 495 (253) — 242 Cash and cash equivalents at beginning of period — — 1 3,668 — 3,669 Cash and cash equivalents at end of period $ — $ — $ 496 $ 3,415 $ — $ 3,911

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Oct. 25, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.
Consolidation	The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation.
Fiscal Period	The Company’s fiscal years 2020, 2019, and 2018 will end or ended on April 24, 2020, April 26, 2019, and April 27, 2018, respectively.
New Accounting Pronouncements	Recently Adopted Leases In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. This guidance also requires additional qualitative and quantitative lease related disclosures in the notes to the consolidated financial statements. The Company adopted this guidance using the modified retrospective method in the first quarter of fiscal year 2020. During the implementation of this recently adopted accounting standard, the Company elected the package of practical expedients available under the transition guidance that allowed an entity not to reassess whether any expired or existing contracts are or contain leases, the classification for any expired or existing leases or any initial direct costs for existing leases. Further, the Company made accounting policy elections to not apply the recognition requirements to short-term leases and to account for lease and nonlease components as a single lease component. The adoption of this guidance resulted in the recognition of right-of-use assets and lease liabilities in an amount of approximately $1.0 billion, an immaterial cumulative-effect adjustment to retained earnings as of April 27, 2019, and expansion of lease related disclosures . The adoption of this guidance did not have a material impact on the Company's consolidated statements of income or consolidated statements of cash flows. Others

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Oct. 25, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The table below illustrates net sales by segment and division for the three and six months ended October 25, 2019 and October 26, 2018: Three months ended (1) Six months ended (1) (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Cardiac Rhythm & Heart Failure $ 1,426 $ 1,472 $ 2,807 $ 2,898 Coronary & Structural Heart 955 906 1,896 1,823 Aortic, Peripheral, & Venous 474 480 942 948 Cardiac and Vascular Group 2,855 2,858 5,645 5,669 Surgical Innovations 1,454 1,393 2,871 2,790 Respiratory, Gastrointestinal, & Renal 688 654 1,371 1,309 Minimally Invasive Therapies Group 2,142 2,047 4,242 4,099 Brain Therapies 772 701 1,512 1,375 Spine 692 656 1,349 1,308 Specialty Therapies 333 322 656 631 Pain Therapies 315 314 607 628 Restorative Therapies Group 2,112 1,993 4,124 3,942 Diabetes Group 596 583 1,188 1,155 Total $ 7,706 $ 7,481 $ 15,199 $ 14,865 (1) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum. During the first quarter of fiscal year 2020, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from Transformative Solutions product lines previously included in Specialty Therapies to a product line under Brain Therapies. As a result, net sales for fiscal year 2019 have been recast to adjust for this realignment. The table below illustrates net sales by market geography for each segment for the three and six months ended October 25, 2019 and October 26, 2018: U.S. (1)(4) Non-U.S. Developed Markets (2)(4) Emerging Markets (3)(4) Three months ended Three months ended Three months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Cardiac and Vascular Group $ 1,455 $ 1,482 $ 890 $ 895 $ 510 $ 481 Minimally Invasive Therapies Group 922 872 782 772 438 403 Restorative Therapies Group 1,440 1,357 416 412 256 224 Diabetes Group 311 334 226 203 59 46 Total $ 4,129 $ 4,045 $ 2,315 $ 2,282 $ 1,262 $ 1,154 U.S. (1)(4) Non-U.S. Developed Markets (2)(4) Emerging Markets (3)(4) Six months ended Six months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Cardiac and Vascular Group $ 2,816 $ 2,871 $ 1,820 $ 1,842 $ 1,009 $ 956 Minimally Invasive Therapies Group 1,835 1,729 1,573 1,600 834 770 Restorative Therapies Group 2,778 2,651 842 840 504 451 Diabetes Group 618 658 457 406 113 91 Total $ 8,046 $ 7,909 $ 4,692 $ 4,688 $ 2,460 $ 2,268 (1) U.S. includes the United States and U.S. territories. (2) Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe. (3) Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Oct. 25, 2019
Business Combinations [Abstract]
Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions	The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Beginning balance $ 269 $ 208 $ 222 $ 173 Purchase price contingent consideration 7 11 65 46 Payments (15) (1) (29) (7) Change in fair value (1) (15) 2 (9) Ending balance $ 260 $ 203 $ 260 $ 203
Fair Value Measurements, Contingent Consideration, Significant Unobservable Inputs	The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: Fair Value at (in millions) October 25, 2019 Valuation Technique Unobservable Input Range Discount rate 11.5% - 32.5% Revenue and other performance-based payments $135 Discounted cash flow Probability of payment 40% - 100% Projected fiscal year of payment 2020 - 2026 Discount rate 5.5% Product development and other milestone-based payments $125 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2020 - 2027

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Oct. 25, 2019
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	The following table summarizes the activity related to the Enterprise Excellence restructuring program for the six months ended October 25, 2019: (in millions) Employee Termination Benefits Associated Costs (1) Asset Write-Downs (2) Other Costs Total April 26, 2019 $ 101 $ 9 $ — $ 12 $ 122 Charges 79 139 6 7 231 Cash payments (118) (136) — (8) (262) Settled non-cash — — (6) — (6) Accrual adjustments (6) — — (7) (13) October 25, 2019 $ 56 $ 12 $ — $ 4 $ 72 (1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses. (2) Recognized within cost of products sold in the consolidated statements of income.

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Oct. 25, 2019
Investments [Abstract]
Investments by Category and Related Balance Sheet Classification, Debt Securities	The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at October 25, 2019 and April 26, 2019: October 25, 2019 Valuation Balance Sheet Classification (in millions) Cost Unrealized Unrealized Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 565 $ 15 $ — $ 580 $ 580 $ — Level 2: Corporate debt securities 3,814 43 (16) 3,841 3,841 — U.S. government and agency securities 858 — (1) 857 857 — Mortgage-backed securities 634 11 (13) 632 632 — Non-U.S. government and agency securities 13 — — 13 13 — Other asset-backed securities 514 2 (3) 513 513 — Total Level 2 5,833 56 (33) 5,856 5,856 — Level 3: Auction rate securities 47 — (3) 44 — 44 Total available-for-sale debt securities $ 6,445 $ 71 $ (36) $ 6,480 $ 6,436 $ 44 April 26, 2019 Valuation Balance Sheet Classification (in millions) Cost Unrealized Unrealized Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 529 $ 1 $ (7) $ 523 $ 523 $ — Level 2: Corporate debt securities 3,500 14 (21) 3,493 3,493 — U.S. government and agency securities 387 1 (7) 381 381 — Mortgage-backed securities 537 3 (20) 520 520 — Non-U.S. government and agency securities 11 — — 11 11 — Other asset-backed securities 529 1 (3) 527 527 — Total Level 2 4,964 19 (51) 4,932 4,932 — Level 3: Auction rate securities 47 — (3) 44 — 44 Total available-for-sale debt securities $ 5,540 $ 20 $ (61) $ 5,499 $ 5,455 $ 44
Available-For-Sale Debt Securities in Continuous Unrealized Loss Position	The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at October 25, 2019 and April 26, 2019: October 25, 2019 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Fair Value Unrealized U.S. government and agency securities $ 140 $ — $ 180 $ (1) Corporate debt securities 484 (9) 129 (7) Mortgage-backed securities 91 (1) 89 (12) Non-U.S. government and agency securities 2 — — — Other asset-backed securities 167 (1) 156 (2) Auction rate securities — — 44 (3) Total $ 884 $ (11) $ 598 $ (25) April 26, 2019 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Fair Value Unrealized U.S. government and agency securities $ 130 $ (1) $ 649 $ (13) Corporate debt securities 582 (5) 1,153 (16) Mortgage-backed securities 73 (1) 250 (19) Other asset-backed securities 290 (2) 85 (1) Auction rate securities — — 44 (3) Total $ 1,075 $ (9) $ 2,181 $ (52)
Activity Related to the Company's Debt Securities Portfolio	Activity related to the Company’s debt securities portfolio is as follows: Three months ended Six months Ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Proceeds from sales $ 1,691 $ 804 $ 3,258 $ 1,916 Gross realized gains 4 2 8 8 Gross realized losses (4) (12) (12) (19)
Available-for-sale Debt Securities Contractual Maturities	The October 25, 2019 balance of available-for-sale debt securities by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) October 25, 2019 Due in one year or less $ 1,975 Due after one year through five years 2,578 Due after five years through ten years 1,881 Due after ten years 46 Total $ 6,480
Summary of Equity and Other Investments	The following table summarizes the Company's equity and other investments at October 25, 2019 and April 26, 2019, which are classified as other assets in the consolidated balance sheets: (in millions) October 25, 2019 April 26, 2019 Investments without readily determinable fair values $ 366 $ 308 Equity method and other investments 66 64 Total equity and other investments $ 432 $ 372
Activity Related to the Company's Equity and Other Investments Portfolio	The table below includes activity related to the Company’s portfolio of equity and other investments. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income. Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Proceeds from sales $ — $ — $ 2 $ 908 Gross gains 14 9 14 123 Gross losses — (13) — (29) Impairment losses recognized (2) (12) (3) (12)

Financing Arrangements (Tables)

Financing Arrangements (Tables)	6 Months Ended
	Oct. 25, 2019
Debt Disclosure [Abstract]
Long-term Debt	The Company's debt obligations consisted of the following: (in millions) Maturity by October 25, 2019 April 26, 2019 Current debt obligations 2020 $ 875 $ 838 Long-term debt 0.000 percent two 2021 1,666 1,681 Floating rate two 2021 833 560 4.125 percent ten 2021 — 500 3.150 percent seven 2022 1,534 2,500 3.125 percent ten 2022 — 675 3.200 percent ten 2023 650 650 0.375 percent four 2023 1,666 1,681 2.750 percent ten 2023 530 530 0.000 percent four 2023 833 — 2.950 percent ten 2024 310 310 3.625 percent ten 2024 432 850 3.500 percent ten 2025 2,700 4,000 0.250 percent seven 2026 1,111 — 1.125 percent eight 2027 1,666 1,681 3.350 percent ten 2027 368 850 1.625 percent twelve 2031 1,111 1,121 1.000 percent thirteen 2032 1,111 — 4.375 percent twenty 2035 1,932 2,382 6.550 percent thirty 2038 253 284 2.250 percent twenty 2039 1,111 1,121 6.500 percent thirty 2039 158 183 5.550 percent thirty 2040 224 306 1.500 percent twenty 2040 1,111 — 4.500 percent thirty 2042 105 129 4.000 percent thirty 2043 305 325 4.625 percent thirty 2044 127 177 4.625 percent thirty 2045 1,813 1,963 1.750 percent thirty 2050 1,111 — Bank borrowings 2021 - 2022 80 83 Debt (discount) premium, net 2020 - 2050 (15) 29 Finance lease obligations 2021 - 2033 27 10 Interest rate swaps N/A — 9 Deferred financing costs 2020 - 2050 (111) (104) Long-term debt $ 24,752 $ 24,486

Derivatives and Currency Exch_2

Derivatives and Currency Exchange Risk Management (Tables)	6 Months Ended
	Oct. 25, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Amount and Location of Gains (Losses) in Statements of Income, Derivative Instruments Not Designated as Hedging Instruments	The amounts and classification of the gains (losses) in the consolidated statements of income related to derivative instruments not designated as hedging instruments for the three and six months ended October 25, 2019 and October 26, 2018 were as follows: Three months ended Six months ended (in millions) Classification October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Currency exchange rate contracts Other operating expense, net $ 12 $ 71 $ 6 $ 201 Total return swaps Other operating expense, net (1) (11) 4 — Total $ 11 $ 60 $ 10 $ 201
Amounts of Gains (Losses) Recognized in AOCI	The amount of the gains (losses) recognized in AOCI related to the currency exchange rate contract derivative instruments designated as cash flow hedges for the three and six months ended October 25, 2019 and October 26, 2018 were as follows: Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Currency exchange rate contracts $ 76 $ 174 $ 103 $ 444
Amount and Location of Gains (Losses) in Statements of Income	The amount of the gains (losses) recognized in the consolidated statements of income related to derivative instruments designated as cash flow hedges for the three and six months ended October 25, 2019 and October 26, 2018 were as follows: Three months ended Six months ended October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 (in millions) Other operating expense, net Other operating expense, net Other operating expense, net Other operating expense, net Total amounts of income and expense line items presented in the consolidated statements of income in which the effects of cash flow hedges are recorded $ 149 $ 70 $ 127 $ 221 Currency exchange rate contracts designated as cash flow hedges: Amount of gain (loss) reclassified from AOCI into income 68 11 125 8
Schedule of Amounts Recorded on Consolidated Balance Sheet Related to Cumulative Basis Adjustments for Fair Value Hedges	The following amounts were recorded on the consolidated balance sheet related to the cumulative basis adjustments for fair value hedges: (in millions) Carrying Amount of Hedged Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Assets/(Liabilities) Location on the Consolidated Balance Sheet October 25, 2019 April 26, 2019 October 25, 2019 April 26, 2019 Long-term debt $ — $ (1,175) $ — $ 9
Amount and Location of Gains (Losses) in Statements of Income, Derivative Instruments Designated as Net Investment Hedges	The amount and classifications of the gains recognized in the consolidated statements of income for the portion of the net investment hedges excluded from the measurement of hedge effectiveness were as follows: Three months ended Six months ended (in millions) Classification October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Net investment hedges Other operating expense, net $ — $ — $ (7) $ —
Amounts of Gains (Losses) Recognized in AOCI for Net Investment Hedges	The amount of the gains recognized in AOCI related to instruments designated as net investment hedges for the three and six months ended October 25, 2019 and October 26, 2018 were as follows: Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Net investment hedges $ 53 $ — $ 152 $ —
Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets	The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at October 25, 2019 and April 26, 2019. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments and are further segregated by type of contract within those two categories. October 25, 2019 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 204 Other accrued expenses $ 3 Currency exchange rate contracts Other assets 86 Other liabilities 4 Total derivatives designated as hedging instruments 290 7 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 21 Other accrued expenses 24 Total return swap Other current assets 2 Other accrued expenses — Cross currency interest rate contracts Other current assets 6 Other accrued expenses — Total derivatives not designated as hedging instruments 29 24 Total derivatives $ 319 $ 31 April 26, 2019 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 234 Other accrued expenses $ 1 Interest rate contracts Other assets 9 Other liabilities — Currency exchange rate contracts Other assets 78 Other liabilities 1 Total derivatives designated as hedging instruments 321 2 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 23 Other accrued expenses 17 Total return swaps Other current assets 15 Other accrued expenses — Cross currency interest rate contracts Other current assets 6 Other accrued expenses — Total derivatives not designated as hedging instruments 44 17 Total derivatives $ 365 $ 19
Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis. October 25, 2019 April 26, 2019 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 311 $ 8 $ 335 $ 30 Derivative liabilities 31 — 19 —
Offsetting Assets	The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. October 25, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 311 $ (29) $ (10) $ 272 Total return swaps 2 — — 2 Cross currency interest rate contracts 6 — — 6 319 (29) (10) 280 Derivative liabilities: Currency exchange rate contracts (31) 29 — (2) Total return swaps — — — — Total $ 288 $ — $ (10) $ 278 April 26, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 335 $ (9) $ (43) $ 283 Interest rate contracts 9 — (1) 8 Total return swaps 15 — — 15 Cross currency interest rate contracts 6 — — 6 365 (9) (44) 312 Derivative liabilities: Currency exchange rate contracts (19) 9 — (10) (19) 9 — (10) Total $ 346 $ — $ (44) $ 302
Offsetting Liabilities	The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. October 25, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 311 $ (29) $ (10) $ 272 Total return swaps 2 — — 2 Cross currency interest rate contracts 6 — — 6 319 (29) (10) 280 Derivative liabilities: Currency exchange rate contracts (31) 29 — (2) Total return swaps — — — — Total $ 288 $ — $ (10) $ 278 April 26, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 335 $ (9) $ (43) $ 283 Interest rate contracts 9 — (1) 8 Total return swaps 15 — — 15 Cross currency interest rate contracts 6 — — 6 365 (9) (44) 312 Derivative liabilities: Currency exchange rate contracts (19) 9 — (10) (19) 9 — (10) Total $ 346 $ — $ (44) $ 302

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Oct. 25, 2019
Inventory Disclosure [Abstract]
Inventory Balances	Inventory balances, net of reserves, were as follows: (in millions) October 25, 2019 April 26, 2019 Finished goods $ 2,686 $ 2,476 Work in-process 594 572 Raw materials 762 705 Total $ 4,042 $ 3,753

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Oct. 25, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The following table presents the changes in the carrying amount of goodwill by segment: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 26, 2019 $ 6,854 $ 20,381 $ 10,821 $ 1,903 $ 39,959 Goodwill as a result of acquisitions — 11 65 16 92 Purchase accounting adjustments 9 2 (5) — 6 Currency translation and other (1) (62) (42) — (105) October 25, 2019 $ 6,862 $ 20,332 $ 10,839 $ 1,919 $ 39,952
Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets	The following table presents the gross carrying amount and accumulated amortization of intangible assets: October 25, 2019 April 26, 2019 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,967 $ (4,581) $ 16,944 $ (4,095) Purchased technology and patents 10,528 (3,990) 11,405 (4,570) Trademarks and tradenames 464 (224) 570 (324) Other 83 (53) 85 (59) Total $ 28,042 $ (8,848) $ 29,004 $ (9,048) Indefinite-lived: IPR&D $ 581 $ — $ 604 $ —
Gross Carrying Amount of Indefinite-Lived Intangible Assets	The following table presents the gross carrying amount and accumulated amortization of intangible assets: October 25, 2019 April 26, 2019 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,967 $ (4,581) $ 16,944 $ (4,095) Purchased technology and patents 10,528 (3,990) 11,405 (4,570) Trademarks and tradenames 464 (224) 570 (324) Other 83 (53) 85 (59) Total $ 28,042 $ (8,848) $ 29,004 $ (9,048) Indefinite-lived: IPR&D $ 581 $ — $ 604 $ —
Estimated Future Aggregate Amortization Expense, Definite-Lived Intangible Assets	Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at October 25, 2019, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows: (in millions) Amortization Expense Remaining 2020 $ 868 2021 1,725 2022 1,684 2023 1,621 2024 1,592 2025 1,565

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Oct. 25, 2019
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The table below sets forth the computation of basic and diluted earnings per share: Three months ended Six months ended (in millions, except per share data) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Numerator: Net income attributable to ordinary shareholders $ 1,364 $ 1,115 $ 2,228 $ 2,190 Denominator: Basic – weighted average shares outstanding 1,340.8 1,349.2 1,340.8 1,350.9 Effect of dilutive securities: Employee stock options 8.0 8.5 7.4 8.4 Employee restricted stock units 2.6 3.1 3.1 3.3 Other — 0.1 0.3 0.4 Diluted – weighted average shares outstanding 1,351.4 1,360.9 1,351.6 1,363.0 Basic earnings per share $ 1.02 $ 0.83 $ 1.66 $ 1.62 Diluted earnings per share $ 1.01 $ 0.82 $ 1.65 $ 1.61

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Oct. 25, 2019
Share-based Payment Arrangement [Abstract]
Components and Classification of Stock-based Compensation Expense	The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, and employee stock purchase plan shares recognized for the three and six months ended October 25, 2019 and October 26, 2018: Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Stock options $ 31 $ 33 $ 40 $ 51 Restricted stock 71 65 113 101 Employee stock purchase plan 6 6 16 16 Total stock-based compensation expense $ 108 $ 104 $ 169 $ 168 Cost of products sold $ 10 $ 12 $ 16 $ 18 Research and development expense 13 13 20 21 Selling, general, and administrative expense 85 79 133 129 Total stock-based compensation expense 108 104 169 168 Income tax benefits (19) (21) (29) (32) Total stock-based compensation expense, net of tax $ 89 $ 83 $ 140 $ 136

Retirement Benefit Plans (Table

Retirement Benefit Plans (Tables)	6 Months Ended
	Oct. 25, 2019
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	The net periodic benefit cost of the defined benefit pension plans included the following components for the three months and six months ended October 25, 2019 and October 26, 2018: U.S. Non-U.S. Three months ended Three months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Service cost $ 26 $ 27 $ 15 $ 15 Interest cost 32 33 7 7 Expected return on plan assets (56) (54) (15) (14) Amortization of net actuarial loss 14 19 4 3 Net periodic benefit cost $ 16 $ 25 $ 11 $ 11 U.S. Non-U.S. Six months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Service cost $ 52 $ 54 $ 30 $ 30 Interest cost 64 66 14 14 Expected return on plan assets (112) (108) (30) (28) Amortization of net actuarial loss 28 38 7 6 Net periodic benefit cost $ 32 $ 50 $ 21 $ 22

Leases (Tables)

Leases (Tables)	6 Months Ended
	Oct. 25, 2019
Leases [Abstract]
Summary of Balance Sheet Classification of Operating Leases and Amounts of Right-of-Use Assets and Lease Liabilities	The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at October 25, 2019: (in millions) Balance Sheet Classification October 25, 2019 Right-of-use assets Other assets $ 989 Current liability Other accrued expenses 176 Non-current liability Other liabilities 834
Schedule of Components of Total Operating Lease Cost and Supplemental Lease Information	The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at October 25, 2019: October 25, 2019 Weighted-average remaining lease term 7.7 years Weighted-average discount rate 3.0% The following table summarizes the components of total operating lease cost for the three and six months ended October 25, 2019: Three months ended Six Months Ended (in millions) October 25, 2019 October 25, 2019 Operating lease cost $ 56 $ 111 Short-term lease cost 11 22 Total operating lease cost $ 67 $ 133 The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for the six months ended October 25, 2019: Six months ended (in millions) October 25, 2019 Cash paid for amounts included in the measurement of operating lease liabilities $ 110 Right-of-use assets obtained in exchange for operating lease liabilities 105
Maturities of Operating Leases	The following table summarizes the maturities of the Company's operating leases at October 25, 2019: (in millions) Operating Leases Remaining 2020 $ 105 2021 193 2022 161 2023 140 2024 117 Thereafter 451 Total expected lease payments 1,167 Less: Imputed interest (157) Total lease liability $ 1,010
Minimum Payments Under Non-Cancelable Operating Leases	As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended April 26, 2019, minimum payments under non-cancelable operating leases at April 26, 2019 were: (in millions) Operating Leases 2020 $ 216 2021 157 2022 103 2023 61 2024 34 Thereafter 81 Total minimum lease payments $ 652

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Oct. 25, 2019
Equity [Abstract]
Changes in AOCI by Component	The following table provides changes in AOCI, net of tax, and by component: (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustments Net Investment Hedges Net Change in Retirement Obligations Unrealized Gain (Loss) on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 26, 2019 $ (45) $ (1,383) $ (169) $ (1,308) $ 194 $ (2,711) Other comprehensive income (loss) before reclassifications 68 (148) 152 (1) 82 153 Reclassifications 5 — — 26 (84) (53) Other comprehensive income (loss) 73 (148) 152 25 (2) 100 October 25, 2019 $ 28 $ (1,531) $ (17) $ (1,283) $ 192 $ (2,611) (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustment Net Investment Hedges Net Change in Retirement Obligations Unrealized (Loss) Gain on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 27, 2018 $ (194) $ (11) $ (257) $ (1,117) $ (207) $ (1,786) Other comprehensive (loss) income before reclassifications (19) (1,252) — — 343 (928) Reclassifications 10 — — 48 (3) 55 Other comprehensive (loss) income (9) (1,252) — 48 340 (873) Cumulative effect of change in accounting principle (1) 47 — — — — 47 October 26, 2018 $ (156) $ (1,263) $ (257) $ (1,069) $ 133 $ (2,612)

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	6 Months Ended
	Oct. 25, 2019
Segment Reporting [Abstract]
Net Sales by Segment	The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements: Net Sales Three months ended (1) Six months ended (1) (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Cardiac and Vascular Group $ 2,855 $ 2,858 $ 5,645 $ 5,669 Minimally Invasive Therapies Group 2,142 2,047 4,242 4,099 Restorative Therapies Group 2,112 1,993 4,124 3,942 Diabetes Group 596 583 1,188 1,155 Total $ 7,706 $ 7,481 $ 15,199 $ 14,865 (1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated	Segment Operating Profit Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Cardiac and Vascular Group $ 1,128 $ 1,137 $ 2,183 $ 2,186 Minimally Invasive Therapies Group 823 792 1,593 1,568 Restorative Therapies Group 840 804 1,633 1,570 Diabetes Group 148 176 297 348 Segment operating profit 2,939 2,909 5,706 5,672 Interest expense (165) (241) (774) (483) Other non-operating income, net 108 52 209 238 Amortization of intangible assets (441) (445) (881) (891) Corporate (350) (342) (657) (645) Centralized distribution costs (424) (482) (768) (928) Restructuring and associated costs (94) (77) (218) (190) Acquisition-related items (27) (4) (46) (40) Certain litigation charges (121) — (168) (103) IPR&D charges — (15) — (15) Exit of businesses (41) — (41) (80) Debt tender premium and other charges — — 7 — Medical device regulations (10) — (18) — Contribution to Medtronic Foundation (80) — (80) — Income before income taxes $ 1,294 $ 1,355 $ 2,271 $ 2,535
Net Sales to External Customers by Geography	The following table presents net sales for the three and six months ended October 25, 2019 and October 26, 2018 for the Company's country of domicile, countries with significant concentrations, and all other countries: Three months ended Six months ended (in millions) October 25, 2019 October 26, 2018 October 25, 2019 October 26, 2018 Ireland $ 23 $ 22 $ 43 $ 44 United States 4,129 4,045 8,046 7,909 Rest of world 3,554 3,414 7,110 6,912 Total other countries, excluding Ireland 7,683 7,459 15,156 14,821 Total $ 7,706 $ 7,481 $ 15,199 $ 14,865

Guarantor Financial Informati_2

Guarantor Financial Information (Tables)	6 Months Ended
	Oct. 25, 2019
Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Financial Statements, Captions [Line Items]
Consolidating Statement of Comprehensive Income, Current Year QTD	Consolidating Statement of Comprehensive Income Three Months Ended October 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 385 $ — $ 7,706 $ (385) $ 7,706 Costs and expenses: Cost of products sold — 350 — 2,354 (310) 2,394 Research and development expense — 178 — 425 — 603 Selling, general, and administrative expense 4 431 — 2,185 — 2,620 Amortization of intangible assets — 3 — 438 — 441 Restructuring charges, net — 7 — 20 — 27 Certain litigation charges — — — 121 — 121 Other operating expense (income), net 13 (629) — 852 (87) 149 Operating profit (loss) (17) 45 — 1,311 12 1,351 Other non-operating (income) expense, net — (73) (241) (425) 631 (108) Interest expense 139 345 119 193 (631) 165 Equity in net (income) loss of subsidiaries (1,518) (581) (1,396) — 3,495 — Income (loss) before income taxes 1,362 354 1,518 1,543 (3,483) 1,294 Income tax provision (2) (30) — (45) — (77) Net income (loss) 1,364 384 1,518 1,588 (3,483) 1,371 Net income attributable to noncontrolling interests — — — (7) — (7) Net income (loss) attributable to Medtronic 1,364 384 1,518 1,581 (3,483) 1,364 Other comprehensive income (loss), net of tax (127) (76) (127) (192) 395 (127) Comprehensive income attributable to — — — (7) — (7) Total comprehensive income (loss) $ 1,237 $ 308 $ 1,391 $ 1,389 $ (3,088) $ 1,237
Consolidating Statement of Comprehensive Income, Current Year YTD	Consolidating Statement of Comprehensive Income Six Months Ended October 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 811 $ — $ 15,199 $ (811) $ 15,199 Costs and expenses: Cost of products sold — 676 — 4,705 (621) 4,760 Research and development expense — 346 — 844 — 1,190 Selling, general, and administrative expense 7 809 — 4,347 — 5,163 Amortization of intangible assets — 6 — 875 — 881 Restructuring charges, net — 9 — 65 — 74 Certain litigation charges — 5 — 163 — 168 Other operating expense (income), net 26 (1,067) (7) 1,352 (177) 127 Operating profit (loss) (33) 27 7 2,848 (13) 2,836 Other non-operating (income) expense, net — (134) (486) (829) 1,240 (209) Interest expense 283 1,056 284 391 (1,240) 774 Equity in net (income) loss of subsidiaries (2,540) (1,192) (2,331) — 6,063 — Income (loss) before income taxes 2,224 297 2,540 3,286 (6,076) 2,271 Income tax provision (4) (159) — 186 — 23 Net income (loss) 2,228 456 2,540 3,100 (6,076) 2,248 Net income attributable to noncontrolling interests — — — (20) — (20) Net income (loss) attributable to Medtronic 2,228 456 2,540 3,080 (6,076) 2,228 Other comprehensive income (loss), net of tax 100 (29) 100 (83) 12 100 Comprehensive income attributable to — — — (20) — (20) Total comprehensive income (loss) $ 2,328 $ 427 $ 2,640 $ 2,997 $ (6,064) $ 2,328
Consolidating Statement of Comprehensive Income, Prior Year QTD	Consolidating Statement of Comprehensive Income Three Months Ended October 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 364 $ — $ 7,481 $ (364) $ 7,481 Costs and expenses: Cost of products sold — 280 — 2,162 (239) 2,203 Research and development expense — 176 — 414 — 590 Selling, general, and administrative expense 4 413 — 2,188 — 2,605 Amortization of intangible assets — 2 — 443 — 445 Restructuring charges, net — 1 — 23 — 24 Other operating expense (income), net 24 (672) — 834 (116) 70 Operating profit (loss) (28) 164 — 1,417 (9) 1,544 Other non-operating (income) expense, net — (138) (175) (429) 690 (52) Interest expense 108 482 113 228 (690) 241 Equity in net (income) loss of subsidiaries (1,249) (762) (1,187) — 3,198 — Income (loss) before income taxes 1,113 582 1,249 1,618 (3,207) 1,355 Income tax provision (2) (15) — 252 — 235 Net income (loss) 1,115 597 1,249 1,366 (3,207) 1,120 Net income attributable to noncontrolling interests — — — (5) — (5) Net income (loss) attributable to Medtronic 1,115 597 1,249 1,361 (3,207) 1,115 Other comprehensive income (loss), net of tax (289) (194) (289) (310) 790 (292) Comprehensive income attributable to noncontrolling interests — — — (2) — (2) Total comprehensive income (loss) $ 826 $ 403 $ 960 $ 1,054 $ (2,417) $ 826
Consolidating Statement of Comprehensive Income, Prior Year YTD	Consolidating Statement of Comprehensive Income Six Months Ended October 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 726 $ — $ 14,865 $ (726) $ 14,865 Costs and expenses: Cost of products sold — 553 — 4,330 (476) 4,407 Research and development expense — 344 — 831 — 1,175 Selling, general, and administrative expense 6 781 — 4,415 — 5,202 Amortization of intangible assets — 4 — 887 — 891 Restructuring charges, net — 11 — 75 — 86 Certain litigation charges — 78 — 25 — 103 Other operating expense (income), net 25 (931) — 1,349 (222) 221 Operating profit (loss) (31) (114) — 2,953 (28) 2,780 Other non-operating (income) expense, net — (297) (339) (934) 1,332 (238) Interest expense 208 946 216 445 (1,332) 483 Equity in net (income) loss of subsidiaries (2,425) (1,568) (2,302) — 6,295 — Income (loss) before income taxes 2,186 805 2,425 3,442 (6,323) 2,535 Income tax provision (4) (119) — 461 — 338 Net income (loss) 2,190 924 2,425 2,981 (6,323) 2,197 Net income attributable to noncontrolling interests — — — (7) — (7) Net income (loss) attributable to Medtronic 2,190 924 2,425 2,974 (6,323) 2,190 Other comprehensive income (loss), net of tax (873) (702) (873) (914) 2,486 (876) Comprehensive income attributable to noncontrolling interests — — — (4) — (4) Total comprehensive income (loss) $ 1,317 $ 222 $ 1,552 $ 2,063 $ (3,837) $ 1,317
Condensed Consolidating Balance Sheet, Current Year	Condensed Consolidating Balance Sheet October 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ 20 $ 204 $ 3,738 $ — $ 3,962 Investments — — — 6,436 — 6,436 Accounts receivable, net — — — 6,118 — 6,118 Inventories, net — 200 — 4,079 (237) 4,042 Intercompany receivable 109 9,352 5 32,385 (41,851) — Other current assets 7 183 2 1,903 — 2,095 Total current assets 116 9,755 211 54,659 (42,088) 22,653 Property, plant, and equipment, net — 1,527 — 3,229 — 4,756 Goodwill — 2,009 — 37,943 — 39,952 Other intangible assets, net — 93 — 19,682 — 19,775 Tax assets — 520 — 1,284 — 1,804 Investment in subsidiaries 66,705 73,122 67,007 — (206,834) — Intercompany loans receivable 3,000 21 30,240 25,120 (58,381) — Other assets — 350 — 1,763 — 2,113 Total assets $ 69,821 $ 87,397 $ 97,458 $ 143,680 $ (307,303) $ 91,053 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 375 $ — $ 875 Accounts payable — 494 — 1,471 — 1,965 Intercompany payable — 21,687 10,697 9,467 (41,851) — Accrued compensation 6 728 — 1,039 — 1,773 Accrued income taxes — — — 442 — 442 Other accrued expenses 21 337 70 2,687 — 3,115 Total current liabilities 27 23,746 10,767 15,481 (41,851) 8,170 Long-term debt — 9,783 13,552 1,417 — 24,752 Accrued compensation and retirement benefits — 1,001 — 572 — 1,573 Accrued income taxes 10 722 — 1,973 — 2,705 Intercompany loans payable 19,206 9,011 13,459 16,705 (58,381) — Deferred tax liabilities — — — 1,376 — 1,376 Other liabilities — 265 — 1,493 — 1,758 Total liabilities 19,243 44,528 37,778 39,017 (100,232) 40,334 Shareholders’ equity 50,578 42,869 59,680 104,522 (207,071) 50,578 Noncontrolling interests — — — 141 — 141 Total equity 50,578 42,869 59,680 104,663 (207,071) 50,719 Total liabilities and equity $ 69,821 $ 87,397 $ 97,458 $ 143,680 $ (307,303) $ 91,053
Condensed Consolidating Balance Sheet, Prior Year	Condensed Consolidating Balance Sheet April 26, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ 18 $ 1 $ 4,374 $ — $ 4,393 Investments — — — 5,455 — 5,455 Accounts receivable, net — — — 6,222 — 6,222 Inventories, net — 188 — 3,792 (227) 3,753 Intercompany receivable 40 9,407 6 19,170 (28,623) — Other current assets 10 190 3 1,941 — 2,144 Total current assets 50 9,803 10 40,954 (28,850) 21,967 Property, plant, and equipment, net — 1,480 — 3,195 — 4,675 Goodwill — 2,009 — 37,950 — 39,959 Other intangible assets, net — 99 — 20,461 — 20,560 Tax assets — 568 — 951 — 1,519 Investment in subsidiaries 64,352 71,129 65,012 — (200,493) — Intercompany loans receivable 3,000 21 27,858 35,398 (66,277) — Other assets — 216 — 798 — 1,014 Total assets $ 67,402 $ 85,325 $ 92,880 $ 139,707 $ (295,620) $ 89,694 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 338 $ — $ 838 Accounts payable — 481 — 1,472 — 1,953 Intercompany payable — 11,971 7,200 9,452 (28,623) — Accrued compensation 3 913 — 1,273 — 2,189 Accrued income taxes — — — 567 — 567 Other accrued expenses 20 331 53 2,521 — 2,925 Total current liabilities 23 14,196 7,253 15,623 (28,623) 8,472 Long-term debt — 14,418 8,621 1,447 — 24,486 Accrued compensation and retirement benefits — 1,069 — 582 — 1,651 Accrued income taxes 10 692 — 2,136 — 2,838 Intercompany loans payable 17,278 12,613 19,682 16,704 (66,277) — Deferred tax liabilities — — — 1,278 — 1,278 Other liabilities — 133 — 624 — 757 Total liabilities 17,311 43,121 35,556 38,394 (94,900) 39,482 Shareholders' equity 50,091 42,204 57,324 101,192 (200,720) 50,091 Noncontrolling interests — — — 121 — 121 Total equity 50,091 42,204 57,324 101,313 (200,720) 50,212 Total liabilities and equity $ 67,402 $ 85,325 $ 92,880 $ 139,707 $ (295,620) $ 89,694
Condensed Consolidating Statement of Cash Flows, Current Year	Condensed Consolidating Statement of Cash Flows Six Months Ended October 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 49 $ (967) $ 295 $ 4,000 $ — $ 3,377 Investing Activities: Acquisitions, net of cash acquired — — — (201) — (201) Additions to property, plant, and equipment — (158) — (426) — (584) Purchases of investments — — — (4,226) — (4,226) Sales and maturities of investments — — — 3,260 — 3,260 Other investing activities — — (5) (11) — (16) Net cash provided by (used in) investing activities — (158) (5) (1,604) — (1,767) Financing Activities: Change in current debt obligations, net — — — 42 — 42 Issuance of long-term debt — — 5,567 1 — 5,568 Payments on long-term debt — (5,016) (515) (63) — (5,594) Dividends to shareholders (1,447) — — — — (1,447) Issuance of ordinary shares 432 — — — — 432 Repurchase of ordinary shares (962) — — — — (962) Net intercompany loan borrowings (repayments) 1,928 6,143 (5,105) (2,966) — — Other financing activities — — (34) (20) — (54) Net cash provided by (used in) financing activities (49) 1,127 (87) (3,006) — (2,015) Effect of exchange rate changes on cash and cash equivalents — — — (26) — (26) Net change in cash and cash equivalents — 2 203 (636) — (431) Cash and cash equivalents at beginning of period — 18 1 4,374 — 4,393 Cash and cash equivalents at end of period $ — $ 20 $ 204 $ 3,738 $ — $ 3,962
Condensed Consolidating Statement of Cash Flows, Prior Year	Condensed Consolidating Statement of Cash Flows Six Months Ended October 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 147 $ (1,335) $ 123 $ 3,930 $ — $ 2,865 Investing Activities: Acquisitions, net of cash acquired — — — (119) — (119) Additions to property, plant, and equipment — (133) — (364) — (497) Purchases of investments — — — (1,444) — (1,444) Sales and maturities of investments — 76 — 2,748 — 2,824 Capital contribution paid (18) (32) — — 50 — Net cash provided by (used in) investing activities (18) (89) — 821 50 764 Financing Activities: Change in current debt obligations, net — — (696) (4) — (700) Issuance of long-term debt — — — 1 — 1 Payments on long-term debt — — — (17) — (17) Dividends to shareholders (1,351) — — — — (1,351) Issuance of ordinary shares 800 — — — — 800 Repurchase of ordinary shares (2,047) — — — — (2,047) Net intercompany loan borrowings (repayments) 2,469 1,428 1,067 (4,964) — — Capital contribution received — — — 50 (50) — Other financing activities — — — 11 — 11 Net cash provided by (used in) financing activities (129) 1,428 371 (4,923) (50) (3,303) Effect of exchange rate changes on cash and cash equivalents — — — (84) — (84) Net change in cash and cash equivalents — 4 494 (256) — 242 Cash and cash equivalents at beginning of period — 20 1 3,648 — 3,669 Cash and cash equivalents at end of period $ — $ 24 $ 495 $ 3,392 $ — $ 3,911
CIFSA Senior Notes
Condensed Financial Statements, Captions [Line Items]
Consolidating Statement of Comprehensive Income, Current Year QTD	Consolidating Statement of Comprehensive Income Three Months Ended October 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,706 $ — $ 7,706 Costs and expenses: Cost of products sold — — — 2,394 — 2,394 Research and development expense — — — 603 — 603 Selling, general, and administrative expense 4 — 1 2,615 — 2,620 Amortization of intangible assets — — — 441 — 441 Restructuring charges, net — — — 27 — 27 Certain litigation charges — — — 121 — 121 Other operating expense (income), net 13 — — 136 — 149 Operating profit (loss) (17) — (1) 1,369 — 1,351 Other non-operating (income) expense, net — (32) (248) (362) 534 (108) Interest expense 139 191 119 250 (534) 165 Equity in net (income) loss of subsidiaries (1,518) (1,220) (1,390) — 4,128 — Income (loss) before income taxes 1,362 1,061 1,518 1,481 (4,128) 1,294 Income tax provision (2) — — (75) — (77) Net income (loss) 1,364 1,061 1,518 1,556 (4,128) 1,371 Net income attributable to noncontrolling interests — — — (7) — (7) Net income (loss) attributable to Medtronic 1,364 1,061 1,518 1,549 (4,128) 1,364 Other comprehensive income (loss), net of tax (127) (95) (127) (180) 402 (127) Comprehensive income attributable to — — — (7) — (7) Total comprehensive income (loss) $ 1,237 $ 966 $ 1,391 $ 1,369 $ (3,726) $ 1,237
Consolidating Statement of Comprehensive Income, Current Year YTD	Consolidating Statement of Comprehensive Income Six Months Ended October 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 15,199 $ — $ 15,199 Costs and expenses: Cost of products sold — — — 4,760 — 4,760 Research and development expense — — — 1,190 — 1,190 Selling, general, and administrative expense 7 — 1 5,155 — 5,163 Amortization of intangible assets — — — 881 — 881 Restructuring charges, net — — — 74 — 74 Certain litigation charges — — — 168 — 168 Other operating expense (income), net 26 — (7) 108 — 127 Operating profit (loss) (33) — 6 2,863 — 2,836 Other non-operating (income) expense, net — (95) (501) (760) 1,147 (209) Interest expense 283 412 284 942 (1,147) 774 Equity in net (income) loss of subsidiaries (2,540) (2,188) (2,317) — 7,045 — Income (loss) before income taxes 2,224 1,871 2,540 2,681 (7,045) 2,271 Income tax provision (4) — — 27 — 23 Net income (loss) 2,228 1,871 2,540 2,654 (7,045) 2,248 Net income attributable to noncontrolling interests — — — (20) — (20) Net income (loss) attributable to Medtronic 2,228 1,871 2,540 2,634 (7,045) 2,228 Other comprehensive income (loss), net of tax 100 (11) 100 (53) (36) 100 Comprehensive income attributable to — — — (20) — (20) Total comprehensive income (loss) $ 2,328 $ 1,860 $ 2,640 $ 2,581 $ (7,081) $ 2,328
Consolidating Statement of Comprehensive Income, Prior Year QTD	Consolidating Statement of Comprehensive Income Three Months Ended October 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,481 $ — $ 7,481 Costs and expenses: Cost of products sold — — — 2,203 — 2,203 Research and development expense — — — 590 — 590 Selling, general, and administrative expense 4 — 1 2,600 — 2,605 Amortization of intangible assets — — — 445 — 445 Restructuring charges, net — — — 24 — 24 Other operating expense, net 24 — — 46 — 70 Operating profit (loss) (28) — (1) 1,573 — 1,544 Other non-operating (income) expense, net — (9) (183) (150) 290 (52) Interest expense 108 22 113 288 (290) 241 Equity in net (income) loss of subsidiaries (1,249) (629) (1,180) — 3,058 — Income (loss) before income taxes 1,113 616 1,249 1,435 (3,058) 1,355 Income tax provision (2) — — 237 — 235 Net income (loss) 1,115 616 1,249 1,198 (3,058) 1,120 Net income attributable to noncontrolling interests — — — (5) — (5) Net income (loss) attributable to Medtronic 1,115 616 1,249 1,193 (3,058) 1,115 Other comprehensive income (loss), net of tax (289) (91) (289) (295) 672 (292) Comprehensive income attributable to — — — (2) — (2) Total comprehensive income (loss) $ 826 $ 525 $ 960 $ 901 $ (2,386) $ 826
Consolidating Statement of Comprehensive Income, Prior Year YTD	Consolidating Statement of Comprehensive Income Six Months Ended October 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 14,865 $ — $ 14,865 Costs and expenses: Cost of products sold — — — 4,407 — 4,407 Research and development expense — — — 1,175 — 1,175 Selling, general, and administrative expense 6 — 1 5,195 — 5,202 Amortization of intangible assets — — — 891 — 891 Restructuring charges, net — — — 86 — 86 Certain litigation charges — — — 103 — 103 Other operating expense, net 25 — — 196 — 221 Operating profit (loss) (31) — (1) 2,812 — 2,780 Other non-operating (income) expense, net — (19) (352) (424) 557 (238) Interest expense 208 43 216 573 (557) 483 Equity in net (income) loss of subsidiaries (2,425) (1,602) (2,290) — 6,317 — Income (loss) before income taxes 2,186 1,578 2,425 2,663 (6,317) 2,535 Income tax provision (4) — — 342 — 338 Net income (loss) 2,190 1,578 2,425 2,321 (6,317) 2,197 Net income attributable to noncontrolling interests — — — (7) — (7) Net income (loss) attributable to Medtronic 2,190 1,578 2,425 2,314 (6,317) 2,190 Other comprehensive income (loss), net of tax (873) (132) (873) (879) 1,881 (876) Comprehensive loss attributable to — — — (4) — (4) Total comprehensive income (loss) $ 1,317 $ 1,446 $ 1,552 $ 1,438 $ (4,436) $ 1,317
Condensed Consolidating Balance Sheet, Current Year	Condensed Consolidating Balance Sheet October 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 204 $ 3,758 $ — $ 3,962 Investments — — — 6,436 — 6,436 Accounts receivable, net — — — 6,118 — 6,118 Inventories, net — — — 4,042 — 4,042 Intercompany receivable 109 — 1,387 10,725 (12,221) — Other current assets 7 — 2 2,086 — 2,095 Total current assets 116 — 1,593 33,165 (12,221) 22,653 Property, plant, and equipment, net — — — 4,756 — 4,756 Goodwill — — — 39,952 — 39,952 Other intangible assets, net — — — 19,775 — 19,775 Tax assets — — — 1,804 — 1,804 Investment in subsidiaries 66,705 58,863 65,631 — (191,199) — Intercompany loans receivable 3,000 3,798 30,240 40,585 (77,623) — Other assets — — — 2,113 — 2,113 Total assets $ 69,821 $ 62,661 $ 97,464 $ 142,150 $ (281,043) $ 91,053 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 875 $ — $ 875 Accounts payable — — — 1,965 — 1,965 Intercompany payable — 1,322 10,698 201 (12,221) — Accrued compensation 6 — — 1,767 — 1,773 Accrued income taxes — — — 442 — 442 Other accrued expenses 21 11 75 3,008 — 3,115 Total current liabilities 27 1,333 10,773 8,258 (12,221) 8,170 Long-term debt — 1,309 13,552 9,891 — 24,752 Accrued compensation and retirement benefits — — — 1,573 — 1,573 Accrued income taxes 10 — — 2,695 — 2,705 Intercompany loans payable 19,206 27,126 13,458 17,833 (77,623) — Deferred tax liabilities — — — 1,376 — 1,376 Other liabilities — — 1 1,757 — 1,758 Total liabilities 19,243 29,768 37,784 43,383 (89,844) 40,334 Shareholders’ equity 50,578 32,893 59,680 98,626 (191,199) 50,578 Noncontrolling interests — — — 141 — 141 Total equity 50,578 32,893 59,680 98,767 (191,199) 50,719 Total liabilities and equity $ 69,821 $ 62,661 $ 97,464 $ 142,150 $ (281,043) $ 91,053
Condensed Consolidating Balance Sheet, Prior Year	Condensed Consolidating Balance Sheet April 26, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 1 $ 4,392 $ — $ 4,393 Investments — — — 5,455 — 5,455 Accounts receivable, net — — — 6,222 — 6,222 Inventories, net — — — 3,753 — 3,753 Intercompany receivable 40 — 1,374 7,212 (8,626) — Other current assets 10 — 3 2,131 — 2,144 Total current assets 50 — 1,378 29,165 (8,626) 21,967 Property, plant, and equipment, net — — — 4,675 — 4,675 Goodwill — — — 39,959 — 39,959 Other intangible assets, net — — — 20,560 — 20,560 Tax assets — — — 1,519 — 1,519 Investment in subsidiaries 64,352 39,557 63,651 — (167,560) — Intercompany loans receivable 3,000 4,119 27,858 29,002 (63,979) — Other assets — — — 1,014 — 1,014 Total assets $ 67,402 $ 43,676 $ 92,887 $ 125,894 $ (240,165) $ 89,694 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 838 $ — $ 838 Accounts payable — — — 1,953 — 1,953 Intercompany payable — 1,308 7,199 119 (8,626) — Accrued compensation 3 — — 2,186 — 2,189 Accrued income taxes — — — 567 — 567 Other accrued expenses 20 11 60 2,834 — 2,925 Total current liabilities 23 1,319 7,259 8,497 (8,626) 8,472 Long-term debt — 1,354 8,621 14,511 — 24,486 Accrued compensation and retirement benefits — — — 1,651 — 1,651 Accrued income taxes 10 — — 2,828 — 2,838 Intercompany loans payable 17,278 9,320 19,682 17,699 (63,979) — Deferred tax liabilities — — — 1,278 — 1,278 Other liabilities — — 1 756 — 757 Total liabilities 17,311 11,993 35,563 47,220 (72,605) 39,482 Shareholders' equity 50,091 31,683 57,324 78,553 (167,560) 50,091 Noncontrolling interests — — — 121 — 121 Total Equity 50,091 31,683 57,324 78,674 (167,560) 50,212 Total liabilities and equity $ 67,402 $ 43,676 $ 92,887 $ 125,894 $ (240,165) $ 89,694
Condensed Consolidating Statement of Cash Flows, Current Year	Condensed Consolidating Statement of Cash Flows Six Months Ended October 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 49 $ (319) $ 309 $ 3,338 $ — $ 3,377 Investing Activities: Acquisitions, net of cash acquired — — — (201) — (201) Additions to property, plant, and equipment — — — (584) — (584) Purchases of investments — — — (4,226) — (4,226) Sales and maturities of investments — — — 3,260 — 3,260 Capital contribution paid — (43) — — 43 — Other investing activities — — (5) (11) — (16) Net cash provided by (used in) investing activities — (43) (5) (1,762) 43 (1,767) Financing Activities: Change in current debt obligations, net — — — 42 — 42 Issuance of long-term debt — — 5,567 1 — 5,568 Payments on long-term debt — (44) (515) (5,035) — (5,594) Dividends to shareholders (1,447) — — — — (1,447) Issuance of ordinary shares 432 — — — — 432 Repurchase of ordinary shares (962) — — — — (962) Net intercompany loan borrowings (repayments) 1,928 406 (5,119) 2,785 — — Capital contribution received — — — 43 (43) — Other financing activities — — (34) (20) — (54) Net cash provided by (used in) financing activities (49) 362 (101) (2,184) (43) (2,015) Effect of exchange rate changes on cash and cash equivalents — — — (26) — (26) Net change in cash and cash equivalents — — 203 (634) — (431) Cash and cash equivalents at beginning of period — — 1 4,392 — 4,393 Cash and cash equivalents at end of period $ — $ — $ 204 $ 3,758 $ — $ 3,962
Condensed Consolidating Statement of Cash Flows, Prior Year	Condensed Consolidating Statement of Cash Flows Six Months Ended October 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 147 $ (35) $ 136 $ 2,617 $ — $ 2,865 Investing Activities: Acquisitions, net of cash acquired — — — (119) — (119) Additions to property, plant, and equipment — — — (497) — (497) Purchases of investments — — — (1,444) — (1,444) Sales and maturities of investments — — — 2,824 — 2,824 Capital contributions paid (18) (187) — — 205 — Net cash provided by (used in) investing activities (18) (187) — 764 205 764 Financing Activities: Change in current debt obligations, net — — (697) (3) — (700) Issuance of long-term debt — — — 1 — 1 Payments on long-term debt — — — (17) — (17) Dividends to shareholders (1,351) — — — — (1,351) Issuance of ordinary shares 800 — — — — 800 Repurchase of ordinary shares (2,047) — — — — (2,047) Net intercompany loan borrowings (repayments) 2,469 222 1,056 (3,747) — — Capital contributions received — — — 205 (205) — Other financing activities — — — 11 — 11 Net cash provided by (used in) financing activities (129) 222 359 (3,550) (205) (3,303) Effect of exchange rate changes on cash and cash equivalents — — — (84) — (84) Net change in cash and cash equivalents — — 495 (253) — 242 Cash and cash equivalents at beginning of period — — 1 3,668 — 3,669 Cash and cash equivalents at end of period $ — $ — $ 496 $ 3,415 $ — $ 3,911

New Accounting Pronouncements (

New Accounting Pronouncements (Details) - USD ($) $ in Millions	Oct. 25, 2019	Apr. 27, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets	$ 989
Total lease liability	$ 1,010
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets		$ 1,000
Total lease liability		$ 1,000

Revenue - Disaggregation of Net

Revenue - Disaggregation of Net Sales by Segment and Division (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Disaggregation of Revenue [Line Items]
Net sales	$ 7,706	$ 7,481	$ 15,199	$ 14,865
Cardiac and Vascular Group
Disaggregation of Revenue [Line Items]
Net sales	2,855	2,858	5,645	5,669
Cardiac and Vascular Group | Cardiac Rhythm & Heart Failure
Disaggregation of Revenue [Line Items]
Net sales	1,426	1,472	2,807	2,898
Cardiac and Vascular Group | Coronary & Structural Heart
Disaggregation of Revenue [Line Items]
Net sales	955	906	1,896	1,823
Cardiac and Vascular Group | Aortic, Peripheral, & Venous
Disaggregation of Revenue [Line Items]
Net sales	474	480	942	948
Minimally Invasive Therapies Group
Disaggregation of Revenue [Line Items]
Net sales	2,142	2,047	4,242	4,099
Minimally Invasive Therapies Group | Surgical Innovations
Disaggregation of Revenue [Line Items]
Net sales	1,454	1,393	2,871	2,790
Minimally Invasive Therapies Group | Respiratory, Gastrointestinal, & Renal
Disaggregation of Revenue [Line Items]
Net sales	688	654	1,371	1,309
Restorative Therapies Group
Disaggregation of Revenue [Line Items]
Net sales	2,112	1,993	4,124	3,942
Restorative Therapies Group | Brain Therapies
Disaggregation of Revenue [Line Items]
Net sales	772	701	1,512	1,375
Restorative Therapies Group | Spine
Disaggregation of Revenue [Line Items]
Net sales	692	656	1,349	1,308
Restorative Therapies Group | Specialty Therapies
Disaggregation of Revenue [Line Items]
Net sales	333	322	656	631
Restorative Therapies Group | Pain Therapies
Disaggregation of Revenue [Line Items]
Net sales	315	314	607	628
Diabetes Group
Disaggregation of Revenue [Line Items]
Net sales	$ 596	$ 583	$ 1,188	$ 1,155

Revenue - Disaggregation of N_2

Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Disaggregation of Revenue [Line Items]
Net sales	$ 7,706	$ 7,481	$ 15,199	$ 14,865
U.S.
Disaggregation of Revenue [Line Items]
Net sales	4,129	4,045	8,046	7,909
Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	2,315	2,282	4,692	4,688
Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	1,262	1,154	2,460	2,268
Cardiac and Vascular Group
Disaggregation of Revenue [Line Items]
Net sales	2,855	2,858	5,645	5,669
Cardiac and Vascular Group | U.S.
Disaggregation of Revenue [Line Items]
Net sales	1,455	1,482	2,816	2,871
Cardiac and Vascular Group | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	890	895	1,820	1,842
Cardiac and Vascular Group | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	510	481	1,009	956
Minimally Invasive Therapies Group
Disaggregation of Revenue [Line Items]
Net sales	2,142	2,047	4,242	4,099
Minimally Invasive Therapies Group | U.S.
Disaggregation of Revenue [Line Items]
Net sales	922	872	1,835	1,729
Minimally Invasive Therapies Group | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	782	772	1,573	1,600
Minimally Invasive Therapies Group | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	438	403	834	770
Restorative Therapies Group
Disaggregation of Revenue [Line Items]
Net sales	2,112	1,993	4,124	3,942
Restorative Therapies Group | U.S.
Disaggregation of Revenue [Line Items]
Net sales	1,440	1,357	2,778	2,651
Restorative Therapies Group | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	416	412	842	840
Restorative Therapies Group | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	256	224	504	451
Diabetes Group
Disaggregation of Revenue [Line Items]
Net sales	596	583	1,188	1,155
Diabetes Group | U.S.
Disaggregation of Revenue [Line Items]
Net sales	311	334	618	658
Diabetes Group | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	226	203	457	406
Diabetes Group | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	$ 59	$ 46	$ 113	$ 91

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Oct. 25, 2019	Apr. 26, 2019
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 291	$ 315
Revenue recognized that was previously included in deferred revenue	150
Estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations	$ 1,100
Period over which remaining performance obligations are expected to be recognized as revenue	four years
Other accrued expenses
Disaggregation of Revenue [Line Items]
Rebate obligations	$ 797	764
Deferred revenue	189	211
Reduction of accounts receivable
Disaggregation of Revenue [Line Items]
Rebate obligations	439	432
Other liabilities
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 102	$ 104

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018	Jul. 26, 2019	Apr. 26, 2019	Jul. 27, 2018	Apr. 27, 2018
Business Acquisition [Line Items]
Goodwill	$ 39,952,000,000		$ 39,952,000,000			$ 39,959,000,000
Contingent consideration liabilities in connection with business combinations	7,000,000	$ 11,000,000	65,000,000	$ 46,000,000
Contingent consideration liabilities	260,000,000	203,000,000	260,000,000	203,000,000	$ 269,000,000	222,000,000	$ 208,000,000	$ 173,000,000
IPR&D
Business Acquisition [Line Items]
In-process research and development acquired in connection with asset acquisition	0	15,000,000	0	15,000,000
Other accrued expenses
Business Acquisition [Line Items]
Contingent consideration liabilities	83,000,000		83,000,000			73,000,000
Other liabilities
Business Acquisition [Line Items]
Contingent consideration liabilities	177,000,000		177,000,000			$ 149,000,000
Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Net assets acquired	272,000,000	166,000,000	272,000,000	166,000,000
Total assets acquired	324,000,000	187,000,000	324,000,000	187,000,000
Total liabilities assumed	52,000,000	21,000,000	52,000,000	21,000,000
Goodwill	92,000,000	60,000,000	92,000,000	60,000,000
Inventory	40,000,000		40,000,000
Contingent consideration liabilities in connection with business combinations			65,000,000
Series of Individually Immaterial Business Acquisitions | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired	139,000,000	$ 100,000,000	$ 139,000,000	$ 100,000,000
Series of Individually Immaterial Business Acquisitions | Technology-Based Intangible Assets | Minimum
Business Acquisition [Line Items]
Estimated useful life			8 years	4 years
Series of Individually Immaterial Business Acquisitions | Technology-Based Intangible Assets | Maximum
Business Acquisition [Line Items]
Estimated useful life			16 years	15 years
Series of Individually Immaterial Business Acquisitions | Customer-Related Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired	$ 26,000,000		$ 26,000,000
Series of Individually Immaterial Business Acquisitions | Customer-Related Intangible Assets | Minimum
Business Acquisition [Line Items]
Estimated useful life			8 years
Series of Individually Immaterial Business Acquisitions | Customer-Related Intangible Assets | Maximum
Business Acquisition [Line Items]
Estimated useful life			16 years

Acquisitions - Reconciliation o

Acquisitions - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Beginning balance	$ 269	$ 208	$ 222	$ 173
Purchase price contingent consideration	7	11	65	46
Payments	(15)	(1)	(29)	(7)
Change in fair value	(1)	(15)	2	(9)
Ending balance	$ 260	$ 203	$ 260	$ 203

Acquisitions - Fair Value Measu

Acquisitions - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details) $ in Millions	Oct. 25, 2019USD ($)	Jul. 26, 2019USD ($)	Apr. 26, 2019USD ($)	Oct. 26, 2018USD ($)	Jul. 27, 2018USD ($)	Apr. 27, 2018USD ($)
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)
Contingent consideration, fair value	$ 260	$ 269	$ 222	$ 203	$ 208	$ 173
Revenue and other performance-based payments | Recurring | Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)
Contingent consideration, fair value	$ 135
Revenue and other performance-based payments | Minimum | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.115
Revenue and other performance-based payments | Minimum | Recurring | Level 3 | Probability of payment
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.40
Revenue and other performance-based payments | Maximum | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.325
Revenue and other performance-based payments | Maximum | Recurring | Level 3 | Probability of payment
Fair Value Inputs
Contingent consideration, significant unobservable inputs	1
Product development and other milestone-based payments | Recurring | Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)
Contingent consideration, fair value	$ 125
Product development and other milestone-based payments | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.055
Product development and other milestone-based payments | Minimum | Recurring | Level 3 | Probability of payment
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.75
Product development and other milestone-based payments | Maximum | Recurring | Level 3 | Probability of payment
Fair Value Inputs
Contingent consideration, significant unobservable inputs	1

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - Enterprise Excellence - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Restructuring Cost and Reserve [Line Items]
Charges	$ 95	$ 75	$ 231	$ 195
Accrual adjustments	1	4	13	2
Cost of products sold
Restructuring Cost and Reserve [Line Items]
Charges	32	22	67	37
Selling, general, and administrative expense
Restructuring Cost and Reserve [Line Items]
Charges	35	$ 31	77	$ 54
Minimum | Pre-tax exit and disposal costs and other
Restructuring Cost and Reserve [Line Items]
Expected cost	1,600		1,600
Maximum | Pre-tax exit and disposal costs and other
Restructuring Cost and Reserve [Line Items]
Expected cost	$ 1,800		$ 1,800

Restructuring - Termination Lia

Restructuring - Termination Liability and Restructuring Reserve (Details) - Enterprise Excellence - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Restructuring Reserve [Roll Forward]
Beginning balance			$ 122
Charges	$ 95	$ 75	231	$ 195
Cash payments			(262)
Settled non-cash			(6)
Accrual adjustments	(1)	$ (4)	(13)	$ (2)
Ending balance	72		72
Employee Termination Benefits
Restructuring Reserve [Roll Forward]
Beginning balance			101
Charges			79
Cash payments			(118)
Settled non-cash			0
Accrual adjustments			(6)
Ending balance	56		56
Associated Costs
Restructuring Reserve [Roll Forward]
Beginning balance			9
Charges			139
Cash payments			(136)
Settled non-cash			0
Accrual adjustments			0
Ending balance	12		12
Asset Write-Downs
Restructuring Reserve [Roll Forward]
Beginning balance			0
Charges			6
Cash payments			0
Settled non-cash			(6)
Accrual adjustments			0
Ending balance	0		0
Other Costs
Restructuring Reserve [Roll Forward]
Beginning balance			12
Charges			7
Cash payments			(8)
Settled non-cash			0
Accrual adjustments			(7)
Ending balance	$ 4		$ 4

Financial Instruments - Investm

Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details) - USD ($) $ in Millions	Oct. 25, 2019	Apr. 26, 2019
Schedule of Investments [Line Items]
Cost	$ 6,445	$ 5,540
Unrealized Gains	71	20
Unrealized Losses	(36)	(61)
Fair Value	6,480	5,499
Investments
Schedule of Investments [Line Items]
Fair Value	6,436	5,455
Other Assets
Schedule of Investments [Line Items]
Fair Value	44	44
Level 2
Schedule of Investments [Line Items]
Cost	5,833	4,964
Unrealized Gains	56	19
Unrealized Losses	(33)	(51)
Fair Value	5,856	4,932
Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	5,856	4,932
Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Corporate debt securities | Level 2
Schedule of Investments [Line Items]
Cost	3,814	3,500
Unrealized Gains	43	14
Unrealized Losses	(16)	(21)
Fair Value	3,841	3,493
Corporate debt securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	3,841	3,493
Corporate debt securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
U.S. government and agency securities | Level 1
Schedule of Investments [Line Items]
Cost	565	529
Unrealized Gains	15	1
Unrealized Losses	0	(7)
Fair Value	580	523
U.S. government and agency securities | Level 1 | Investments
Schedule of Investments [Line Items]
Fair Value	580	523
U.S. government and agency securities | Level 1 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
U.S. government and agency securities | Level 2
Schedule of Investments [Line Items]
Cost	858	387
Unrealized Gains	0	1
Unrealized Losses	(1)	(7)
Fair Value	857	381
U.S. government and agency securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	857	381
U.S. government and agency securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Mortgage-backed securities | Level 2
Schedule of Investments [Line Items]
Cost	634	537
Unrealized Gains	11	3
Unrealized Losses	(13)	(20)
Fair Value	632	520
Mortgage-backed securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	632	520
Mortgage-backed securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Non-U.S. government and agency securities | Level 2
Schedule of Investments [Line Items]
Cost	13	11
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	13	11
Non-U.S. government and agency securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	13	11
Non-U.S. government and agency securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Other asset-backed securities | Level 2
Schedule of Investments [Line Items]
Cost	514	529
Unrealized Gains	2	1
Unrealized Losses	(3)	(3)
Fair Value	513	527
Other asset-backed securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	513	527
Other asset-backed securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Auction rate securities | Level 3
Schedule of Investments [Line Items]
Cost	47	47
Unrealized Gains	0	0
Unrealized Losses	(3)	(3)
Fair Value	44	44
Auction rate securities | Level 3 | Investments
Schedule of Investments [Line Items]
Fair Value	0	0
Auction rate securities | Level 3 | Other Assets
Schedule of Investments [Line Items]
Fair Value	$ 44	$ 44

Financial Instruments - Availab

Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details) - USD ($) $ in Millions	Oct. 25, 2019	Apr. 26, 2019
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	$ 884	$ 1,075
Less than 12 months, Unrealized Losses	(11)	(9)
More than 12 months, Fair Value	598	2,181
More than 12 months, Unrealized Losses	(25)	(52)
U.S. government and agency securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	140	130
Less than 12 months, Unrealized Losses	0	(1)
More than 12 months, Fair Value	180	649
More than 12 months, Unrealized Losses	(1)	(13)
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	484	582
Less than 12 months, Unrealized Losses	(9)	(5)
More than 12 months, Fair Value	129	1,153
More than 12 months, Unrealized Losses	(7)	(16)
Mortgage-backed securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	91	73
Less than 12 months, Unrealized Losses	(1)	(1)
More than 12 months, Fair Value	89	250
More than 12 months, Unrealized Losses	(12)	(19)
Non-U.S. government and agency securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	2
Less than 12 months, Unrealized Losses	0
More than 12 months, Fair Value	0
More than 12 months, Unrealized Losses	0
Other asset-backed securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	167	290
Less than 12 months, Unrealized Losses	(1)	(2)
More than 12 months, Fair Value	156	85
More than 12 months, Unrealized Losses	(2)	(1)
Auction rate securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	0	0
Less than 12 months, Unrealized Losses	0	0
More than 12 months, Fair Value	44	44
More than 12 months, Unrealized Losses	$ (3)	$ (3)

Financial Instruments - Activit

Financial Instruments - Activity Related to the Company's Investment Portfolio and Available-for-sale Debt Securities Contractual Maturities (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018	Apr. 26, 2019
Activities Related to Investment Portfolio
Proceeds from sales	$ 1,691	$ 804	$ 3,258	$ 1,916
Gross realized gains	4	2	8	8
Gross realized losses	(4)	$ (12)	(12)	$ (19)
AFS Debt Maturities
Due in one year or less	1,975		1,975
Due after one year through five years	2,578		2,578
Due after five years through ten years	1,881		1,881
Due after ten years	46		46
Fair Value	$ 6,480		$ 6,480		$ 5,499

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018	Apr. 26, 2019
Investments [Abstract]
Credit loss portion of other-than-temporary impairments	$ 0		$ 0		$ 0
Reductions for available-for-sale securities sold	0	$ 0
Equity and Other Investments
Gain (Loss) on Securities [Line Items]
Net gains (losses) recognized	14,000,000	(4,000,000)	14,000,000	$ 94,000,000
Net realized gains (losses) on equity and other investments sold during the period				45,000,000
Net unrealized gains (losses) on equity and other investments still held	$ 14,000,000	$ (4,000,000)	$ 14,000,000	$ 49,000,000

Financial Instruments - Summary

Financial Instruments - Summary of Equity and Other Investments (Details) - Other Assets - USD ($) $ in Millions	Oct. 25, 2019	Apr. 26, 2019
Investment [Line Items]
Investments without readily determinable fair values	$ 366	$ 308
Equity method and other investments	66	64
Total equity and other investments	$ 432	$ 372

Financial Instruments - Activ_2

Financial Instruments - Activity Related to the Company's Investment Portfolio, Equity and Other Investments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Investment [Line Items]
Proceeds from sales			$ 3,260	$ 2,824
Equity and Other Investments
Investment [Line Items]
Proceeds from sales	$ 0	$ 0	2	908
Gross gains	14	9	14	123
Gross losses	0	(13)	0	(29)
Impairment losses recognized	$ (2)	$ (12)	$ (3)	$ (12)

Financing Arrangements - Narrat

Financing Arrangements - Narrative (Details)	1 Months Ended			3 Months Ended	6 Months Ended
	Aug. 30, 2019USD ($)	Jul. 31, 2019USD ($)	Jun. 30, 2019USD ($)	Jul. 26, 2019USD ($)	Oct. 25, 2019USD ($)	Oct. 26, 2018USD ($)	Jun. 30, 2019EUR (€)tranche	Apr. 26, 2019USD ($)
Senior Notes
Principal value					$ 25,300,000,000			$ 25,000,000,000
Cash proceeds, net of discounts and issuance costs					5,568,000,000	$ 1,000,000
Loss on extinguishment of debt					406,000,000	$ 0
Financial Instruments Not Measured at Fair Value
Long-term debt, including the current portion, fair value					27,300,000,000			26,200,000,000
Commercial Paper Program | Commercial Paper
Commercial Paper [Abstract]
Commercial paper, maximum borrowing amount					3,500,000,000
Commercial paper, amount outstanding					0			0
Credit Facility | Line of Credit
Line of Credit Facility
Line of credit, maximum capacity					$ 3,500,000,000
Term of debt instrument					5 years
Line of credit, amount outstanding					$ 0			$ 0
Senior Notes 2019 | Senior notes | Medtronic Luxco
Senior Notes
Number of tranches | tranche							6
Principal value | €							€ 5,000,000,000
Cash proceeds, net of discounts and issuance costs			$ 5,600,000,000
Floating Rate Notes due 2021 | Senior notes
Line of Credit Facility
Term of debt instrument					2 years
Floating Rate Notes due 2021 | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							250,000,000
0.000 percent four-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					4 years
Senior Notes
Stated interest rate					0.00%
0.000 percent four-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 750,000,000
Stated interest rate							0.00%
0.250 percent seven-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					7 years
Senior Notes
Stated interest rate					0.25%
0.250 percent seven-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 1,000,000,000
Stated interest rate							0.25%
1.000 percent thirteen-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					13 years
Senior Notes
Stated interest rate					1.00%
1.000 percent thirteen-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 1,000,000,000
Stated interest rate							1.00%
1.500 percent twenty-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					20 years
Senior Notes
Stated interest rate					1.50%
1.500 percent twenty-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 1,000,000,000
Stated interest rate							1.50%
1.750 percent thirty-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					30 years
Senior Notes
Stated interest rate					1.75%
1.750 percent thirty-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 1,000,000,000
Stated interest rate							1.75%
Medtronic Inc, CIFSA, and Medtronic Luxco Senior Notes | Senior notes
Senior Notes
Cash tender offer, amount of outstanding debt	$ 533,000,000	$ 4,600,000,000
Total consideration		$ 5,000,000,000
Loss on extinguishment of debt				$ 413,000,000
Early redemption premium	$ 16,000,000

Financing Arrangements - Long-T

Financing Arrangements - Long-Term Debt (Details) - USD ($) $ in Millions	6 Months Ended
	Oct. 25, 2019	Apr. 26, 2019
Debt Instrument [Line Items]
Current debt obligations	$ 875	$ 838
Long-term debt
Debt (discount) premium, net	(15)	29
Deferred financing costs	(111)	(104)
Long-term debt	$ 24,752	24,486
Senior notes | 0.000 percent two-year 2019 senior notes
Long-term debt
Stated interest rate	0.00%
Term of debt instrument	2 years
Long-term debt, gross	$ 1,666	1,681
Senior notes | Floating rate two-year 2019 senior notes
Long-term debt
Term of debt instrument	2 years
Long-term debt, gross	$ 833	560
Senior notes | 4.125 percent ten-year 2011 senior notes
Long-term debt
Stated interest rate	4.125%
Term of debt instrument	10 years
Long-term debt, gross	$ 0	500
Senior notes | 3.150 percent seven-year 2015 senior notes
Long-term debt
Stated interest rate	3.15%
Term of debt instrument	7 years
Long-term debt, gross	$ 1,534	2,500
Senior notes | 3.125 percent ten-year 2012 senior notes
Long-term debt
Stated interest rate	3.125%
Term of debt instrument	10 years
Long-term debt, gross	$ 0	675
Senior notes | 3.200 percent ten-year 2012 CIFSA senior notes
Long-term debt
Stated interest rate	3.20%
Term of debt instrument	10 years
Long-term debt, gross	$ 650	650
Senior notes | 0.375 percent four-year 2019 senior notes
Long-term debt
Stated interest rate	0.375%
Term of debt instrument	4 years
Long-term debt, gross	$ 1,666	1,681
Senior notes | 2.750 percent ten-year 2013 senior notes
Long-term debt
Stated interest rate	2.75%
Term of debt instrument	10 years
Long-term debt, gross	$ 530	530
Senior notes | 0.000 percent four-year 2019 senior notes
Long-term debt
Stated interest rate	0.00%
Term of debt instrument	4 years
Long-term debt, gross	$ 833	0
Senior notes | 2.950 percent ten-year 2013 CIFSA senior notes
Long-term debt
Stated interest rate	2.95%
Term of debt instrument	10 years
Long-term debt, gross	$ 310	310
Senior notes | 3.625 percent ten-year 2014 senior notes
Long-term debt
Stated interest rate	3.625%
Term of debt instrument	10 years
Long-term debt, gross	$ 432	850
Senior notes | 3.500 percent ten-year 2015 senior notes
Long-term debt
Stated interest rate	3.50%
Term of debt instrument	10 years
Long-term debt, gross	$ 2,700	4,000
Senior notes | 0.250 percent seven-year 2019 senior notes
Long-term debt
Stated interest rate	0.25%
Term of debt instrument	7 years
Long-term debt, gross	$ 1,111	0
Senior notes | 1.125 percent eight-year 2019 senior notes
Long-term debt
Stated interest rate	1.125%
Term of debt instrument	8 years
Long-term debt, gross	$ 1,666	1,681
Senior notes | 3.350 percent ten-year 2017 senior notes
Long-term debt
Stated interest rate	3.35%
Term of debt instrument	10 years
Long-term debt, gross	$ 368	850
Senior notes | 1.625 percent twelve-year 2019 senior notes
Long-term debt
Stated interest rate	1.625%
Term of debt instrument	12 years
Long-term debt, gross	$ 1,111	1,121
Senior notes | 1.000 percent thirteen-year 2019 senior notes
Long-term debt
Stated interest rate	1.00%
Term of debt instrument	13 years
Long-term debt, gross	$ 1,111	0
Senior notes | 4.375 percent twenty-year 2015 senior notes
Long-term debt
Stated interest rate	4.375%
Term of debt instrument	20 years
Long-term debt, gross	$ 1,932	2,382
Senior notes | 6.550 percent thirty-year 2007 CIFSA senior notes
Long-term debt
Stated interest rate	6.55%
Term of debt instrument	30 years
Long-term debt, gross	$ 253	284
Senior notes | 2.250 percent twenty-year 2019 senior notes
Long-term debt
Stated interest rate	2.25%
Term of debt instrument	20 years
Long-term debt, gross	$ 1,111	1,121
Senior notes | 6.500 percent thirty-year 2009 senior notes
Long-term debt
Stated interest rate	6.50%
Term of debt instrument	30 years
Long-term debt, gross	$ 158	183
Senior notes | 5.550 percent thirty-year 2010 senior notes
Long-term debt
Stated interest rate	5.55%
Term of debt instrument	30 years
Long-term debt, gross	$ 224	306
Senior notes | 1.500 percent twenty-year 2019 senior notes
Long-term debt
Stated interest rate	1.50%
Term of debt instrument	20 years
Long-term debt, gross	$ 1,111	0
Senior notes | 4.500 percent thirty-year 2012 senior notes
Long-term debt
Stated interest rate	4.50%
Term of debt instrument	30 years
Long-term debt, gross	$ 105	129
Senior notes | 4.000 percent thirty-year 2013 senior notes
Long-term debt
Stated interest rate	4.00%
Term of debt instrument	30 years
Long-term debt, gross	$ 305	325
Senior notes | 4.625 percent thirty-year 2014 senior notes
Long-term debt
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term debt, gross	$ 127	177
Senior notes | 4.625 percent thirty-year 2015 senior notes
Long-term debt
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term debt, gross	$ 1,813	1,963
Senior notes | 1.750 percent thirty-year 2019 senior notes
Long-term debt
Stated interest rate	1.75%
Term of debt instrument	30 years
Long-term debt, gross	$ 1,111	0
Bank borrowings
Long-term debt
Long-term debt, gross	80	83
Finance lease obligations
Long-term debt
Finance lease obligations	27
Finance lease obligations		10
Interest rate swaps
Long-term debt
Interest rate swaps	$ 0	$ 9

Derivatives and Currency Exch_3

Derivatives and Currency Exchange Risk Management - Narrative (Details) € in Billions	3 Months Ended		6 Months Ended
	Oct. 25, 2019USD ($)derivative	Oct. 26, 2018USD ($)	Oct. 25, 2019USD ($)derivative	Oct. 26, 2018USD ($)	Oct. 25, 2019EUR (€)derivative	Apr. 26, 2019USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI	$ 192,000,000		$ 192,000,000			$ 194,000,000
Cash flow hedge unrealized gains to be reclassified over the next 12 months			165,000,000
Debt, face amount	25,300,000,000		25,300,000,000			25,000,000,000
Gains (losses) on firm commitments that no longer qualify as fair value hedges	0	$ 0	0	$ 0
After-tax net unrealized gains (losses) associated with net investment hedging instruments recorded in AOCI			(17,000,000)	(169,000,000)
Net investment hedge unrealized gains or losses to be reclassified over the next twelve months, net of tax			0
Gains (losses) on firm commitments that no longer qualify as net investment hedges	$ 0	$ 0	$ 0	$ 0
4.125 percent ten-year 2011 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Stated interest rate	4.125%		4.125%		4.125%
3.125 percent ten-year 2012 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Stated interest rate	3.125%		3.125%		3.125%
Currency exchange rate contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	$ 10,900,000,000		$ 10,900,000,000			11,100,000,000
Currency exchange rate contracts | Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	4,300,000,000		4,300,000,000			4,300,000,000
Currency exchange rate contracts | Derivatives designated as hedging instruments | Cash flow hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	6,500,000,000		$ 6,500,000,000			6,800,000,000
Maximum remaining maturity of foreign currency derivatives			2 years
Currency exchange rate contracts | Derivatives designated as hedging instruments | Net investment hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	13,300,000,000		$ 13,300,000,000		€ 12
Total return swaps | Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	$ 191,000,000		$ 191,000,000			191,000,000
Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount						1,200,000,000
Number of interest rate swaps outstanding | derivative	0		0		0
Market value of outstanding interest rate swap agreements - net unrealized gain						9,000,000
Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging | 4.125 percent ten-year 2011 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Debt, face amount						$ 500,000,000
Stated interest rate						4.125%
Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging | 3.125 percent ten-year 2012 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Debt, face amount						$ 675,000,000
Stated interest rate						3.125%

Derivatives and Currency Exch_4

Derivatives and Currency Exchange Risk Management - Derivative Gains (Losses) Not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Total	$ 11	$ 60	$ 10	$ 201
Other operating expense, net | Currency exchange rate contracts
Derivative Instruments, Gain (Loss) [Line Items]
Total	12	71	6	201
Other operating expense, net | Total return swaps
Derivative Instruments, Gain (Loss) [Line Items]
Total	$ (1)	$ (11)	$ 4	$ 0

Derivatives and Currency Exch_5

Derivatives and Currency Exchange Risk Management - Gains (Losses) Recognized in AOCI, Cash Flow Hedges (Details) - Currency exchange rate contracts - Cash flow hedging - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in AOCI, Cash flow hedges	$ 76		$ 103
Recognized in AOCI, Cash flow hedges		$ 174		$ 444

Derivatives and Currency Exch_6

Derivatives and Currency Exchange Risk Management - Amount of Gains (Losses) Recognized in Consolidated Statements of Income, Cash Flow Hedges (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Other operating expense, net	$ 149	$ 70	$ 127	$ 221
Cash flow hedging | Currency exchange rate contracts | Other operating expense, net
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain (loss) reclassified from AOCI into income	$ 68		$ 125
Amount of gain (loss) reclassified from AOCI into income		$ 11		$ 8

Derivatives and Currency Exch_7

Derivatives and Currency Exchange Risk Management - Schedule of Amounts Recorded on Consolidated Balance Sheet Related to Cumulative Basis Adjustments for Fair Value Hedges (Details) - Long-term debt - USD ($) $ in Millions	Oct. 25, 2019	Apr. 26, 2019
Derivatives, Fair Value [Line Items]
Carrying Amount of Hedged Assets/(Liabilities)	$ 0	$ (1,175)
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Assets/(Liabilities)	$ 0	$ 9

Derivatives and Currency Exch_8

Derivatives and Currency Exchange Risk Management - Gains (Losses) Recognized in Income, Net Investment Hedges (Details) - Currency exchange rate contracts - Other operating expense, net - Net investment hedges - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in Income, Net investment hedges	$ 0		$ (7)
Recognized in Income, Net investment hedges		$ 0		$ 0

Derivatives and Currency Exch_9

Derivatives and Currency Exchange Risk Management - Gains Losses Recognized in AOCI, Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in AOCI, Net investment hedges	$ 53		$ 152
Recognized in AOCI, Net investment hedges		$ 0		$ 0
Currency exchange rate contracts | Net investment hedges
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in AOCI, Net investment hedges	$ 53		$ 152
Recognized in AOCI, Net investment hedges		$ 0		$ 0

Derivatives and Currency Exc_10

Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details) - USD ($) $ in Millions	Oct. 25, 2019	Apr. 26, 2019
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	$ 319	$ 365
Derivative Liabilities, Fair Value	31	19
Currency exchange rate contracts
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	311	335
Derivative Liabilities, Fair Value	31	19
Interest rate contracts
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value		9
Total return swaps
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	2	15
Derivative Liabilities, Fair Value	0
Cross currency interest rate contracts
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	6	6
Derivatives designated as hedging instruments
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	290	321
Derivative Liabilities, Fair Value	7	2
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	204	234
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	86	78
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	3	1
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other liabilities
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	4	1
Derivatives designated as hedging instruments | Interest rate contracts | Other assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value		9
Derivatives designated as hedging instruments | Interest rate contracts | Other liabilities
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value		0
Derivatives not designated as hedging instruments
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	29	44
Derivative Liabilities, Fair Value	24	17
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	21	23
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	24	17
Derivatives not designated as hedging instruments | Total return swaps | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	2	15
Derivatives not designated as hedging instruments | Total return swaps | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	0	0
Derivatives not designated as hedging instruments | Cross currency interest rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	6	6
Derivatives not designated as hedging instruments | Cross currency interest rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	$ 0	$ 0

Derivatives and Currency Exc_11

Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring - USD ($) $ in Millions	Oct. 25, 2019	Apr. 26, 2019
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	$ 311	$ 335
Derivative liabilities	31	19
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	8	30
Derivative liabilities	$ 0	$ 0

Derivatives and Currency Exc_12

Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details) - USD ($) $ in Millions	Oct. 25, 2019	Apr. 26, 2019
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)	$ 319	$ 365
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(29)	(9)
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	(10)	(44)
Net Amount	280	312
Derivative liabilities:
Gross Amount of Recorded Assets (Liabilities)	(31)	(19)
Gross Amount Not Offset on the Balance Sheet, Financial Instruments		9
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)		0
Net Amount		(10)
Total
Gross Amount of Recorded Assets (Liabilities)	288	346
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	(10)	(44)
Net Amount	278	302
Currency exchange rate contracts
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)	311	335
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(29)	(9)
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	(10)	(43)
Net Amount	272	283
Derivative liabilities:
Gross Amount of Recorded Assets (Liabilities)	(31)	(19)
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	29	9
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	0	0
Net Amount	(2)	(10)
Interest rate contracts
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)		9
Gross Amount Not Offset on the Balance Sheet, Financial Instruments		0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)		(1)
Net Amount		8
Total return swaps
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)	2	15
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	0	0
Net Amount	2	15
Derivative liabilities:
Gross Amount of Recorded Assets (Liabilities)	0
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	0
Net Amount	0
Cross currency interest rate contracts
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)	6	6
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	0	0
Net Amount	$ 6	$ 6

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Oct. 25, 2019	Apr. 26, 2019
Inventory Disclosure [Abstract]
Finished goods	$ 2,686	$ 2,476
Work in-process	594	572
Raw materials	762	705
Total	$ 4,042	$ 3,753

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) $ in Millions	6 Months Ended
	Oct. 25, 2019USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 39,959
Goodwill as a result of acquisitions	92
Purchase accounting adjustments	6
Currency translation and other	(105)
Ending balance	39,952
Cardiac and Vascular Group
Goodwill [Roll Forward]
Beginning balance	6,854
Goodwill as a result of acquisitions	0
Purchase accounting adjustments	9
Currency translation and other	(1)
Ending balance	6,862
Minimally Invasive Therapies Group
Goodwill [Roll Forward]
Beginning balance	20,381
Goodwill as a result of acquisitions	11
Purchase accounting adjustments	2
Currency translation and other	(62)
Ending balance	20,332
Restorative Therapies Group
Goodwill [Roll Forward]
Beginning balance	10,821
Goodwill as a result of acquisitions	65
Purchase accounting adjustments	(5)
Currency translation and other	(42)
Ending balance	10,839
Diabetes Group
Goodwill [Roll Forward]
Beginning balance	1,903
Goodwill as a result of acquisitions	16
Purchase accounting adjustments	0
Currency translation and other	0
Ending balance	$ 1,919

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment	$ 0	$ 0	$ 0	$ 0
Definite-lived intangible asset charges	33,000,000	0	33,000,000	61,000,000
Impairment of indefinite-lived intangible assets	0	0	0	0
Amortization expense	$ 441,000,000	$ 445,000,000	$ 881,000,000	$ 891,000,000

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Millions	Oct. 25, 2019	Apr. 26, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 28,042	$ 29,004
Accumulated Amortization	(8,848)	(9,048)
IPR&D
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Indefinite-lived	581	604
Customer-related
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	16,967	16,944
Accumulated Amortization	(4,581)	(4,095)
Purchased technology and patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	10,528	11,405
Accumulated Amortization	(3,990)	(4,570)
Trademarks and tradenames
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	464	570
Accumulated Amortization	(224)	(324)
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	83	85
Accumulated Amortization	$ (53)	$ (59)

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets - Estimated Future Aggregate Amortization Expense of Amortizable Intangible Assets (Details) $ in Millions	Oct. 25, 2019USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining 2020	$ 868
2021	1,725
2022	1,684
2023	1,621
2024	1,592
2025	$ 1,565

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018	Apr. 26, 2019
Income Tax Disclosure [Abstract]
Effective tax rate	(6.00%)	17.30%	1.00%	13.30%
Certain tax adjustments	$ (251)	$ 58	$ (281)	$ 29
Benefit related to tax legislative changes in Switzerland	251		251
Net charge (benefit) related to measurement period adjustment related to U.S. Tax Reform		37	(30)	(13)
Charge related to recognition of prepaid tax expense		$ 21		$ 42
Gross unrecognized tax benefits	1,800		1,800		$ 1,800
Accrued gross interest and penalties	196		196
Unrecognized tax benefits that would impact effective tax rate	$ 1,800		$ 1,800
Amortizable Asset Created for Swiss Federal Income Tax Purposes
Finite-Lived Intangible Assets [Line Items]
Period over which amortizable asset will be amortized and deducted	10 years		10 years

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Numerator:
Net income attributable to ordinary shareholders	$ 1,364	$ 1,115	$ 2,228	$ 2,190
Denominator:
Basic - weighted average shares outstanding (shares)	1,340.8	1,349.2	1,340.8	1,350.9
Effect of dilutive securities:
Employee stock options (shares)	8	8.5	7.4	8.4
Employee restricted stock units (shares)	2.6	3.1	3.1	3.3
Other (shares)	0	0.1	0.3	0.4
Diluted - weighted average shares outstanding (shares)	1,351.4	1,360.9	1,351.6	1,363
Basic earnings per share (usd per share)	$ 1.02	$ 0.83	$ 1.66	$ 1.62
Diluted earnings per share (usd per share)	$ 1.01	$ 0.82	$ 1.65	$ 1.61

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	4	7	4	6

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 108	$ 104	$ 169	$ 168
Income tax benefits	(19)	(21)	(29)	(32)
Total stock-based compensation expense, net of tax	89	83	140	136
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	10	12	16	18
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	13	13	20	21
Selling, general, and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	85	79	133	129
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	31	33	40	51
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	71	65	113	101
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 6	$ 6	$ 16	$ 16

Retirement Benefit Plans (Detai

Retirement Benefit Plans (Details) - Pension plans - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
U.S.
Net Periodic Benefit Cost
Service cost	$ 26	$ 27	$ 52	$ 54
Interest cost	32	33	64	66
Expected return on plan assets	(56)	(54)	(112)	(108)
Amortization of net actuarial loss	14	19	28	38
Net periodic benefit cost	16	25	32	50
Non-U.S.
Net Periodic Benefit Cost
Service cost	15	15	30	30
Interest cost	7	7	14	14
Expected return on plan assets	(15)	(14)	(30)	(28)
Amortization of net actuarial loss	4	3	7	6
Net periodic benefit cost	$ 11	$ 11	$ 21	$ 22

Leases - Balance Sheet Classifi

Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details) $ in Millions	Oct. 25, 2019USD ($)
Leases [Abstract]
Right-of-use assets	$ 989
Current liability	176
Non-current liability	$ 834

Leases - Weighted-Average Remai

Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details)	Oct. 25, 2019
Leases [Abstract]
Weighted-average remaining lease term	7 years 8 months 12 days
Weighted-average discount rate	3.00%

Leases - Components of Total Op

Leases - Components of Total Operating Lease Cost (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Oct. 25, 2019	Oct. 25, 2019
Leases [Abstract]
Operating lease cost	$ 56	$ 111
Short-term lease cost	11	22
Total operating lease cost	$ 67	$ 133

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) $ in Millions	6 Months Ended
	Oct. 25, 2019USD ($)
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 110
Right-of-use assets obtained in exchange for operating lease liabilities	$ 105

Leases - Maturities of Operatin

Leases - Maturities of Operating Leases (Details) $ in Millions	Oct. 25, 2019USD ($)
Leases [Abstract]
Remaining 2020	$ 105
2021	193
2022	161
2023	140
2024	117
Thereafter	451
Total expected lease payments	1,167
Less: Imputed interest	(157)
Total lease liability	$ 1,010

Leases - Minimum Payments Under

Leases - Minimum Payments Under Non-Cancelable Operating Leases (Details) $ in Millions	Apr. 26, 2019USD ($)
Leases [Abstract]
2020	$ 216
2021	157
2022	103
2023	61
2024	34
Thereafter	81
Total minimum lease payments	$ 652

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Changes in AOCI (Details) - USD ($)		3 Months Ended				6 Months Ended
		Oct. 25, 2019	Jul. 26, 2019	Oct. 26, 2018	Jul. 27, 2018	Oct. 25, 2019	Oct. 26, 2018	Apr. 27, 2019	[1]	Apr. 28, 2018
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		$ 50,497,000,000	$ 50,212,000,000	$ 50,329,000,000	$ 50,822,000,000	$ 50,212,000,000	$ 50,822,000,000
Other comprehensive (loss) income		(127,000,000)	227,000,000	(292,000,000)	(584,000,000)	100,000,000	(876,000,000)
Cumulative effect of change in accounting principle								$ (33,000,000)		$ 0	[2]
Ending balance		50,719,000,000	50,497,000,000	49,714,000,000	50,329,000,000	50,719,000,000	49,714,000,000
Unrealized (Loss) Gain on Investment Securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			(45,000,000)		(194,000,000)	(45,000,000)	(194,000,000)
Other comprehensive (loss) income before reclassifications						68,000,000	(19,000,000)
Reclassifications						5,000,000	10,000,000
Other comprehensive (loss) income						73,000,000	(9,000,000)
Cumulative effect of change in accounting principle										47,000,000
Ending balance		28,000,000		(156,000,000)		28,000,000	(156,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)						1,000,000	(1,000,000)
Reclassifications, tax expense (benefit)						(2,000,000)	0
Cumulative Translation Adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			(1,383,000,000)		(11,000,000)	(1,383,000,000)	(11,000,000)
Other comprehensive (loss) income before reclassifications						(148,000,000)	(1,252,000,000)
Reclassifications						0	0
Other comprehensive (loss) income						(148,000,000)	(1,252,000,000)
Cumulative effect of change in accounting principle										0
Ending balance		(1,531,000,000)		(1,263,000,000)		(1,531,000,000)	(1,263,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)						0	(5,000,000)
Net Investment Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			(169,000,000)			(169,000,000)
Other comprehensive (loss) income before reclassifications						152,000,000
Reclassifications						0
Other comprehensive (loss) income						152,000,000
Ending balance		(17,000,000)				(17,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)						0
Net Investment Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance					(257,000,000)		(257,000,000)
Other comprehensive (loss) income before reclassifications							0
Reclassifications							0
Other comprehensive (loss) income							0
Cumulative effect of change in accounting principle										0
Ending balance				(257,000,000)			(257,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)							0
Net Change in Retirement Obligations
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			(1,308,000,000)		(1,117,000,000)	(1,308,000,000)	(1,117,000,000)
Other comprehensive (loss) income before reclassifications						(1,000,000)	0
Reclassifications						26,000,000	48,000,000
Other comprehensive (loss) income						25,000,000	48,000,000
Cumulative effect of change in accounting principle										0
Ending balance		(1,283,000,000)		(1,069,000,000)		(1,283,000,000)	(1,069,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)						0	0
Reclassifications, tax expense (benefit)						(6,000,000)	(10,000,000)
Unrealized Gain (Loss) on Cash Flow Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			194,000,000			194,000,000
Other comprehensive (loss) income before reclassifications						82,000,000
Reclassifications						(84,000,000)
Other comprehensive (loss) income						(2,000,000)
Ending balance		192,000,000				192,000,000
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)						21,000,000
Reclassifications, tax expense (benefit)						(26,000,000)
Unrealized (Loss) Gain on Cash Flow Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance					(207,000,000)		(207,000,000)
Other comprehensive (loss) income before reclassifications							343,000,000
Reclassifications							(3,000,000)
Other comprehensive (loss) income							340,000,000
Cumulative effect of change in accounting principle										0
Ending balance				133,000,000			133,000,000
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)							100,000,000
Reclassifications, tax expense (benefit)							(3,000,000)
Total Accumulated Other Comprehensive (Loss) Income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(2,484,000,000)	(2,711,000,000)	(2,323,000,000)	(1,786,000,000)	(2,711,000,000)	(1,786,000,000)
Other comprehensive (loss) income before reclassifications						153,000,000	(928,000,000)
Reclassifications						(53,000,000)	55,000,000
Other comprehensive (loss) income		(127,000,000)	227,000,000	(289,000,000)	(584,000,000)	100,000,000	(873,000,000)
Cumulative effect of change in accounting principle	[2]									47,000,000
Ending balance		(2,611,000,000)	(2,484,000,000)	(2,612,000,000)	(2,323,000,000)	(2,611,000,000)	(2,612,000,000)
Retained Earnings
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		26,377,000,000	26,270,000,000	24,730,000,000	24,379,000,000	26,270,000,000	24,379,000,000
Cumulative effect of change in accounting principle								$ (33,000,000)		$ (47,000,000)	[2]
Ending balance		$ 27,018,000,000	$ 26,377,000,000	$ 25,171,000,000	$ 24,730,000,000	$ 27,018,000,000	$ 25,171,000,000
[1]	See Note 2 to the consolidated financial statements for discussion regarding the adoption of accounting standards during the first quarter fiscal year 2020.
[2]	The cumulative effect of change in accounting principle during the first quarter of fiscal year 2019 resulted from the adoption of accounting guidance that requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. As a result of the adoption, the Company reclassified $47 million from accumulated other comprehensive loss to the opening balance of retained earnings as of April 28, 2018.

Commitments and Contingencies (

Commitments and Contingencies (Details)	Nov. 06, 2019claim	Nov. 28, 2018USD ($)	Dec. 14, 2011patent	Jun. 29, 2007	May 31, 2017claim	Oct. 25, 2019USD ($)claim	Oct. 26, 2018USD ($)	Oct. 25, 2019USD ($)landfillclaimsubsidiarymanufacturer	Oct. 26, 2018USD ($)	Apr. 29, 2016USD ($)claim	Apr. 26, 2019USD ($)
Loss Contingencies [Line Items]
Certain litigation charges						$ 121,000,000	$ 0	$ 168,000,000	$ 103,000,000
Accrued litigation charges						$ 600,000,000		$ 600,000,000			$ 500,000,000
Covidien
Loss Contingencies [Line Items]
Tax sharing percentage, parent				42.00%
Tax sharing percentage, former parent				27.00%
Tax sharing percentage, former affiliate				31.00%
Orrington, Maine chemical manufacturing facility
Loss Contingencies [Line Items]
Number of landfills requiring removal | landfill								2
Number of landfills requiring capping | landfill								3
Pelvic mesh | Product liability litigation
Loss Contingencies [Line Items]
Number of subsidiaries | subsidiary								2
Number of manufacturers | manufacturer								1
Amount of settlement received										$ 121,000,000
Number of claims settled | claim					5,000					11,000
Number of pending claims | claim						15,800		15,800
Pelvic mesh | Product liability litigation | Subsequent Event
Loss Contingencies [Line Items]
Number of claims settled | claim	15,400
Ethicon
Loss Contingencies [Line Items]
Patents infringed | patent			1
Patents not infringed upon | patent			6
Sasso
Loss Contingencies [Line Items]
Approximate amount of verdict returned against the Company		$ 112,000,000

Segment and Geographic Inform_3

Segment and Geographic Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018	Oct. 25, 2019	Oct. 26, 2018
Segment Reporting Information [Line Items]
Net sales	$ 7,706,000,000	$ 7,481,000,000	$ 15,199,000,000	$ 14,865,000,000
Income before Income Taxes by Reportable Segment
Segment operating profit	1,351,000,000	1,544,000,000	2,836,000,000	2,780,000,000
Interest expense	(165,000,000)	(241,000,000)	(774,000,000)	(483,000,000)
Amortization of intangible assets	(441,000,000)	(445,000,000)	(881,000,000)	(891,000,000)
Restructuring and associated costs	(27,000,000)	(24,000,000)	(74,000,000)	(86,000,000)
Certain litigation charges	(121,000,000)	0	(168,000,000)	(103,000,000)
Income (loss) before income taxes	1,294,000,000	1,355,000,000	2,271,000,000	2,535,000,000
Ireland
Segment Reporting Information [Line Items]
Net sales	23,000,000	22,000,000	43,000,000	44,000,000
United States
Segment Reporting Information [Line Items]
Net sales	4,129,000,000	4,045,000,000	8,046,000,000	7,909,000,000
Rest of world
Segment Reporting Information [Line Items]
Net sales	3,554,000,000	3,414,000,000	7,110,000,000	6,912,000,000
Total other countries, excluding Ireland
Segment Reporting Information [Line Items]
Net sales	7,683,000,000	7,459,000,000	15,156,000,000	14,821,000,000
Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	2,939,000,000	2,909,000,000	5,706,000,000	5,672,000,000
Segment Reconciling Items
Income before Income Taxes by Reportable Segment
Interest expense	(165,000,000)	(241,000,000)	(774,000,000)	(483,000,000)
Other non-operating income, net	108,000,000	52,000,000	209,000,000	238,000,000
Amortization of intangible assets	(441,000,000)	(445,000,000)	(881,000,000)	(891,000,000)
Corporate	(350,000,000)	(342,000,000)	(657,000,000)	(645,000,000)
Centralized distribution costs	(424,000,000)	(482,000,000)	(768,000,000)	(928,000,000)
Restructuring and associated costs	(94,000,000)	(77,000,000)	(218,000,000)	(190,000,000)
Acquisition-related items	(27,000,000)	(4,000,000)	(46,000,000)	(40,000,000)
Certain litigation charges	(121,000,000)	0	(168,000,000)	(103,000,000)
IPR&D charges	0	(15,000,000)	0	(15,000,000)
Exit of businesses	(41,000,000)	0	(41,000,000)	(80,000,000)
Debt tender premium and other charges	0	0	7,000,000	0
Medical device regulations	(10,000,000)	0	(18,000,000)	0
Contribution to Medtronic Foundation	(80,000,000)	0	(80,000,000)	0
Cardiac and Vascular Group
Segment Reporting Information [Line Items]
Net sales	2,855,000,000	2,858,000,000	5,645,000,000	5,669,000,000
Cardiac and Vascular Group | United States
Segment Reporting Information [Line Items]
Net sales	1,455,000,000	1,482,000,000	2,816,000,000	2,871,000,000
Cardiac and Vascular Group | Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	1,128,000,000	1,137,000,000	2,183,000,000	2,186,000,000
Minimally Invasive Therapies Group
Segment Reporting Information [Line Items]
Net sales	2,142,000,000	2,047,000,000	4,242,000,000	4,099,000,000
Minimally Invasive Therapies Group | United States
Segment Reporting Information [Line Items]
Net sales	922,000,000	872,000,000	1,835,000,000	1,729,000,000
Minimally Invasive Therapies Group | Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	823,000,000	792,000,000	1,593,000,000	1,568,000,000
Restorative Therapies Group
Segment Reporting Information [Line Items]
Net sales	2,112,000,000	1,993,000,000	4,124,000,000	3,942,000,000
Restorative Therapies Group | United States
Segment Reporting Information [Line Items]
Net sales	1,440,000,000	1,357,000,000	2,778,000,000	2,651,000,000
Restorative Therapies Group | Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	840,000,000	804,000,000	1,633,000,000	1,570,000,000
Diabetes Group
Segment Reporting Information [Line Items]
Net sales	596,000,000	583,000,000	1,188,000,000	1,155,000,000
Diabetes Group | United States
Segment Reporting Information [Line Items]
Net sales	311,000,000	334,000,000	618,000,000	658,000,000
Diabetes Group | Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	$ 148,000,000	$ 176,000,000	$ 297,000,000	$ 348,000,000

Guarantor Financial Informati_3

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Details) - USD ($)	3 Months Ended				6 Months Ended
	Oct. 25, 2019	Jul. 26, 2019	Oct. 26, 2018	Jul. 27, 2018	Oct. 25, 2019	Oct. 26, 2018
Condensed Statement of Income Captions [Line Items]
Net sales	$ 7,706,000,000		$ 7,481,000,000		$ 15,199,000,000	$ 14,865,000,000
Costs and expenses:
Cost of products sold	2,394,000,000		2,203,000,000		4,760,000,000	4,407,000,000
Research and development expense	603,000,000		590,000,000		1,190,000,000	1,175,000,000
Selling, general, and administrative expense	2,620,000,000		2,605,000,000		5,163,000,000	5,202,000,000
Amortization of intangible assets	441,000,000		445,000,000		881,000,000	891,000,000
Restructuring charges, net	27,000,000		24,000,000		74,000,000	86,000,000
Certain litigation charges	121,000,000		0		168,000,000	103,000,000
Other operating expense (income), net	149,000,000		70,000,000		127,000,000	221,000,000
Operating profit (loss)	1,351,000,000		1,544,000,000		2,836,000,000	2,780,000,000
Other non-operating (income) expense, net	(108,000,000)		(52,000,000)		(209,000,000)	(238,000,000)
Interest expense	165,000,000		241,000,000		774,000,000	483,000,000
Equity in net (income) loss of subsidiaries	0		0		0	0
Income (loss) before income taxes	1,294,000,000		1,355,000,000		2,271,000,000	2,535,000,000
Income tax provision	(77,000,000)		235,000,000		23,000,000	338,000,000
Net income (loss)	1,371,000,000	$ 877,000,000	1,120,000,000	$ 1,077,000,000	2,248,000,000	2,197,000,000
Net income attributable to noncontrolling interests	(7,000,000)		(5,000,000)		(20,000,000)	(7,000,000)
Net income (loss) attributable to Medtronic	1,364,000,000		1,115,000,000		2,228,000,000	2,190,000,000
Other comprehensive income (loss), net of tax	(127,000,000)	$ 227,000,000	(292,000,000)	$ (584,000,000)	100,000,000	(876,000,000)
Comprehensive income attributable to noncontrolling interests	(7,000,000)		(2,000,000)		(20,000,000)	(4,000,000)
Comprehensive income attributable to Medtronic	1,237,000,000		826,000,000		2,328,000,000	1,317,000,000
Consolidating Adjustments | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	(385,000,000)		(364,000,000)		(811,000,000)	(726,000,000)
Costs and expenses:
Cost of products sold	(310,000,000)		(239,000,000)		(621,000,000)	(476,000,000)
Research and development expense	0		0		0	0
Selling, general, and administrative expense	0		0		0	0
Amortization of intangible assets	0		0		0	0
Restructuring charges, net	0		0		0	0
Certain litigation charges	0				0	0
Other operating expense (income), net	(87,000,000)		(116,000,000)		(177,000,000)	(222,000,000)
Operating profit (loss)	12,000,000		(9,000,000)		(13,000,000)	(28,000,000)
Other non-operating (income) expense, net	631,000,000		690,000,000		1,240,000,000	1,332,000,000
Interest expense	(631,000,000)		(690,000,000)		(1,240,000,000)	(1,332,000,000)
Equity in net (income) loss of subsidiaries	3,495,000,000		3,198,000,000		6,063,000,000	6,295,000,000
Income (loss) before income taxes	(3,483,000,000)		(3,207,000,000)		(6,076,000,000)	(6,323,000,000)
Income tax provision	0		0		0	0
Net income (loss)	(3,483,000,000)		(3,207,000,000)		(6,076,000,000)	(6,323,000,000)
Net income attributable to noncontrolling interests	0		0		0	0
Net income (loss) attributable to Medtronic	(3,483,000,000)		(3,207,000,000)		(6,076,000,000)	(6,323,000,000)
Other comprehensive income (loss), net of tax	395,000,000		790,000,000		12,000,000	2,486,000,000
Comprehensive income attributable to noncontrolling interests	0		0		0	0
Comprehensive income attributable to Medtronic	(3,088,000,000)		(2,417,000,000)		(6,064,000,000)	(3,837,000,000)
Consolidating Adjustments | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0		0		0	0
Costs and expenses:
Cost of products sold	0		0		0	0
Research and development expense	0		0		0	0
Selling, general, and administrative expense	0		0		0	0
Amortization of intangible assets	0		0		0	0
Restructuring charges, net	0		0		0	0
Certain litigation charges	0				0	0
Other operating expense (income), net	0		0		0	0
Operating profit (loss)	0		0		0	0
Other non-operating (income) expense, net	534,000,000		290,000,000		1,147,000,000	557,000,000
Interest expense	(534,000,000)		(290,000,000)		(1,147,000,000)	(557,000,000)
Equity in net (income) loss of subsidiaries	4,128,000,000		3,058,000,000		7,045,000,000	6,317,000,000
Income (loss) before income taxes	(4,128,000,000)		(3,058,000,000)		(7,045,000,000)	(6,317,000,000)
Income tax provision	0		0		0	0
Net income (loss)	(4,128,000,000)		(3,058,000,000)		(7,045,000,000)	(6,317,000,000)
Net income attributable to noncontrolling interests	0		0		0	0
Net income (loss) attributable to Medtronic	(4,128,000,000)		(3,058,000,000)		(7,045,000,000)	(6,317,000,000)
Other comprehensive income (loss), net of tax	402,000,000		672,000,000		(36,000,000)	1,881,000,000
Comprehensive income attributable to noncontrolling interests	0		0		0	0
Comprehensive income attributable to Medtronic	(3,726,000,000)		(2,386,000,000)		(7,081,000,000)	(4,436,000,000)
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0		0		0	0
Costs and expenses:
Cost of products sold	0		0		0	0
Research and development expense	0		0		0	0
Selling, general, and administrative expense	4,000,000		4,000,000		7,000,000	6,000,000
Amortization of intangible assets	0		0		0	0
Restructuring charges, net	0		0		0	0
Certain litigation charges	0				0	0
Other operating expense (income), net	13,000,000		24,000,000		26,000,000	25,000,000
Operating profit (loss)	(17,000,000)		(28,000,000)		(33,000,000)	(31,000,000)
Other non-operating (income) expense, net	0		0		0	0
Interest expense	139,000,000		108,000,000		283,000,000	208,000,000
Equity in net (income) loss of subsidiaries	(1,518,000,000)		(1,249,000,000)		(2,540,000,000)	(2,425,000,000)
Income (loss) before income taxes	1,362,000,000		1,113,000,000		2,224,000,000	2,186,000,000
Income tax provision	(2,000,000)		(2,000,000)		(4,000,000)	(4,000,000)
Net income (loss)	1,364,000,000		1,115,000,000		2,228,000,000	2,190,000,000
Net income attributable to noncontrolling interests	0		0		0	0
Net income (loss) attributable to Medtronic	1,364,000,000		1,115,000,000		2,228,000,000	2,190,000,000
Other comprehensive income (loss), net of tax	(127,000,000)		(289,000,000)		100,000,000	(873,000,000)
Comprehensive income attributable to noncontrolling interests	0		0		0	0
Comprehensive income attributable to Medtronic	1,237,000,000		826,000,000		2,328,000,000	1,317,000,000
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0		0		0	0
Costs and expenses:
Cost of products sold	0		0		0	0
Research and development expense	0		0		0	0
Selling, general, and administrative expense	4,000,000		4,000,000		7,000,000	6,000,000
Amortization of intangible assets	0		0		0	0
Restructuring charges, net	0		0		0	0
Certain litigation charges	0				0	0
Other operating expense (income), net	13,000,000		24,000,000		26,000,000	25,000,000
Operating profit (loss)	(17,000,000)		(28,000,000)		(33,000,000)	(31,000,000)
Other non-operating (income) expense, net	0		0		0	0
Interest expense	139,000,000		108,000,000		283,000,000	208,000,000
Equity in net (income) loss of subsidiaries	(1,518,000,000)		(1,249,000,000)		(2,540,000,000)	(2,425,000,000)
Income (loss) before income taxes	1,362,000,000		1,113,000,000		2,224,000,000	2,186,000,000
Income tax provision	(2,000,000)		(2,000,000)		(4,000,000)	(4,000,000)
Net income (loss)	1,364,000,000		1,115,000,000		2,228,000,000	2,190,000,000
Net income attributable to noncontrolling interests	0		0		0	0
Net income (loss) attributable to Medtronic	1,364,000,000		1,115,000,000		2,228,000,000	2,190,000,000
Other comprehensive income (loss), net of tax	(127,000,000)		(289,000,000)		100,000,000	(873,000,000)
Comprehensive income attributable to noncontrolling interests	0		0		0	0
Comprehensive income attributable to Medtronic	1,237,000,000		826,000,000		2,328,000,000	1,317,000,000
Subsidiary Issuer | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	385,000,000		364,000,000		811,000,000	726,000,000
Costs and expenses:
Cost of products sold	350,000,000		280,000,000		676,000,000	553,000,000
Research and development expense	178,000,000		176,000,000		346,000,000	344,000,000
Selling, general, and administrative expense	431,000,000		413,000,000		809,000,000	781,000,000
Amortization of intangible assets	3,000,000		2,000,000		6,000,000	4,000,000
Restructuring charges, net	7,000,000		1,000,000		9,000,000	11,000,000
Certain litigation charges	0				5,000,000	78,000,000
Other operating expense (income), net	(629,000,000)		(672,000,000)		(1,067,000,000)	(931,000,000)
Operating profit (loss)	45,000,000		164,000,000		27,000,000	(114,000,000)
Other non-operating (income) expense, net	(73,000,000)		(138,000,000)		(134,000,000)	(297,000,000)
Interest expense	345,000,000		482,000,000		1,056,000,000	946,000,000
Equity in net (income) loss of subsidiaries	(581,000,000)		(762,000,000)		(1,192,000,000)	(1,568,000,000)
Income (loss) before income taxes	354,000,000		582,000,000		297,000,000	805,000,000
Income tax provision	(30,000,000)		(15,000,000)		(159,000,000)	(119,000,000)
Net income (loss)	384,000,000		597,000,000		456,000,000	924,000,000
Net income attributable to noncontrolling interests	0		0		0	0
Net income (loss) attributable to Medtronic	384,000,000		597,000,000		456,000,000	924,000,000
Other comprehensive income (loss), net of tax	(76,000,000)		(194,000,000)		(29,000,000)	(702,000,000)
Comprehensive income attributable to noncontrolling interests	0		0		0	0
Comprehensive income attributable to Medtronic	308,000,000		403,000,000		427,000,000	222,000,000
Subsidiary Issuer | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0		0		0	0
Costs and expenses:
Cost of products sold	0		0		0	0
Research and development expense	0		0		0	0
Selling, general, and administrative expense	0		0		0	0
Amortization of intangible assets	0		0		0	0
Restructuring charges, net	0		0		0	0
Certain litigation charges	0				0	0
Other operating expense (income), net	0		0		0	0
Operating profit (loss)	0		0		0	0
Other non-operating (income) expense, net	(32,000,000)		(9,000,000)		(95,000,000)	(19,000,000)
Interest expense	191,000,000		22,000,000		412,000,000	43,000,000
Equity in net (income) loss of subsidiaries	(1,220,000,000)		(629,000,000)		(2,188,000,000)	(1,602,000,000)
Income (loss) before income taxes	1,061,000,000		616,000,000		1,871,000,000	1,578,000,000
Income tax provision	0		0		0	0
Net income (loss)	1,061,000,000		616,000,000		1,871,000,000	1,578,000,000
Net income attributable to noncontrolling interests	0		0		0	0
Net income (loss) attributable to Medtronic	1,061,000,000		616,000,000		1,871,000,000	1,578,000,000
Other comprehensive income (loss), net of tax	(95,000,000)		(91,000,000)		(11,000,000)	(132,000,000)
Comprehensive income attributable to noncontrolling interests	0		0		0	0
Comprehensive income attributable to Medtronic	966,000,000		525,000,000		1,860,000,000	1,446,000,000
Subsidiary Guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0		0		0	0
Costs and expenses:
Cost of products sold	0		0		0	0
Research and development expense	0		0		0	0
Selling, general, and administrative expense	0		0		0	0
Amortization of intangible assets	0		0		0	0
Restructuring charges, net	0		0		0	0
Certain litigation charges	0				0	0
Other operating expense (income), net	0		0		(7,000,000)	0
Operating profit (loss)	0		0		7,000,000	0
Other non-operating (income) expense, net	(241,000,000)		(175,000,000)		(486,000,000)	(339,000,000)
Interest expense	119,000,000		113,000,000		284,000,000	216,000,000
Equity in net (income) loss of subsidiaries	(1,396,000,000)		(1,187,000,000)		(2,331,000,000)	(2,302,000,000)
Income (loss) before income taxes	1,518,000,000		1,249,000,000		2,540,000,000	2,425,000,000
Income tax provision	0		0		0	0
Net income (loss)	1,518,000,000		1,249,000,000		2,540,000,000	2,425,000,000
Net income attributable to noncontrolling interests	0		0		0	0
Net income (loss) attributable to Medtronic	1,518,000,000		1,249,000,000		2,540,000,000	2,425,000,000
Other comprehensive income (loss), net of tax	(127,000,000)		(289,000,000)		100,000,000	(873,000,000)
Comprehensive income attributable to noncontrolling interests	0		0		0	0
Comprehensive income attributable to Medtronic	1,391,000,000		960,000,000		2,640,000,000	1,552,000,000
Subsidiary Guarantors | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0		0		0	0
Costs and expenses:
Cost of products sold	0		0		0	0
Research and development expense	0		0		0	0
Selling, general, and administrative expense	1,000,000		1,000,000		1,000,000	1,000,000
Amortization of intangible assets	0		0		0	0
Restructuring charges, net	0		0		0	0
Certain litigation charges	0				0	0
Other operating expense (income), net	0		0		(7,000,000)	0
Operating profit (loss)	(1,000,000)		(1,000,000)		6,000,000	(1,000,000)
Other non-operating (income) expense, net	(248,000,000)		(183,000,000)		(501,000,000)	(352,000,000)
Interest expense	119,000,000		113,000,000		284,000,000	216,000,000
Equity in net (income) loss of subsidiaries	(1,390,000,000)		(1,180,000,000)		(2,317,000,000)	(2,290,000,000)
Income (loss) before income taxes	1,518,000,000		1,249,000,000		2,540,000,000	2,425,000,000
Income tax provision	0		0		0	0
Net income (loss)	1,518,000,000		1,249,000,000		2,540,000,000	2,425,000,000
Net income attributable to noncontrolling interests	0		0		0	0
Net income (loss) attributable to Medtronic	1,518,000,000		1,249,000,000		2,540,000,000	2,425,000,000
Other comprehensive income (loss), net of tax	(127,000,000)		(289,000,000)		100,000,000	(873,000,000)
Comprehensive income attributable to noncontrolling interests	0		0		0	0
Comprehensive income attributable to Medtronic	1,391,000,000		960,000,000		2,640,000,000	1,552,000,000
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	7,706,000,000		7,481,000,000		15,199,000,000	14,865,000,000
Costs and expenses:
Cost of products sold	2,354,000,000		2,162,000,000		4,705,000,000	4,330,000,000
Research and development expense	425,000,000		414,000,000		844,000,000	831,000,000
Selling, general, and administrative expense	2,185,000,000		2,188,000,000		4,347,000,000	4,415,000,000
Amortization of intangible assets	438,000,000		443,000,000		875,000,000	887,000,000
Restructuring charges, net	20,000,000		23,000,000		65,000,000	75,000,000
Certain litigation charges	121,000,000				163,000,000	25,000,000
Other operating expense (income), net	852,000,000		834,000,000		1,352,000,000	1,349,000,000
Operating profit (loss)	1,311,000,000		1,417,000,000		2,848,000,000	2,953,000,000
Other non-operating (income) expense, net	(425,000,000)		(429,000,000)		(829,000,000)	(934,000,000)
Interest expense	193,000,000		228,000,000		391,000,000	445,000,000
Equity in net (income) loss of subsidiaries	0		0		0	0
Income (loss) before income taxes	1,543,000,000		1,618,000,000		3,286,000,000	3,442,000,000
Income tax provision	(45,000,000)		252,000,000		186,000,000	461,000,000
Net income (loss)	1,588,000,000		1,366,000,000		3,100,000,000	2,981,000,000
Net income attributable to noncontrolling interests	(7,000,000)		(5,000,000)		(20,000,000)	(7,000,000)
Net income (loss) attributable to Medtronic	1,581,000,000		1,361,000,000		3,080,000,000	2,974,000,000
Other comprehensive income (loss), net of tax	(192,000,000)		(310,000,000)		(83,000,000)	(914,000,000)
Comprehensive income attributable to noncontrolling interests	(7,000,000)		(2,000,000)		(20,000,000)	(4,000,000)
Comprehensive income attributable to Medtronic	1,389,000,000		1,054,000,000		2,997,000,000	2,063,000,000
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	7,706,000,000		7,481,000,000		15,199,000,000	14,865,000,000
Costs and expenses:
Cost of products sold	2,394,000,000		2,203,000,000		4,760,000,000	4,407,000,000
Research and development expense	603,000,000		590,000,000		1,190,000,000	1,175,000,000
Selling, general, and administrative expense	2,615,000,000		2,600,000,000		5,155,000,000	5,195,000,000
Amortization of intangible assets	441,000,000		445,000,000		881,000,000	891,000,000
Restructuring charges, net	27,000,000		24,000,000		74,000,000	86,000,000
Certain litigation charges	121,000,000				168,000,000	103,000,000
Other operating expense (income), net	136,000,000		46,000,000		108,000,000	196,000,000
Operating profit (loss)	1,369,000,000		1,573,000,000		2,863,000,000	2,812,000,000
Other non-operating (income) expense, net	(362,000,000)		(150,000,000)		(760,000,000)	(424,000,000)
Interest expense	250,000,000		288,000,000		942,000,000	573,000,000
Equity in net (income) loss of subsidiaries	0		0		0	0
Income (loss) before income taxes	1,481,000,000		1,435,000,000		2,681,000,000	2,663,000,000
Income tax provision	(75,000,000)		237,000,000		27,000,000	342,000,000
Net income (loss)	1,556,000,000		1,198,000,000		2,654,000,000	2,321,000,000
Net income attributable to noncontrolling interests	(7,000,000)		(5,000,000)		(20,000,000)	(7,000,000)
Net income (loss) attributable to Medtronic	1,549,000,000		1,193,000,000		2,634,000,000	2,314,000,000
Other comprehensive income (loss), net of tax	(180,000,000)		(295,000,000)		(53,000,000)	(879,000,000)
Comprehensive income attributable to noncontrolling interests	(7,000,000)		(2,000,000)		(20,000,000)	(4,000,000)
Comprehensive income attributable to Medtronic	$ 1,369,000,000		$ 901,000,000		$ 2,581,000,000	$ 1,438,000,000

Guarantor Financial Informati_4

Guarantor Financial Information - Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Millions	Oct. 25, 2019	Jul. 26, 2019	Apr. 26, 2019	Oct. 26, 2018	Jul. 27, 2018	Apr. 27, 2018
Current assets:
Cash and cash equivalents	$ 3,962		$ 4,393
Investments	6,436		5,455
Accounts receivable, net	6,118		6,222
Inventories, net	4,042		3,753
Intercompany receivable	0		0
Other current assets	2,095		2,144
Total current assets	22,653		21,967
Property, plant, and equipment, net	4,756		4,675
Goodwill	39,952		39,959
Other intangible assets, net	19,775		20,560
Tax assets	1,804		1,519
Investment in subsidiaries	0		0
Intercompany loans receivable	0		0
Other assets	2,113		1,014
Total assets	91,053		89,694
Current liabilities:
Current debt obligations	875		838
Accounts payable	1,965		1,953
Intercompany payable	0		0
Accrued compensation	1,773		2,189
Accrued income taxes	442		567
Other accrued expenses	3,115		2,925
Total current liabilities	8,170		8,472
Long-term debt	24,752		24,486
Accrued compensation and retirement benefits	1,573		1,651
Accrued income taxes	2,705		2,838
Intercompany loans payable	0		0
Deferred tax liabilities	1,376		1,278
Other liabilities	1,758		757
Total liabilities	40,334		39,482
Shareholders’ equity	50,578		50,091
Noncontrolling interests	141		121
Total equity	50,719	$ 50,497	50,212	$ 49,714	$ 50,329	$ 50,822
Total liabilities and equity	91,053		89,694
Consolidating Adjustments | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	0		0
Investments	0		0
Accounts receivable, net	0		0
Inventories, net	(237)		(227)
Intercompany receivable	(41,851)		(28,623)
Other current assets	0		0
Total current assets	(42,088)		(28,850)
Property, plant, and equipment, net	0		0
Goodwill	0		0
Other intangible assets, net	0		0
Tax assets	0		0
Investment in subsidiaries	(206,834)		(200,493)
Intercompany loans receivable	(58,381)		(66,277)
Other assets	0		0
Total assets	(307,303)		(295,620)
Current liabilities:
Current debt obligations	0		0
Accounts payable	0		0
Intercompany payable	(41,851)		(28,623)
Accrued compensation	0		0
Accrued income taxes	0		0
Other accrued expenses	0		0
Total current liabilities	(41,851)		(28,623)
Long-term debt	0		0
Accrued compensation and retirement benefits	0		0
Accrued income taxes	0		0
Intercompany loans payable	(58,381)		(66,277)
Deferred tax liabilities	0		0
Other liabilities	0		0
Total liabilities	(100,232)		(94,900)
Shareholders’ equity	(207,071)		(200,720)
Noncontrolling interests	0		0
Total equity	(207,071)		(200,720)
Total liabilities and equity	(307,303)		(295,620)
Consolidating Adjustments | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0		0
Investments	0		0
Accounts receivable, net	0		0
Inventories, net	0		0
Intercompany receivable	(12,221)		(8,626)
Other current assets	0		0
Total current assets	(12,221)		(8,626)
Property, plant, and equipment, net	0		0
Goodwill	0		0
Other intangible assets, net	0		0
Tax assets	0		0
Investment in subsidiaries	(191,199)		(167,560)
Intercompany loans receivable	(77,623)		(63,979)
Other assets	0		0
Total assets	(281,043)		(240,165)
Current liabilities:
Current debt obligations	0		0
Accounts payable	0		0
Intercompany payable	(12,221)		(8,626)
Accrued compensation	0		0
Accrued income taxes	0		0
Other accrued expenses	0		0
Total current liabilities	(12,221)		(8,626)
Long-term debt	0		0
Accrued compensation and retirement benefits	0		0
Accrued income taxes	0		0
Intercompany loans payable	(77,623)		(63,979)
Deferred tax liabilities	0		0
Other liabilities	0		0
Total liabilities	(89,844)		(72,605)
Shareholders’ equity	(191,199)		(167,560)
Noncontrolling interests	0		0
Total equity	(191,199)		(167,560)
Total liabilities and equity	(281,043)		(240,165)
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	0		0
Investments	0		0
Accounts receivable, net	0		0
Inventories, net	0		0
Intercompany receivable	109		40
Other current assets	7		10
Total current assets	116		50
Property, plant, and equipment, net	0		0
Goodwill	0		0
Other intangible assets, net	0		0
Tax assets	0		0
Investment in subsidiaries	66,705		64,352
Intercompany loans receivable	3,000		3,000
Other assets	0		0
Total assets	69,821		67,402
Current liabilities:
Current debt obligations	0		0
Accounts payable	0		0
Intercompany payable	0		0
Accrued compensation	6		3
Accrued income taxes	0		0
Other accrued expenses	21		20
Total current liabilities	27		23
Long-term debt	0		0
Accrued compensation and retirement benefits	0		0
Accrued income taxes	10		10
Intercompany loans payable	19,206		17,278
Deferred tax liabilities	0		0
Other liabilities	0		0
Total liabilities	19,243		17,311
Shareholders’ equity	50,578		50,091
Noncontrolling interests	0		0
Total equity	50,578		50,091
Total liabilities and equity	69,821		67,402
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0		0
Investments	0		0
Accounts receivable, net	0		0
Inventories, net	0		0
Intercompany receivable	109		40
Other current assets	7		10
Total current assets	116		50
Property, plant, and equipment, net	0		0
Goodwill	0		0
Other intangible assets, net	0		0
Tax assets	0		0
Investment in subsidiaries	66,705		64,352
Intercompany loans receivable	3,000		3,000
Other assets	0		0
Total assets	69,821		67,402
Current liabilities:
Current debt obligations	0		0
Accounts payable	0		0
Intercompany payable	0		0
Accrued compensation	6		3
Accrued income taxes	0		0
Other accrued expenses	21		20
Total current liabilities	27		23
Long-term debt	0		0
Accrued compensation and retirement benefits	0		0
Accrued income taxes	10		10
Intercompany loans payable	19,206		17,278
Deferred tax liabilities	0		0
Other liabilities	0		0
Total liabilities	19,243		17,311
Shareholders’ equity	50,578		50,091
Noncontrolling interests	0		0
Total equity	50,578		50,091
Total liabilities and equity	69,821		67,402
Subsidiary Issuer | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	20		18
Investments	0		0
Accounts receivable, net	0		0
Inventories, net	200		188
Intercompany receivable	9,352		9,407
Other current assets	183		190
Total current assets	9,755		9,803
Property, plant, and equipment, net	1,527		1,480
Goodwill	2,009		2,009
Other intangible assets, net	93		99
Tax assets	520		568
Investment in subsidiaries	73,122		71,129
Intercompany loans receivable	21		21
Other assets	350		216
Total assets	87,397		85,325
Current liabilities:
Current debt obligations	500		500
Accounts payable	494		481
Intercompany payable	21,687		11,971
Accrued compensation	728		913
Accrued income taxes	0		0
Other accrued expenses	337		331
Total current liabilities	23,746		14,196
Long-term debt	9,783		14,418
Accrued compensation and retirement benefits	1,001		1,069
Accrued income taxes	722		692
Intercompany loans payable	9,011		12,613
Deferred tax liabilities	0		0
Other liabilities	265		133
Total liabilities	44,528		43,121
Shareholders’ equity	42,869		42,204
Noncontrolling interests	0		0
Total equity	42,869		42,204
Total liabilities and equity	87,397		85,325
Subsidiary Issuer | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0		0
Investments	0		0
Accounts receivable, net	0		0
Inventories, net	0		0
Intercompany receivable	0		0
Other current assets	0		0
Total current assets	0		0
Property, plant, and equipment, net	0		0
Goodwill	0		0
Other intangible assets, net	0		0
Tax assets	0		0
Investment in subsidiaries	58,863		39,557
Intercompany loans receivable	3,798		4,119
Other assets	0		0
Total assets	62,661		43,676
Current liabilities:
Current debt obligations	0		0
Accounts payable	0		0
Intercompany payable	1,322		1,308
Accrued compensation	0		0
Accrued income taxes	0		0
Other accrued expenses	11		11
Total current liabilities	1,333		1,319
Long-term debt	1,309		1,354
Accrued compensation and retirement benefits	0		0
Accrued income taxes	0		0
Intercompany loans payable	27,126		9,320
Deferred tax liabilities	0		0
Other liabilities	0		0
Total liabilities	29,768		11,993
Shareholders’ equity	32,893		31,683
Noncontrolling interests	0		0
Total equity	32,893		31,683
Total liabilities and equity	62,661		43,676
Subsidiary Guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	204		1
Investments	0		0
Accounts receivable, net	0		0
Inventories, net	0		0
Intercompany receivable	5		6
Other current assets	2		3
Total current assets	211		10
Property, plant, and equipment, net	0		0
Goodwill	0		0
Other intangible assets, net	0		0
Tax assets	0		0
Investment in subsidiaries	67,007		65,012
Intercompany loans receivable	30,240		27,858
Other assets	0		0
Total assets	97,458		92,880
Current liabilities:
Current debt obligations	0		0
Accounts payable	0		0
Intercompany payable	10,697		7,200
Accrued compensation	0		0
Accrued income taxes	0		0
Other accrued expenses	70		53
Total current liabilities	10,767		7,253
Long-term debt	13,552		8,621
Accrued compensation and retirement benefits	0		0
Accrued income taxes	0		0
Intercompany loans payable	13,459		19,682
Deferred tax liabilities	0		0
Other liabilities	0		0
Total liabilities	37,778		35,556
Shareholders’ equity	59,680		57,324
Noncontrolling interests	0		0
Total equity	59,680		57,324
Total liabilities and equity	97,458		92,880
Subsidiary Guarantors | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	204		1
Investments	0		0
Accounts receivable, net	0		0
Inventories, net	0		0
Intercompany receivable	1,387		1,374
Other current assets	2		3
Total current assets	1,593		1,378
Property, plant, and equipment, net	0		0
Goodwill	0		0
Other intangible assets, net	0		0
Tax assets	0		0
Investment in subsidiaries	65,631		63,651
Intercompany loans receivable	30,240		27,858
Other assets	0		0
Total assets	97,464		92,887
Current liabilities:
Current debt obligations	0		0
Accounts payable	0		0
Intercompany payable	10,698		7,199
Accrued compensation	0		0
Accrued income taxes	0		0
Other accrued expenses	75		60
Total current liabilities	10,773		7,259
Long-term debt	13,552		8,621
Accrued compensation and retirement benefits	0		0
Accrued income taxes	0		0
Intercompany loans payable	13,458		19,682
Deferred tax liabilities	0		0
Other liabilities	1		1
Total liabilities	37,784		35,563
Shareholders’ equity	59,680		57,324
Noncontrolling interests	0		0
Total equity	59,680		57,324
Total liabilities and equity	97,464		92,887
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	3,738		4,374
Investments	6,436		5,455
Accounts receivable, net	6,118		6,222
Inventories, net	4,079		3,792
Intercompany receivable	32,385		19,170
Other current assets	1,903		1,941
Total current assets	54,659		40,954
Property, plant, and equipment, net	3,229		3,195
Goodwill	37,943		37,950
Other intangible assets, net	19,682		20,461
Tax assets	1,284		951
Investment in subsidiaries	0		0
Intercompany loans receivable	25,120		35,398
Other assets	1,763		798
Total assets	143,680		139,707
Current liabilities:
Current debt obligations	375		338
Accounts payable	1,471		1,472
Intercompany payable	9,467		9,452
Accrued compensation	1,039		1,273
Accrued income taxes	442		567
Other accrued expenses	2,687		2,521
Total current liabilities	15,481		15,623
Long-term debt	1,417		1,447
Accrued compensation and retirement benefits	572		582
Accrued income taxes	1,973		2,136
Intercompany loans payable	16,705		16,704
Deferred tax liabilities	1,376		1,278
Other liabilities	1,493		624
Total liabilities	39,017		38,394
Shareholders’ equity	104,522		101,192
Noncontrolling interests	141		121
Total equity	104,663		101,313
Total liabilities and equity	143,680		139,707
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	3,758		4,392
Investments	6,436		5,455
Accounts receivable, net	6,118		6,222
Inventories, net	4,042		3,753
Intercompany receivable	10,725		7,212
Other current assets	2,086		2,131
Total current assets	33,165		29,165
Property, plant, and equipment, net	4,756		4,675
Goodwill	39,952		39,959
Other intangible assets, net	19,775		20,560
Tax assets	1,804		1,519
Investment in subsidiaries	0		0
Intercompany loans receivable	40,585		29,002
Other assets	2,113		1,014
Total assets	142,150		125,894
Current liabilities:
Current debt obligations	875		838
Accounts payable	1,965		1,953
Intercompany payable	201		119
Accrued compensation	1,767		2,186
Accrued income taxes	442		567
Other accrued expenses	3,008		2,834
Total current liabilities	8,258		8,497
Long-term debt	9,891		14,511
Accrued compensation and retirement benefits	1,573		1,651
Accrued income taxes	2,695		2,828
Intercompany loans payable	17,833		17,699
Deferred tax liabilities	1,376		1,278
Other liabilities	1,757		756
Total liabilities	43,383		47,220
Shareholders’ equity	98,626		78,553
Noncontrolling interests	141		121
Total equity	98,767		78,674
Total liabilities and equity	$ 142,150		$ 125,894

Guarantor Financial Informati_5

Guarantor Financial Information - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Millions	6 Months Ended
	Oct. 25, 2019	Oct. 26, 2018
Operating Activities:
Net cash provided by (used in) operating activities	$ 3,377	$ 2,865
Investing Activities:
Acquisitions, net of cash acquired	(201)	(119)
Additions to property, plant, and equipment	(584)	(497)
Purchases of investments	(4,226)	(1,444)
Sales and maturities of investments	3,260	2,824
Capital contribution paid	0	0
Other investing activities	(16)	0
Net cash (used in) provided by investing activities	(1,767)	764
Financing Activities:
Change in current debt obligations, net	42	(700)
Issuance of long-term debt	5,568	1
Payments on long-term debt	(5,594)	(17)
Dividends to shareholders	(1,447)	(1,351)
Issuance of ordinary shares	432	800
Repurchase of ordinary shares	(962)	(2,047)
Net intercompany loan borrowings (repayments)	0	0
Capital contribution received	0	0
Other financing activities	(54)	11
Net cash provided by (used in) financing activities	(2,015)	(3,303)
Effect of exchange rate changes on cash and cash equivalents	(26)	(84)
Net change in cash and cash equivalents	(431)	242
Cash and cash equivalents at beginning of period	4,393	3,669
Cash and cash equivalents at end of period	3,962	3,911
Consolidating Adjustments | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	0	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid		50
Other investing activities	0
Net cash (used in) provided by investing activities	0	50
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	0	0
Capital contribution received		(50)
Other financing activities	0	0
Net cash provided by (used in) financing activities	0	(50)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Consolidating Adjustments | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	0	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	43	205
Other investing activities	0
Net cash (used in) provided by investing activities	43	205
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	0	0
Capital contribution received	(43)	(205)
Other financing activities	0	0
Net cash provided by (used in) financing activities	(43)	(205)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	49	147
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid		(18)
Other investing activities	0
Net cash (used in) provided by investing activities	0	(18)
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	(1,447)	(1,351)
Issuance of ordinary shares	432	800
Repurchase of ordinary shares	(962)	(2,047)
Net intercompany loan borrowings (repayments)	1,928	2,469
Capital contribution received		0
Other financing activities	0	0
Net cash provided by (used in) financing activities	(49)	(129)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	49	147
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	0	(18)
Other investing activities	0
Net cash (used in) provided by investing activities	0	(18)
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	(1,447)	(1,351)
Issuance of ordinary shares	432	800
Repurchase of ordinary shares	(962)	(2,047)
Net intercompany loan borrowings (repayments)	1,928	2,469
Capital contribution received	0	0
Other financing activities	0	0
Net cash provided by (used in) financing activities	(49)	(129)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Subsidiary Issuer | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	(967)	(1,335)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	(158)	(133)
Purchases of investments	0	0
Sales and maturities of investments	0	76
Capital contribution paid		(32)
Other investing activities	0
Net cash (used in) provided by investing activities	(158)	(89)
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	(5,016)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	6,143	1,428
Capital contribution received		0
Other financing activities	0	0
Net cash provided by (used in) financing activities	1,127	1,428
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	2	4
Cash and cash equivalents at beginning of period	18	20
Cash and cash equivalents at end of period	20	24
Subsidiary Issuer | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	(319)	(35)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	(43)	(187)
Other investing activities	0
Net cash (used in) provided by investing activities	(43)	(187)
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	(44)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	406	222
Capital contribution received	0	0
Other financing activities	0	0
Net cash provided by (used in) financing activities	362	222
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Subsidiary Guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	295	123
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid		0
Other investing activities	(5)
Net cash (used in) provided by investing activities	(5)	0
Financing Activities:
Change in current debt obligations, net	0	(696)
Issuance of long-term debt	5,567	0
Payments on long-term debt	(515)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(5,105)	1,067
Capital contribution received		0
Other financing activities	(34)	0
Net cash provided by (used in) financing activities	(87)	371
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	203	494
Cash and cash equivalents at beginning of period	1	1
Cash and cash equivalents at end of period	204	495
Subsidiary Guarantors | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	309	136
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	0	0
Other investing activities	(5)
Net cash (used in) provided by investing activities	(5)	0
Financing Activities:
Change in current debt obligations, net	0	(697)
Issuance of long-term debt	5,567	0
Payments on long-term debt	(515)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(5,119)	1,056
Capital contribution received	0	0
Other financing activities	(34)	0
Net cash provided by (used in) financing activities	(101)	359
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	203	495
Cash and cash equivalents at beginning of period	1	1
Cash and cash equivalents at end of period	204	496
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	4,000	3,930
Investing Activities:
Acquisitions, net of cash acquired	(201)	(119)
Additions to property, plant, and equipment	(426)	(364)
Purchases of investments	(4,226)	(1,444)
Sales and maturities of investments	3,260	2,748
Capital contribution paid		0
Other investing activities	(11)
Net cash (used in) provided by investing activities	(1,604)	821
Financing Activities:
Change in current debt obligations, net	42	(4)
Issuance of long-term debt	1	1
Payments on long-term debt	(63)	(17)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(2,966)	(4,964)
Capital contribution received		50
Other financing activities	(20)	11
Net cash provided by (used in) financing activities	(3,006)	(4,923)
Effect of exchange rate changes on cash and cash equivalents	(26)	(84)
Net change in cash and cash equivalents	(636)	(256)
Cash and cash equivalents at beginning of period	4,374	3,648
Cash and cash equivalents at end of period	3,738	3,392
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	3,338	2,617
Investing Activities:
Acquisitions, net of cash acquired	(201)	(119)
Additions to property, plant, and equipment	(584)	(497)
Purchases of investments	(4,226)	(1,444)
Sales and maturities of investments	3,260	2,824
Capital contribution paid	0	0
Other investing activities	(11)
Net cash (used in) provided by investing activities	(1,762)	764
Financing Activities:
Change in current debt obligations, net	42	(3)
Issuance of long-term debt	1	1
Payments on long-term debt	(5,035)	(17)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	2,785	(3,747)
Capital contribution received	43	205
Other financing activities	(20)	11
Net cash provided by (used in) financing activities	(2,184)	(3,550)
Effect of exchange rate changes on cash and cash equivalents	(26)	(84)
Net change in cash and cash equivalents	(634)	(253)
Cash and cash equivalents at beginning of period	4,392	3,668
Cash and cash equivalents at end of period	$ 3,758	$ 3,415

Uncategorized Items - mdt-20191

Label	Element	Value
Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (33,000,000)	[1]
[1]	See Note 2 to the consolidated financial statements for discussion regarding the adoption of accounting standards during the first quarter fiscal year 2020.